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Abstract 
 
The gut microbiota, a dense microbial community present in the human large intestine, plays a 
significant role in the maintenance of human health. Apart from digestion of complex carbohydrates, 
these beneficial mutualists compete with invading pathogens and are involved in the modulation of 
human immune system. 
Despite being home to hundreds of different species of bacteria, two bacteria phyla dominate the 
human gut – Gram-positive Firmicutes and Gram-negative Bacteroidetes. Bacteroides spp., prominent 
members of this microbial ecosystem, degrade a vast range of dietary and host-derived glycans by 
utilizing a complex trans-envelope machinery known as Sus-like systems encoded by co-regulated 
clusters of genes known as polysaccharide utilization loci (PUL).  Each Bacteroides spp. can have >100 
PULs, each specialised in targeting and degrading different glycans, with majority of glycans having 1 
to 2 dedicated PULs. 
Glycans are the major nutrients available to the human colonic microbiota and come from both dietary 
and host sources. While dietary plant glycans are the most prominent in terms of quantity, the ability 
to access host mucin O-glycans appears to be important for gut survival and is a trait shared by many 
members of the microbiota. Various N-glycosylated dietary and host proteins are also found in the 
human gut in significant quantities. These include antibodies and the terminal domains of mucins, 
however, it is currently unclear whether these N-glycans are also accessed as nutrients by the gut 
microbiota and if so, how they are broken down. 
In this study, several prominent Bacteroides spp. were shown to be capable of utilising complex N-
glycans as a sole carbon source. Transcriptomic analysis identified the genes upregulated in one of 
these, B. thetaiotaomicron, during the growth on complex N-glycans. These include 16 predicted 
carbohydrate-active enzymes encoded by multiple discrete loci, some of which, such as BT0455-0461, 
do not fit classical PUL model due to the lack of SusC/D pair, SGBP and a regulator. Biochemical 
characterisation of the activated enzymes provided an insight into their role in N-glycan breakdown. 
Four GH20-family β-hexosaminidases with overlapping specificities were characterised and were 
found to employ a novel CBM domain to bind N-glycan structures. The crystal structure of one of these 
GH20s, BT0459GH20, suggests this glycosidase could utilize a novel strategy to target N-glycan 
substrates.  
The combination of the cellular localization, gene deletion analysis and biochemical characterization 
data allowed us to propose a model for N-glycan degradation where the structure is degraded 
sequentially and requires a cooperative activity of numerous glycosidases encoded by multiple 
discrete loci. The N-glycan degradation begins at the cell surface with a cleavage of the complex N-
glycan structures off the protein backbones by endo-glycosidase BT1044GH18. This step was found to 
be critical in complex bi-antennary N-glycan utilization. The liberated N-glycan structures are then 
imported into the cell where they are sequentially broken down into monosaccharides by the 
specialised exo-glycosidases.  
Variants of this intricate N-glycan utilization apparatus were identified in a number of other 
members of Bacteroides spp., suggesting this model of degradation could be widely employed by the 
human gut Bacteroides. 
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Chapter 1: Introduction 
 
1.1. The Human Gut Microbiota 
 
The human body is home to a vast collection of microorganisms that have co-evolved with the host 
to create a highly complex, accomodating, habitat-specific relationships. These include bacteria, 
viruses, fungi, archaea and protists (Wang et al., 2016). The mucosal surfaces of the human 
gastrointestinal tract (GIT) are home to one of the largest populations of microorganisms that 
usually maintain mutualistic relationship with the host (Figure 1.1). This vast and highly competitive 
microbial ecosystem is known as the gut microbiota (Rothschild et al., 2018). The human gut 
microbiota is established shortly after birth and is incredibly dense, diverse and dynamic. It is 
estimated that there are trillions of organisms present in the human colon and they collectively 
encode more genes than the host, the majority of which are responsible for metabolic functions 
required to derive nutrients from the food we consume (Ley et al., 2008; Marchesi et al., 2016; 
Sender et al., 2016).  
 
Figure 1.1: A representative model of human gut microbial colonisation. Cell numbers are displayed. 
Large intestine harbours the highest population of microorganisms. Figure was adapted from Griffiths et al., 
2015. 
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1.1.1. The acquisition and diversity of the human gut microbiota 
 
During the last decade the rise of low-cost and high-throughput sequencing methods has given rise 
to numerous projects aimed at investigating the human microbiota of a number of bodily niches, 
including the gastrointestinal tract. One of these projects is the US based Human Microbiome 
Project (HMP), which aimed to characterize the genetic and metabolic functions of microbial 
communities co-existing with the human host. The combined data from the HMP and the European 
Metagenomics of the Human Intestinal Tract (MetaHIT) studies allowed for hundreds of bacterial 
species and their functions to be identified, in turn influencing human health and potential risk of 
developing a disease (Turnbaugh et al., 2007; Marchesi et al., 2016; Thursby et al., 2017). 
The human gut microbiota is established shortly after birth and plays a major role in metabolic and 
immunologic pathways throughout the human life. The human microbiome co-evolves with the host 
and the disruption of the microbial colonization process was shown to negatively influence the 
human health by increasing the susceptibility to disease during life (Rodriguez et al., 2015). Culture-
based techniques, high-throughput sequencing and metagenomics approaches have identified the 
composition of the human gut microbiota throughout the different stages of life (Koenig et al., 
2011). The exposure to the maternal microbiota allows for the formation of the first infant gut 
inoculum. The composition of the infant gut microbiota rapidly develops in response to dietary 
stimuli and stabilises, forming an adult-like microbiota by the age of 3-5 years (Figure 1.2) (Rodriguez 
et al., 2015). Influenced by the environmental factors, such as diet, the composition of the human 
gut microbiota converges as we age and reaches the peak complexity by adulthood (Ottman et al., 
2012).  
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Figure 1.2: The composition of the human gut microbiota throughout life. The schematic gives a 
global overview of relative abundance of key bacterial phyla present in the human gut through different life 
stages. The data was obtained using metagenomics approaches (DNA) or 16S RNA sequencing. Figure was 
adapted from Ottoman et al., 2012.  
 
Despite being home to hundreds of different species of bacteria, two bacteria phyla dominate the 
healthy human gut – Gram-positive Firmicutes and Gram-negative Bacteroidetes (Figure 1.3), both of 
which have a significant impact on human health (Arumugam et al., 2011; Ley et al., 2008; Thursby 
et al., 2017). The benefits of human gut microbiota activity to the host are undeniable; however, 
there is no clear evidence which microbes are the key species or whether cooperative activity of the 
microbial community is more important than any individual. It is worth noting that some strains of 
the same bacterial species can be beneficial, yet others are pathogens. For instance, one strain of 
Escherichia coli is used as a probiotic while the other was shown to cause inflammatory bowel 
disease (IBD) (Marchesi et al., 2016). 
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Figure 1.3: Phylogenetic profile of human gut microbiome. The genetic abundance box plot of 30 most 
abundant genera in human gut microbiota. Samples were collected from 35 individuals. Reference-genome-
based mapping with 85% and 65% sequence similarity cut-off was used to calculate the phylum and genus 
abundances. Figure was adapted from Arumugam et al., 2011. 
 
The bacterial colonisation can differ greatly among the individual people. Comparative studies 
indicate that diet is a primary environmental factor influencing the inter-individual gut microbiota 
variation. The so-called Western diet, which includes fast food high in saturated fats and sugar 
content, results in accumulation of higher numbers of Firmicutes and was shown to play a key role in 
dramatic increase of prevalence of inflammatory intestinal diseases such as Crohn’s disease (CD) in 
21st century (Agus et al., 2016). It was also observed that type 2 diabetes drug metformin modifies 
gut microbiome which in turn mediates the effect of the drug (Wu et al., 2017; Koropatkin et al., 
2017). 
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1.1.2. The role of host-microbe interactions in human health and disease 
 
The microbial community that inhabits the human gut is incredibly vast and complex, so it is not 
surprising that it has a huge impact on human health. The Bacteroidetes and the Firmicutes are the 
two phyla of beneficial bacteria that usually dominate the human gut. However, it was shown that 
the changes in the microbial composition of the GIT can have major consequences to host wellbeing 
(Ley et al., 2005).  Normally, microorganisms residing in the human gut are under constant selective 
pressure from both the microbe competitors and the host, which usually results in a stable and 
balanced microbial ecosystem that exists in homeostasis with the human body (Arumugam et al., 
2011). Although diversity is predominantly thought to be advantageous for the stability of gut 
microbiota, some bacterial species occur in higher abundance than others; most likely thanks to the 
huge repertoire of cellular responses to stress they possess (Backhed et al., 2005; Arumugam et al., 
2011). There is also evidence that depletion of a single species from the gut microbiota community 
can have a negative impact, for example a depletion of the major member of Firmicutes, 
Faecalibacterium prausnitzii, has been associated with inflammatory bowel disease (IBD) (Marchesi 
et al., 2016). It is clear that this continuously fluctuating microbial community diversity can be both 
beneficial and disadvantageous to the human host. 
 Modulation of gastrointestinal metabolites is one of the most important functions performed by the 
gut microbiota. To benefit the host, gut microbiota is usually organized in a cooperative “food web” 
structure in order to efficiently break down food and produce the metabolites the host requires 
(Valdes et al., 2018). Generated short chair fatty acids (SCFAs) mediate a variety of important 
functions, such as regulation of immune system responses and development (Figure 1.4) (Blacher et 
al., 2017). In the human GIT, the immune system plays an important role in protecting the body from 
invading pathogens and keeping a fine balance by maintaining tolerance to commensal gut 
microbiota. This is possible because antigen presenting cells (APCs) have co-evolved with microbiota, 
some developing specific phenotypes rendering them inactive against commensal microbes under 
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homeostatic conditions (Bessman et al., 2016). One of the most important roles of commensal gut 
microbiota in immune system homeostasis is the induction of CD4+ T cell differentiation, required to 
regulate the immune response and subsequently control the infection (Wu et al., 2012).  Along with 
the dietary polysaccharide degradation and immune system modulation, the microbes in the human 
gut are also capable of synthesizing and supplying vitamins required by their host. It was shown that 
the human gut microbiota is capable of synthesizing B vitamins such as riboflavin, nicotinic acid, 
biotin, folates, cobalamin and thiamine along with the vitamin K (LeBlanc et al., 2013).  
 
Figure 1.4: The effects of microbiota-associated metabolites to host health. Metabolites, such as 
acetate, propionate and butyrate, produced by the fermentation of carbohydrates by the microbiota 
contribute to the host-microbiome network of communications as: 1) an energy source to epithelial cells; 2) in 
differentiation of naïve T cells to produce regulatory T cells (Treg); 3) to neutrophils chemotaxis; 4) as histone 
deacetylase (HDAC) inhibitors and to overall intestinal homeostasis. Figure was adapted from Blacher et al., 
2017.  
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Under normal conditions, gut microbiota functions in cooperation with the host, maintaining a 
mutualistic relationship. However, it has been recognised that even the slightest disruption to the 
composition of normal gut microbiota can result in imbalance of the microbe-host relationship, 
which could potentially lead to alterations in the microbiota composition known as dysbiosis (Cerf-
Bensussan et al., 2010) (Figure 1.5).  
 
Figure 1.5: Host-microbiome interaction comparison in healthy and inflamed gut. A) Healthy gut 
environment is composed of a balanced, physiological microbiota. Efficient immune barrier is maintained and 
supported by the commensal ‘Peace-keeping’ bacteria that release anti-inflammatory metabolites. Pathogenic 
(pathobiont) bacteria numbers are low, thus maintaining intestinal homeostasis. B) Altered gut environment 
leads to dysbiosis. It can be caused by use of antibiotics, changes in diet or hygiene, pollutants and viruses. The 
numbers of the ‘peace-keeping’ bacteria decrease and the numbers of pathobionts increase. Due to damaged 
epithelial barrier, bacterial adherence and penetration increases ultimately leading to pathological 
inflammation. Immunodeficient patients are highly susceptible to dysbiosis. Figure was adapted from Cerf-
Bensussan et al., 2010.  
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Currently the majority of host–microbiome relationship research is focused on generating data 
derived from faecal samples. This technique is limited because it can only detect culturable intestinal 
microbes. Hence, utilising novel experimental techniques that exploit the genetic machinery, which 
microbiota have evolved to survive in the gut is of utmost importance in studying the relationship in 
detail (Marchesi et al., 2016). 
 
1.1.3. The mucus layer of the gastrointestinal (GI) tract 
Human epithelial surfaces are lined with a layer of mucus that forms a protective barrier against 
various environmental factors (Koropatkin et al., 2012). Intestinal mucus is secreted by the goblet 
cells and contains a mixture of enzymes, peptides, proteoglycans and glycoproteins, such as 
secretory IgA antibody, which collectively function to limit infection and protect epithelial cells from 
damage (Li et al., 2015).  
Studies on mucus composition of the mammalian gastrointestinal (GI) tract revealed that it is 
composed of two layers in stomach and colon whereas only one layer covers the small intestine. The 
inner, thinner layer is secreted by the goblet cells and is firmly attached to the epithelium whereas 
the upper, much thicker loosely attached layer is home to numerous gut microbes (Figure 1.6) 
(Johansson et al., 2011).  This thick inner layer provides a physical barrier against invading pathogens 
while the looser outer layer provides lubrication to allow for a smooth passage for digested food (Li 
et al., 2015). 
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Figure 1.6: Schematic representation of how mucus layers are composed in the gut.  The mucus 
layer is composed of outer (O) and inner, stratified (S) layers that differ in thickness and composition in 
stomach, small intestine and colon. Mucins forming the gel-like mucus layer in stomach are encoded by 
MUC5AC gene whereas MUC2 encodes mucins in small intestine and colon. The thick outer mucus layer in 
colon provides a niche glycan source for specialized gut microbes, such as B. thetaiotaomicron (red dots). 
Figure is taken from Johansson et al., 2011. 
 
Several studies have associated thinning of the colonic mucus layer with the reduced availability of 
dietary fibre (Earle et al., 2015; Hedemann et al., 2009). Some prominent members of the human 
gut microbiota, such as B. thetaiotaomicron, were observed to shift from metabolising dietary 
polysaccharides to utilising mucus glycans (Sonnenburg et al., 2005). Regular consumption of dietary 
fibre, such as plant-derived glycans, helps to maintain healthy gut microbiota composition and 
prevent erosion of the colonic mucus layers. A study of a synthetic gut microbiota assembled in 
germ-free mice using 14 commensal members of human gut microbiota and a pathogen observed 
that a low-fibre diet promotes the growth of colonic mucin-utilising bacteria (Figure 1.7) (Desai et 
al., 2016).  The dietary fibre deprivation changes the physiological composition of a gut microbiota 
and promotes the growth of mucus-degrading bacteria, thus thinning the mucus layer and 
promoting greater epithelial access that ultimately increases the risk of infection by enteric 
pathogens (Makki et al., 2018; Desai et al., 2016).   
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Figure 1.7: Fibre-deprived gut microbiota degrades colonic mucus layer and promotes enteric 
pathogen infection. The diagram shows the impact fibre-rich and fibre-free diet has on the thickness of the 
mucus layer in mice. Fibre-free diet leads to growth of mucin-utilising bacteria, which in turn thins the mucus 
layer and reduces resistance to infection by mucosal pathogens (Desai et al. 2016).  
 
 
1.2. Nutrition Sources for The Human Gut Microbiota 
 
Fermentable polysaccharides are the main energy source for mammalian hosts and their resident 
gut microbiota. Numerous plant-associated polysaccharides are commonly found in the human diet, 
such as fructans, starches, cellulose, hemicelluloses and pectins. Most of these plant glycans cannot 
be digested by the host and degradation of these structures relies entirely on cooperative activity of 
intestinal microorganisms. The gut microbiota has a vast repertoire of metabolic machinery enabling 
them to utilize various dietary and host-derived glycans, including plant polysaccharides, milk 
oligosaccharides, mucin O-Glycans and N-glycans (Figure 1.8) (Koropatkin et al., 2012; Sonnenburg 
et al., 2005). 
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Figure 1.8: Nutrition sources of human gut microbiota. The schematic illustration of the sources and 
chemical composition of glycans available in the gut. The centre illustrates an intestine and five sources of 
glycans: plant polysaccharides, mucus glycans (O- and N-linked), milk oligosaccharides, endogenous microbe 
glycans and dietary mammalian tissue glycans. The structures shown can be much more complex and diverse 
in nature. The lower panel shows a stained section of germ-free colon highlighting fragments of plant cell wall 
(PW), host mucus-secreting goblet cells (GC), mucus layer (ML) and secreted mucus (SM). Figure was adapted 
from Koropatkin et al., 2012. 
 
Although humans derive only a small amount of dietary energy (up to ~10%) through the gut 
microbiota activities, the impact they have on human health is undeniable and can be heavily 
influenced by the carbohydrate content the intestinal microbial communities are exposed to (Flint et 
al., 2012). Gut microbiota has adapted and nutritionally-specialized to degrade and utilize specific 
dietary carbohydrates the host consumes into short-chain fatty acids (SCFAs) and gases that can also 
be used as an energy source for other specialist gut microorganisms. However, it has been shown 
that drastic changes in host diet can result in decrease in one species of bacteria and increase in 
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others, better specialized to metabolize new carbohydrate structures, which could have negative 
effects on health and potentially lead to disease (Sonnenburg et al., 2005, Flint et al., 2012, Marchesi 
et al., 2016).  
 
1.2.1. Mucins 
 
The majority of biochemical properties of mucus layer come from mucins secreted by the epithelial 
cells. These glycoproteins are composed of polypeptide chains rich in threonine and serine amino 
acids that are extensively glycosylated with small, negatively charged chains of glycans (Johansson et 
al., 2011). The heavy glycosylation and intertwining of these huge thread-like polymers is what gives 
the mucus bilayer the viscoelastic texture and protective abilities. Mucus glycoproteins are also 
normally heavily sialylated, making them polyanionic and enabling interactions with positively 
charged immune system effector molecules (Li et al., 2015). Mucins are either membrane-bound or 
secreted extracellular glycoproteins that all share similar characteristics. Membrane-bound mucins 
are biologically important structural building blocks of mucosal glycocalyx and are involved in cell 
signalling, cell-cell and cell-matrix interactions whereas secreted mucins are essential for protection 
against pathogens and they can also act as nutrient source to several prominent members of gut 
microbiota due to their complex glycosylation patterns (Figure 1.9) (Tailford et al., 2015; Li et al., 
2015). 
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Figure 1.9: Schematic representation of mammalian O- and N-linked glycosylation of mucins. O-
glycosylation occurs via serine or threonine (Ser/Thr) residues whereas N-glycosylation occurs through 
aspargine (Asn). Figure is adapted from Munkley et al., 2016.  
 
 
There are 21 known genes in the human genome encoding mucins: 7 genes encode secreted mucin 
glycoproteins and 13 genes encode the membrane-bound mucin polypeptides (Figure 1.10-A). The 
mucin expression profile varies greatly among the host tissues, with majority of genes encoding 
mucins localised and expressed within the gastrointestinal (GI) tract (Tailford et al., 2015; Parkham 
et al., 2011). The main characteristic of mucin proteins is a central domain made of proline and 
threonine rich tandem repeats (Figure 1.10-B). MUC2 mucin is the major mucin found in both small 
and large intestinal mucus. The MUC2 protein is around 550kDa in size and is made of two heavily O-
glycosylated PTS domains (Proline/Threonine/Serine) (van der Post et al., 2014).  
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Figure 1.10: A list of currently known mucin-encoding human genes and a typical structural 
organization of a secreted mucin. a) The list of secreted and membrane-bound mucins encoded by human 
genome. b) A structure of a characteristic mucin polymer. Long, heavily glycosylated polypeptide chains are 
cross-linked to form large polymeric structures that give mucus its characteristic properties. Figure is adapted 
from Parkham et al., 2011. 
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1.2.2. O-linked glycans 
 
Mucin function is heavily influenced by their glycosylation pattern. It contributes to protein 
conformation, developmental processes and regulation of protein activities. Numerous studies have 
concluded that human glycoproteins can have two types of glycosylation patterns: O-glycosylation 
and N-glycosylation (Staudacher et al., 2015). O-glycosylation of mucins is the most common and 
one of the most important post-translational modifications. It was shown that alteration of N- and 
O-glycosylation patterns in cancer has detrimental effects to protein function (Munkley et al., 2016).  
These tumor-associated alterations in glycosylation patterns can result in changes in glycoprotein 
conformation, cell turnover and oligomerization. Most notable altered O-glycans include Tn 
antigens, sialylated Tn antigens and sialylated Lewis antigens that have been associated with altered 
cell signalling pathways and metastasis (Stowell et al., 2015). Interestingly, an oral pathogen 
Fusobacterium nucleatum was shown to enable immune evasion and accelerate colorectral 
adenocarcinoma (CRC) tumor progression by recognizing and binding Gal-GalNac moieties of O-
glycans, produced by tumor-associated cells in abnormally high levels (Rubinstein et al., 2013; Abed 
et al., 2017).  
O-glycan structures of mammalian mucus glycoproteins are very complex and diverse, consisting 
mainly of alpha- and beta-linked GlcNAc (N-acetylglucosamine), GalNAc (N-acetylgalactosamine) or 
Galactose sugar residues covalently attached to the serine (Ser) or threonine (Thr) amino acids 
(Figure 1.11) (Jensen et al., 2010). The biosynthesis of an O-glycan structure begins by the addition 
of GalNAc residue to the protein backbone, followed by an assembly of other monosaccharides, 
forming various structures and linkages. The core 1-4 mucin-type structures are further elongated 
and often modified by addition of sialic acid or fucose residues. Core 1 (Gal-β1,3-GalNAc-α1-Ser/Thr) 
and core 2 (Gal-β1,3-(GlcNAc-β1,6)-GalNAc-α1-Ser/Thr) structures are commonly found on duodenal 
and gastric mucins whereas the core 3 (GlcNAc-β1,3-GalNAc-α1-Ser/Thr) and core 4 (GlcNAc-β1,6-
(GlcNAc-β1,3)-GalNAc-α1-Ser/Thr) are predominantly found in colon (Tailford et al., 2015).  
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Any changes in O-glycosylation patterns of mucins have been linked with a number of debilitating 
conditions in humans, such as colonic cancer, inflammatory bowel disease, Crohn’s disease and 
ulcerative colitis (Leroy et al., 2006; Theodoratou et al., 2014; Simurina et al., 2018) 
 
Figure 1.11: The structures of glycans found in the GI tract. A) Main O-glycan core structures found in 
gastrointestinal (GI) tract. B) Common glycan epitopes found in the human gut. Human blood classification 
system is based on the expression of glycoproteins known as Lewis antigens: Lewisa and Lewisb. These 
structures can be further glycosylated on O-glycans to form Lewisx, Lewisy and sialylated forms that are 
important in cell-to-cell recognition. In adults, overexpression of LewisY has been linked with epithelial cell 
cancer. Tn antigen is commonly found on gastroduodenal mucins. It is also a tumor-associated antigen that is 
not normally found in blood cells or peripheral tissues. Figure is adapted from Tailford et al., 2015.  
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1.2.3. N-linked glycans 
 
N-glycosylation is one of the most important types of post-translational modifications of secreted 
and membrane-bound glycoproteins; it is involved in the regulation of protein activity, cellular 
targeting and stability enhancement (Jensen et al., 2010). N-linked glycans are oligosaccharides 
formed by linking an N-acetylglucosamine (GlcNAc) residue to an amino group of an asparagine (Asn) 
in a certain Asn-X-Ser/Thr sequon in ER (Staudacher et al., 2015). N-glycosylation is a non-templated 
process that relies on using a range of specialised enzymes to add or remove monosaccharides from 
the glycan chains, producing a diverse range of structures. All N-glycans share a common tri-
mannosyl chitobiose core, Man-α1,6(Man-α1,3)Man-β1,4GlcNAc-β1,4GlcNAc-β1-Asn, and can be 
divided into three main classes depending on the capping structures added to this core structure: 
high mannose, complex and hybrid structures (Figure 1.12). High mannose N-glycans contain only 
1,2/3/6-linked mannose residues attached to the core structure whereas the typical complex N-
glycan structures usually contain β1,2/4/6-linked GlcNAc, β1,4-linked galactose and 2,3/6-linked 
sialic acid residues, but these structures can vary greatly depending on the type of the glycoprotein 
they are found on. Hybrid N-glycans contain only mannose residues on one arm whereas the other 
arm is made of GlcNAc and galactose residues (Bieberich et al., 2014). Complex N-glycan and hybrid 
structures can be further elongated with a bisecting GlcNAc-β1,4-, where GlcNAc residue is attached 
to the central mannose residue of the tri-mannosyl core residue (Man-β1,4-GlcNAc). Depending on 
the function of the glycoprotein, complex N-glycan structures can be incredibly diverse and be 
further glycosylated with galactose, sialic acid, core and antennary fucose or GalNAc residues (Sethi 
et al., 2015). Altered expression of branched fucosylated N-glycans has been observed in cancer cells 
(Stowell et al., 2015). 
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Figure 1.12: Types of N-glycan structures. High mannose, complex and hybrid are the main three N-glycan 
structures found on N-glycoproteins. They all share a common trimannosyl-chitobiose core (highlighted in 
red). The unusual paucimannose type N-glycan structures can be found in pathogen-infected humans (e.g. 
lungs). Figure is adapted from Sethi et al., 2015.  
 
N-glycans are very abundant and can be found on various human, animal, yeast, bacteria, archaea, 
insect and plant glycoproteins. Depending on the function of the glycoprotein, the N-glycan 
structures found in these organisms can vary greatly (Figure 1.13) (Wang et al., 2017). The complex 
N-glycan structures are the most common type of N-glycans found in mammalians and plants 
whereas the high-mannose N-glycans are the most prevalent in yeast (Strasser et al., 2016). 
Furthermore, human glycoproteins can only be capped with N-acetylneuraminic acid (Neu5Ac) caps 
whereas animal N-glycans contain both Neu5Ac caps and N-glycolyneuraminic acid (Neu5Gc) caps 
(Dell et al., 2010).  
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Figure 1.13: The schematic representation and comparison of types of N-glycans produced in 
different organisms. Common N-glycan structures found in mammals, plants, insects and yeast are shown. 
Mammalian N-glycan structures are usually complex and capped with terminal sialic acid residues (Neu5Ac) 
Plant N-glycans typically contain core N-glycan structure capped with GlcNAc residues and further glycosylated 
with a fucose and xylose. Insects typically produce a double-fucosylated core N-glycan structure whereas yeast 
typically produce oligomannose N-glycan structures (Strasser et al., 2016). 
 
In the human gut, the microbiota can scavenge on N-glycan structures acquired from a diverse range 
of sources. These include host-derived N-glycoproteins such as mucins and antibodies (e.g. antibody 
IgA) (Munkley et al., 2016). There is also an abundance of dietary-derived complex N-glycans from 
animal (e.g. eggs, milk, meat) and plant sources. These include complex bi-antennary and tetra-
antennary N-glycan structures (Valdes et al., 2018). Furthermore, human gut microbiota was shown 
to be capable of scavenging high-mannose N-glycans present on yeast mannan (Cuskin et al., 2015). 
Although it appears to be clear that N-glycans are prominent in the human gastrointestinal (GI) tract, 
the influence of the abundance of N-glycan sources on the proliferation of the symbiotic gut 
microbiota members is lacking.  
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1.3. Carbohydrate-Active Enzymes (CAZymes) 
 
Fermentable carbohydrates are the primary energy source for mammalian hosts and their resident 
gut microbiota. Along with the maintenance of a variety of biosynthetic processes in the body, 
metabolites derived from the diet are involved in regulation of host-microbe interactions (Cantarel 
et al., 2009). Carbohydrate structures found in nature are extremely varied, composed of different 
inter-sugar linkages and complex glycosylation patterns. Numerous separate monosaccharide units 
can be joined together via various glycosidic linkages to form complex polysaccharides. These can be 
broadly classified into simple (e.g. glucose, galactose and fructose) and complex (e.g. starch and 
cellulose) dietary carbohydrates (Bhattacharya et al., 2015). Many of these glycans cannot be 
digested by the host and degradation of these structures relies entirely on cooperative activity of 
intestinal microorganisms. To bind, catabolise and utilize these carbohydrates, the gut microbiota 
produces a huge number of carbohydrate-active enzymes (CAZymes) that, based on their amino acid 
sequence, are typically assigned to three broad classes: polysaccharide lyases (PLs), carbohydrate 
esterases (CE) and glycoside hydrolases (GHs). Glycoside hydrolases (GHs) and polysaccharide lyases 
(PLs) are the most abundantly produced CAZymes by Bacteroides species (Figure 1.14) (Kaoutari et 
al., 2013). All currently known carbohydrate-active enzymes and their associated non-catalytic 
modules are listed in the Carbohydrate Active enzyme (CAZy) database (www.cazy.org). 
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Figure 1.14: Comparison of a number of genes encoding carbohydrate-active enzymes versus a 
number of different glycoside hydrolases (GH) and polysaccharide lyases (PLs) families encoded by 
members of human gut microbiota. The Bacteroidetes genomes generally contain significantly more 
enzyme-coding genes and more different Cazy families than the rest of the phyla present, suggesting they can 
utilise a wider range of glycan substrates. Figure is taken from Kaoutari et al., 2013.  
 
 
 
1.3.1. Glycoside Hydrolases (GHs) 
 
Glycoside hydrolases are the major class of enzymes specialised in cleaving the glycosidic bonds. 
Based on their amino acid sequence, glycoside hydrolases are classified into different GH families on 
the CAZy database (Berlemont et al., 2016). To date, there are a total of 153 GH families. The amino 
acid sequences of predicted carbohydrate-active enzymes enable for the specific GH domains and 
conserved catalytic residues to be identified and overall mechanistic information to be derived, 
which allows for the prediction of their evolutionary relationships and basic substrate specificity 
(Henrissat et al., 1995). For example, presence of the GH20 domains predicts a β-hexosaminidase 
activity for the enzyme (Liu et al., 2012). The relationship between the amino acid sequence and 
folding similarities also allows for the prediction of structural features of novel enzymes. However, a 
full biochemical characterisation is required to fully understand their roles. 
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Based on the research done using a mini-microbiome, the majority of GHs encoded by the dominant 
members of the gut microbiota are predicted to be involved in breakdown of plant glycans such as 
starch, fructans and plant cell wall polysaccharides, with only a small proportion involved in animal 
glycan degradation (Figure 1.15).  
 
Figure 1.15: Variation of the glycoside hydrolase (GH) families in mini-microbiome.  
a) A graph showing the most abundant GH families. The enzymes from GH18, GH20, GH38 and GH92 families 
are only involved in the breakdown of screened animal glycans. b) Venn diagram comparison of substrate 
specificities of glycoside hydrolases (GHs) and polysaccharide lyases (PLs). Mini-microbiome refers to genes 
encoded by the dominant members of human gut microbiota, such as Firmicutes, Bacteroidetes, 
Proteobacteria and Actinobacteria.  Out of these, Bacteroidetes encode the largest and most diverse number 
of glycoside hydrolases (GHs) and polysaccharide lyases (PLs). Figure is adapted from Kaoutari et al., 2013.  
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1.3.1.1. Catalytic mechanisms of glycoside hydrolases 
 
In most cases, the classification system of the glycoside hydrolase (GH) families enables for a 
relatively easy prediction of catalytic residues and catalytic mechanisms because they are usually 
conserved in majority of characterised GH enzymes (Henrissat et al., 1995).  Depending on the 
change in the configuration of the anomeric oxygen during the reaction, Koshland et al. (1953) 
grouped GH families into two categories: retaining and inverting. A classic retaining glycoside 
hydrolase employs a two-step action and requires a nucleophile and a catalytic acid/base catalyst to 
form a covalent intermediate whereas an inverting glycosidase needs both a catalytic base and a 
catalytic acid residue (Figure 1.16). In both cases, the mechanism of action is heavily dependent on 
the catalytic residues (Vuong et al., 2010).  
 
 
Figure 1.16: A schematic diagram of main two mechanisms of glycoside hydrolases. B-: a catalytic 
base residue; AH: a catalytic acid residue; Nuc: a nucleophile; HOR: an exogenous nucleophile (e.g. H2O) and R: 
carbohydrate derivative. Figure is taken from Vuong et al., 2010. 
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Some enzymes rely on a substrate-assisted catalysis (SAC) where a functional group of the substrate 
is required for the catalysis by the enzyme. This type of catalysis was first demonstrated in serine 
proteases, GTPases and hexose-1-phosphate uridylyl transferases (Dall’Acqua et al., 2000). It 
depends on the stereochemical, mechanistic and structural properties of the glycosidase. The 
substrate-assisted catalysis was also observed in GH20 β-hexosaminidase from S. plicatus SpHEX 
(Figure 1.17). Here the catalytic mechanism of the β-glycosyl hydrolase depends on the C2-
acetamido group present on the substrate (Figure 1.17-B). This group replaces enzyme nucleophile 
residue to form a stable covalent, cyclic intermediate which is then hydrolysed at the anomeric 
centre in a manner similar to the double displacement mechanism (Mark et al., 2000). 
 
Figure 1.17: Proposed catalytic mechanism for the S. plicatus β-hexosaminidase SpHEX. A) The steps 
of the substrate-assisted catalysis of the NAG-thiazoline by SpHEX. B) The cyclic intermediate analogue NAG-
thiazoline structure. The predicted general acid/base (Glu314) and the residue (Asp313) are shown. For clarity, C6 
and hydroxyl groups were removed from the pyranose ring. Figure was adapted from Mark et al., 2000.  
 
 
 
 25 
 
Glycoside hydrolases can be further classified into exo- and endoglycosidases (Kaoutari et al., 2013). 
Exoglycosidases are enzymes that have an active site pocket topology and release monosaccharide 
residues from the terminal ends of the glycans whereas the endoglycosidases have an open cleft 
topology that enables them to target the internal linkages of the sugar chains. Some exo-
glycosidases, such as cellobiohydrolases, can have a tunnel topology (Figure 1.18-A; Davies and 
Henrissat, 1995). Endoglycosidases are specialised to cleave N-linked glycans off protein backbones 
(Figure 1.18-B). The examples include the PNGaseF endoglycosidase that cleaves between the core 
GlcNAc and aspargine residue of the complex, high-mannose and hybrid N-glycans; and GH18-family 
endo-β-N-acetylglucosaminidases that cleave the chitobiose (GlcNAc-β1,4-GlcNAc) linkages of the N-
glycan core structures (Kobata et al., 2013). 
 
 
Figure 1.18: The comparison of the exo- and endo-glycosyl hydrolases.  
A) The GH active site topology. Cleft, pocket and tunnel topologies are displayed with the active sites 
highlighted in red. Figure was adapted from Davies and Henrissat, 1995. B) Examples of exo-glycosidase and 
endo-glycosidase cleavage points on a complex bi-antennary N-glycan. Two types of endo-glycosidases are 
displayed: GH18 and PNGaseF. Figure was made using a GlycanBuilder tool (Expasy). 
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1.3.1.2.  Sub-sites of Glycoside Hydrolases 
 
The substrate binding sites of glycoside hydrolases (GHs) can be divided into sub-sites and 
numbered. The nomenclature was proposed by Henrissat and Davies (1997) and divides the sub-
sites into negative (donor) and positive (acceptor) sub-sites, depending which side of the cleavage 
point they are located (Figure 1.19). Sub-sites on the non-reducing side are denoted by negative (-1, 
-2, -3) numbers while sub-sites located at the reducing end are positively labelled (+1, +2, +3). The 
number of sub-sites varies from enzyme to enzyme and depends on the substrate binding pathway 
(Bissaro et al., 2015).  
 
Figure 1.19: Glycoside hydrolase glycan binding sub-sites.  
Enzyme point of cleavage is located between -1 and +1 sub-sites and is denoted with a red arrow. Positive 
(acceptor) sub-sites are located on reducing end whereas negative (donor) sub-sites are located at the non-
reducing end. Figure was adapted from Bissaro et al., 2015. 
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1.3.2. Carbohydrate esterases (CEs) 
 
Carbohydrate esterases are enzymes that catalyse the de-O or de-N-acetylation of ester bonds of 
glycans. CEs are widely spread in nature – they are produced by both prokaryotes and eukaryotes. 
Most of CEs are general-acting and based on their substrate specificities are divided into 16 families 
on the CAZy database. The removal of steric ester-based modifications of glycans by carbohydrate 
CEs enhances the access of enzymes to these sugar structures, accelerating the glycan degradation. 
Thus, esterases are widely used in a range of biological and biotechnological applications (Nakamura 
et al., 2017). The majority of the carbohydrate esterases utilize the Asp-His-Ser catalytic triad (Figure 
1.20) (Hakulinen et al., 2000). However, some CEs were observed to rely only the His-Ser diad or the 
Zn+ ion (Adesioye et al. 2016). 
 
Figure 1.20: The schematic diagram of carbohydrate esterase catalytic mechanism.   
The carbohydrate esterase requires Asp-His-Ser triad for its activity. The aspartate (Asp) activates the serine 
(Ser) residue which results in nucleophilic attack on the acetyl group, resulting in tetrahedral oxyanion 
transition state. Enzyme oxyanion hole stabilises the transition state while the histidine (His) utilises the water 
molecule to hydrolyse the cleavage of the acetyl group. Figure is from Hakulinen et al., 2000.  
 
Sialic-acid-specific esterases are of particular importance due to the prevalence of acetylation 
modification of sialic acids found on glycans produced by mammalian cells. 9-O-acetylation is the 
most common modification of the sialic acids, such as Neu5Ac. For example, Neu5,9Ac is commonly 
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found in ocular tear film-secreted mucins and human colonic mucins (Corfield et al., 2005). These 
decorations sterically inhibit the access of most sialidases and thus, require a sialic-acid-specific 9-O-
acetylesterase to remove. Several sialic-acid-specific 9-O-acetylesterases are produced by human gut 
microbiota (Zhu et al., 2004).  It was recently observed that the sialic-acid specific O-acetyl esterase 
EstA from B. fragilis enhances the efficiency of liberation of sialic acids from bovine submaxillary 
mucin (BSM) by B. fragilis sialidase NanH and B. thetaiotaomicron sialidase NanH (BT0455), thus 
mediating the cross-species foraging of sialoglycans by the members of gut microbiota (Robinson et 
al., 2017). Sialic-acid-specific 9-O-acetylesterase, NanS, was also observed to enhance the sialic acid 
release by the sialidase NanH produced by oral pathogen Tannerella forsythia (Phansopa et al., 
2015). Interestingly, the increase of production of sialoglycoproteins containing Neu5,9Ac has also 
been observed in hematopoietic cells from children suffering from acute lymphoblastic leukemia 
(Ghosh et al., 2007). 
 
1.3.3. Carbohydrate binding modules (CBMs) 
 
Many carbohydrate-active enzymes have a complex molecular architecture comprised of multiple 
discrete modules. This domain composition commonly includes a catalytic domain and a 
carbohydrate-binding module (CBM). Traditionally, CBMs were associated with plant cell wall-
degrading enzymes. However, novel CBMs are increasingly being identified in many host-derived 
glycan-degrading enzymes. The CBMs are involved in binding of the glycan and anchoring it in the 
close proximity of the catalytic domain, promoting catalysis (Shoseyov et al., 2006). In enzymes 
specialised in plant cell wall degradation, the CBM domains are attached to the catalytic domains via 
a long, flexible linker domain where they function to anchor the enzyme to their target 
polysaccharide substrates. Meanwhile, the CBM domains present in enzymes specialised in host-
derived glycan degradation are usually much more closely associated with the catalytic domain, 
promoting the efficient degradation of their target glycans (Gilbert et al., 2013). Examples of CBMs 
present in the starch-degrading enzyme SusG from B. thetaiotaomicron and mucin glycan-targeting 
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enzyme NagJ from C. perfringens are displayed in Figure 1.21 (Arnal et al., 2018; Ficko-Blean et al., 
2009). 
 
Figure 1.21: Examples of enzymes that contain carbohydrate-binding modules (CBMs).  
A) A structure of amylase SusG from B. thetaiotaomicron showing the binding of CBM58 domain to pullulan 
oligosaccharide (black and red sticks). Figure was adapted from Arnal et al., 2018. B) A structure of O-
GlcNAcase NagJ (GH84C) from C. perfringens showing the binding of the CBM32 domain to N-
Acetyllactosamine (blue and red sticks), a disaccharide commonly found on mucin glycans. Figure was adapted 
from Ficko-Blean et al., 2009.  
 
 
The first carbohydrate-binding module (CBM) described was involved in binding of crystalline 
cellulose and was initially called cellulose binding domain (CBDs) (Gilkes et al., 1988). Since then, 
numerous CBMs have been identified and were shown to display a great variation in substrate 
specificity. Based on their properties and sequence similarities, the carbohydrate-binding modules 
(CBMs) have been classified into 81 families on the CAZy database (Cantarel et al., 2009). However, 
because the CAZy classification is based on the sequence similarities, it does not always accurately 
predict substrate specificity of the CBMs. Some families were shown to be poly-specific, for example 
CBM4 binds xylan, cellulose and various β-glucans (Abou-Hachem et al., 2000). Based on their mode 
of ligand recognition and conformation of the ligand and CBM binding site, CBM families can also be 
subdivided into surface-binding (type A), endo-type (type B) and exo-type (type C) binding CBMs 
(Figure 1.22; Boraston et al., 2004; Gilbert et al., 2013). In type A, the polysaccharide interacts with 
the hydrophobic surface-binding site of the CBM. In type B, the ligand-binding site of the CBM has a 
cleft topology that allows for internal accommodation of the glycan chains. In type C, the CBM has 
an exo- pocket-like binding site (Gilbert et al., 2013). 
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Figure 1.22: The types of carbohydrate-binding modules. Type A shows a surface-binding site (colored 
in red) of CBM2a from the Cellulomonas fimi xylanase (PDB 1XG); Type B shows an endo-binding site of a 
CBM15 from C. japonicas xylanase (PDB 1GNY); Type C shows an exo-type pocket-binding site of the CBM9 
from a Thermotoga maritima xylanase (PDB 1I82). The structures are coloured from N-terminal (blue) to C-
terminal (red). Ligands are displayed as green/red sticks. Figure was adapted from Gilbert et al., 2013. 
 
 
It is widely recognised that carbohydrate-binding modules (CBMs) are involved in enhancing the 
efficiency of the hydrolysis of various host and dietary-derived glycans (Herve et al., 2010). In some 
instances, the catalytic efficiency of the enzyme is dependent on the CBM domain. For example, the 
CBM32 domain of the GH5-family mannanase CtMan5A participates in substrate recognition and 
together with the catalytic domain forms a substrate-binding site required for the catalysis of host-
derived mannotetraose by Clostridium thermocellum (Mizutani et al., 2014). Furthermore, CBM51 
domains of GH95-family α-fucosidase and GH98-family endo-β-galactosidase from Clostridium 
perfringens were shown to be involved in recognition and binding of O- and N-glycan structures, 
thus enhancing the efficiency of glycan degradation (Gregg et al., 2008). And finally, a novel CBM 
domain of a NanH sialidase from an oral pathogen Tannerella forsythia was shown to bind 
sialoglycans, where it was observed that the association with the catalytic domain enhanced the 
CBM binding activity (Frey et al., 2018). 
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1.4. Glycan Degradation by Human Gut Microbiota 
 
Complex glycans are a major nutrient source for the human gut microbiota. The glycosylation 
patterns of these structures can be extremely complex and varied, composed of different glycosidic 
linkages and thus, require a cooperative activity of multiple specialised carbohydrate-active enzymes 
to degrade. It is estimated that the glycobiome of human gut microbiota contains over 9000 genes 
involved in carbohydrate metabolism, majority of which are encoded by the members of Firmicutes, 
Bifidobacterium and Bacteroides species (Kaoutari et al., 2013). In these microorganisms, the 
carbohydrate-active enzymes are usually organised into polysaccharide utilization loci (PULs), each 
specialized to degrade different polysaccharides, oligosaccharides and glycoconjugates into readily 
metabolisable monosaccharides. The products of anaerobic sugar fermentation are short-chain fatty 
acids (SCFAs) such as acetate, butyrate and propionate that play many roles in maintaining human 
health (Carding et al., 2015).   
 
1.4.1. Glycan utilisation by human gut Bacteroides 
 
The ability of commensal gut microbes to persist and adapt to constantly changing environmental 
conditions in mammalian GI tract largely depends on a vast collection of genes they possess that 
encode catabolic machinery required to bind and degrade a wide spectrum of dietary and host-
derived glycans (Bjursell et al., 2006). The Gram-negative Bacteroides are one of the dominant 
species in the human gut primarily because of their ability to utilize a vast number of glycans. Based 
on the number and variety of CAZymes encoded by the members of Bacteroides species, they are 
classified as generalists that drive microbial evolution and dispersion (Sriswasdi et al., 2017). 
Furthermore, genetic manipulability of B. thetaiotaomicron and B. ovatus makes them ideal models 
for studying glycan utilization pathways of Bacteroides. It was found that all members of 
Bacteroidetes encode homologous glycan-specific outer membrane transporter systems (SusC/Ds) 
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so it was suggested that glycan utilisation model is similar in all members of this phylum (Bolam et 
al., 2012).   
Combined comprehensive metagenomic analyses and in vivo experiments show that B. 
thetaiotaomicron is a prominent human gut symbiont that possesses hundreds of genes required for 
dietary and host-derived glycan utilization (Koropatkin et al., 2012). The sequencing of the B. 
thetaiotaomicron genome has allowed for the identification of 260 predicted glycoside hydrolases 
(GHs), an incredibly huge number for a single organism (Xu et al., 2003). Since then, only B. ovatus 
and A. cellulolyticus were found to encode a higher number of GHs (Wegmann et al., 2016; Barabote 
et al., 2009). In overall, members of Bacteroides species encode a much larger number of CAZymes 
compared to the other residents of human gut (Kaoutari et al., 2013).  
In Bacteroides, these enzymes are usually found in Sus-like complexes specialized to target and 
degrade specific dietary polysaccharides and host-derived glycans, such as mucins (Martens et al., 
2008). The starch-utilization system (Sus) was the first multi-protein carbohydrate degradation 
system described in B. thetaiotaomicron. It encodes eight cell-envelope associated proteins 
SusABCDEFGR: starch degrading enzymes Sus A, B, and G, TonB-dependent transporter SusC, three 
starch-binding proteins SusD, E and F, and sensor/regulator SusR. Together these proteins are 
working to bind, degrade and import starch molecules into the cell (Figure 1.23) (Anderson and 
Salyers, 1989; Shipman et al., 1999, Koropatkin et al., 2012).   
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Figure 1.23: Schematic representation of a starch utilization system (Sus) in B. thetaiotaomicron. 
Starch utilization is initiated by binding to extracellular E and F proteins and initial degradation by SusG α-
amylase (GH13). The oligosaccharides are then imported into the periplasm by TonB-dependent SusC/D 
complex where they are further degraded by SusA neopullulanase (GH13) and SusB α-glucosidase (GH97). 
Maltose is used as transcription regulator for the periplasmic sensor SusR whereas glucose is imported into the 
cell for fermentation. GH – glycosyl hydrolase. Figure is adapted from Koropatkin et al., 2012. 
 
Clusters of genes that encode Sus-like systems are termed polysaccharide utilization loci (PULs) and 
are characteristically defined by the presence of homologous TonB-dependent outer membrane 
transporter (SusC) and a glycan-binding protein (SusD) pair along with numerous enzymes targeting 
various dietary and host-derived glycan structures (Koropatkin et al., 2009). A ‘pedal-bin’ mechanism 
of substrate binding and transport has been recently proposed for the SusC/D complexes where the 
SusD acts like a ‘lid’, moving away from the SusC in the absence of a substrate which leaves the 
substrate-binding site open and exposed to the extracellular environment (Glenwright et al., 2017).  
So far, 88 polysaccharide utilization loci (PULs), comprised of 866 genes, have been identified in B. 
thetaiotaomicron (Martens et al., 2011).  These PULs are listed on PUL Database (PULDB), an 
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automated prediction tool designed by CAZy team that lists over 4000 predicted PULs from 
approximately 70 Bacteroidetes, such as Bacteroides, Alistipes, Prevotella, Tannerella and 
Parabecteroides. Interestingly, some of the PULs listed on the PULDB lack SusC/D pair but encode 
them elsewhere in the genome (Grondin et al., 2017). The overall key feature of these diverse cell 
envelope-associated systems is the coordinated, step-wise activity of multiple proteins that bind and 
digest complex extracellular carbohydrates into simple metabolites that can be easily absorbed by 
the host (Martens et al., 2009). The PUL activity is regulated by either metal-dependent regulators, 
extra-cytoplasmic function (ECF) σ-factor/anti-σ-factor or most commonly hybrid two-component 
system (HTCS). These regulators are PUL-specific and allow bacteria to sense and target 
carbohydrates they are designed to degrade. SusE/F-like proteins in typical PULs are named surface 
glycan-binding proteins (SGBPs). Most of the characterised SGBPs are specialised to recognise and 
bind to specific glycans (Bolam et al., 2012). These TonB-dependent transporter systems are 
widespread in Gram-negative microorganisms and can transport not only carbohydrates, but also 
vitamin B12 and ferric chelates known as siderophores, such as haemoglobin, serum transferrin and 
hemin (Noinaj et al., 2011). 
Transcriptional profiling of Bacteroides grown on different plant or host-derived mucosal glycan 
sources has shown that each Sus-like system targets a unique carbohydrate substrate, sometimes 
working in collaboration with other PULs (Sonnenburg et al., 2005; Martens et al., 2008; Martens et 
al., 2011). A highly extensive xylan utilisation apparatus has been described in B. ovatus where 
degradation depends on two discrete PULs – PUL-XylL and PUL-XylS. Combined, these PULs 
encode three SusC/D-like pairs of proteins, two surface xylan-binding proteins, two HTCS 
sensors/regulators and numerous xylan-debranching enzymes (Rogowski et al., 2015). A complex 
degrading apparatus was also identified in B. thetaiotaomicron where plant rhamnogalacturonan-
II (RG-II) is degraded by a cooperative activity of RGII-binding proteins and degrading enzymes 
encoded by three discrete PULs – RG-II PUL 1, 2 and 3 (Ndeh et al., 2017). Similar apparatus is 
employed by B. thetaiotaomicron to utilise yeast mannan where degradation is dependent on the 
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activity of enzymes encoded by three discrete PULs – PUL-Man 1, 2 and 3 (Cuskin et al., 2015). B. 
thetaiotaomicron is also capable of utilising host glycosaminoglycans heparan sulfate (HS) and 
heparin (Hep) (Cartmell et al., 2017). The abundance and diversity of these highly-organized systems 
of extracellular and periplasmic proteins involved in sensing, regulation, degradation and transport 
of carbohydrates is what makes Bacteroides such highly-competitive members of the mammalian 
gut microbiota. The comparative analysis of these PULs is an efficient way to understand the 
community dynamics and nutrient niche colonization of the gut microbiota. For example, B. ovatus 
and B. thetaiotaomicron contain over 100 PULs but surprisingly very few of these PULs are 
homologous, suggesting these dominant members of human gut microbiota have distinct glycan 
niches (Martens et al., 2011). These findings suggest that these Bacteroidetes have adapted to 
forage on different nutrient sources. 
B. thetaiotaomicron is a generalist capable of degrading numerous distinct types of glycans, 
including complex O- and N-glycan structures found on mucins. Generalists, specialising in 
degradation of broad-range of glycans have an evolutionary advantage over specialists, which focus 
on one or few glycan types and may become extinct if host diet was to change (Pudlo et al., 2015). 
Plant polysaccharides can be incredibly complex and the task of degrading such structures is further 
complicated by the presence of plant cell wall, which not many species have a capacity to access. B. 
thetaiotaomicron possess numerous polysaccharide utilization loci (PULs) encoding Sus-like 
metabolic systems targeting a diverse range of plant glycans, including pectin, hemicellulose, xylan 
with the notable exception of cellulose (Koropatkin et al., 2012). Previous studies have shown that B. 
thetaiotaomicron is also one of the few endogenous gut microbes that is capable of growing on host-
derived mucins in the absence of dietary carbohydrate input (Martens et al., 2008). It was shown 
that in B. thetaiotaomicron 15 different polysaccharide utilization loci (PULs) are upregulated in the 
presence of different glycan fractions derived from porcine gastric mucin (PGM) compared to the 
glucose control (Martens et al., 2008; Koropatkin et al., 2014). It was suggested that host glycan 
foraging by B. thetaiotaomicron helps to stabilize the microbial community population affected by 
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the alterations in dietary glycan intake, in turn avoiding dysbiosis of the gut microbiota and potential 
disease (Tailford et al., 2015).  
1.4.2. N-glycan degradation pathways 
 
The last two decades of human microbiome research has produced a tremendous amount of data 
that collectively reveals the significant impact the gut microbiota has on human metabolism, 
physiology and overall health (Sender et al., 2016). Although we now possess an extensive 
knowledge about the degradation pathways of major classes of glycans by human gut microbiota, 
such as plant polysaccharides, fungal cell walls and host glycosaminoglycans (GAGs), there is a 
paucity of data describing the underlying processes of N-glycan degradation by the gut microbiota, 
particularly dietary and host-derived complex N-glycoproteins. As previously discussed, N-glycans 
are prominent and may be an important nutrient source for the members of gut microbiota. 
Because glycosylation patterns of N-glycoproteins are incredibly complex and diverse, these 
structures would require an extensive metabolic machinery to degrade.  
The gut microbiota possesses numerous enzymes that allow degradation of various macromolecular 
structures, but little information is available on mechanisms gut microbes employ to degrade N-
glycan structures. Up to date, the N-glycan degradation pathway research has been mainly focused 
on pathogenic microbes. Efficient N-glycan utilisation has been observed by Bacteroides fragilis in 
vitro. This opportunistic pathogen was shown to employ an outer member protein complex termed 
Don to deglycosylate human serum glycoprotein transferrin. The Don PUL is composed of seven 
genes, encoding a SusC/D-like protein pair, a GH18 endo-N-acetyl-β-d-glucosaminidase and a α-N-
acetylglucosaminidase. The sialylated N-glycan degradation by B. fragilis also requires the 
cooperative activity of a neuraminidase NanH to release terminal sialic acid residues (Cao et al., 
2014). Similar PUL was identified in Capnocytophaga canimorsus, a Gram-negative bacterium 
commonly found in the dog oral cavity that can cause severe infections in humans. It was observed 
that C. canimorsus is capable of deglycosylating N-glycan structures found on human IgG antibody 
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and fetal calf serum fetuin in vitro by employing a large Sus-like system consisting of the GpdCDGEF 
proteins and a sialidase SiaC. The N-glycans are cleaved off the protein backbone by a GH18 family 
endoglycosidase GpdG before being imported into the cell. This ability of C. canimorsus to harvest N-
glycans was found to be important for bacterial growth in vivo (Renzi et al., 2011). However, the rest 
of the degradation pathway is not known.  
Complex N-glycan degradation was also observed by the exoglycosidases encoded by the 
opportunistic pathogen Streptococcus pneumoniae (King et al., 2006).  In S. pneumoniae, the 
complex N-glycan structures are first depolymerised down to the Man3GlcNAc2 core before it is 
released from the protein backbone by the endo-β-N-acetylglucosaminidase (EndoD) and imported 
into the cell for further processing. S. pneumoniae was shown to be capable of deglycosylating 
lactoferrin, IgA-1 and α1-acid glycoprotein, where the utilisation of α1-acid glycoprotein N-glycans as 
a sole carbon source was enough to sustain bacterial growth (Burnaugh et al., 2008). 
A common human pathogen, Streptococcus pyogenes, secretes a large GH18 family endoglycosidase 
termed EndoS that was shown to be capable of cleaving the N-glycan structures off the protein 
backbones of human IgG antibodies (Collin et al., 2001). This activity was linked to the enhanced 
host immune response evasion and subsequent increased rate of survival of the bacterium in human 
blood ex vivo (Collin et al., 2002). 
Furthermore, a human oral pathogen Tannerella forsythia secretes a sialidase NanH that was shown 
to be capable of cleaving sialic acid residues off bovine fetal serum fetuin and bovine submaxillary 
mucin (BSM) in vitro. It was suggested that the utilisation of glycoprotein-associated sialic acid 
promotes the growth of T. forsythia biofilm in vivo (Roy et al., 2011).  
In addition, humans can only synthesize N-acetylneuraminic acid (Neu5Ac) whereas non-human 
mammals can synthesize both Neu5Ac and N-Glycolylneuraminic acid (Neu5Gc). Interestingly, it was 
observed that humans are capable of incorporating the non-human sialic acid variant Neu5Gc into 
their cells which in turn stimulates the xeno-autoimmunity (Varki et al., 2017). Considering that the 
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sialic acids are the common attachment sites for many pathogens, it is not surprising that Shiga toxin 
(Stx) produced by Shigella dysenteriae and Typhoid toxin produced by Salmonella enterica were 
observed to be capable of targeting both the human Neu5Ac and non-human Neu5Gc that was 
incorporated into human glycoproteins (Varki et al., 2009).  
Overall these data suggest that the N-glycan structures are utilised by the bacterial pathogens not 
only as a nutrient source in the gut but also as a mechanism to evade host immune responses extra-
intestinally (e.g. in the gut wound, blood). Although the N-glycan degradation was observed by 
various pathogens discussed above, the full utilisation pathway has not been described yet. It is also 
not clear whether similar degradation model would be employed by mutualistic gut microbiota 
species that can access N-glycans. B. thetaiotaomicron was previously shown to be capable of 
breakdown of high-mannose N-glycans but it was not known if it can access complex and hybrid N-
glycan structures (Cuskin et al., 2015).  
 
1.5. Research objectives 
It was previously shown that a number of polysaccharide utilization loci (PULs) are upregulated by 
Bacteroides thetaiotaomicron during the growth in the presence of complex mucin-derived glycan 
structures (Martens et al., 2008). Despite the extensive characterization of PULs involved in foraging 
of host-derived glycans by various pathogenic bacteria, the knowledge of N-glycan degradation 
pathways by mutualists residing in the human gut is lacking. Understanding the precise mechanisms 
employed by commensal gut microbiota to degrade these complex glycoproteins can have major 
implications not only in promotion of human health but also in an industrial context.   
To achieve this aim, the project was divided into two main goals: 
i. Investigating complex N-glycan utilization by human gut Bacteroides 
This study aimed to 1) investigate whether human gut Bacteroides can utilize complex N-glycans 
(Chapter 3), 2) identify potential N-glycan utilization loci in B. thetaiotaomicron using transcriptomic 
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analyses (Chapter 3) and 2) biochemically and structurally characterize the function of enzymes and 
glycan binding proteins predicted to be involved in N-glycan utilization (Chapter 4).  
ii. To propose an N-glycan degradation model 
N-glycosylation patterns are exceptionally intricate and diverse. To fully degrade such complex 
structures, bacteria require a cooperative activity of numerous glycan binding proteins, enzymes, 
transporters and regulators. The identification of N-glycan structure linkages these enzymes target 
allows for a rational understanding of the degradative mechanism and provides insight whether it 
requires a cooperative activity of multiple PULs. Combined, this information would allow for an N-
glycan degradation model to be proposed. 
This study aimed to 1) investigate potential cooperative activity of multiple N-glycan binding 
proteins and degrading enzymes, 2) determine their cellular localization, 3) investigate the 
importance of key enzymes to N-glycan utilization and 4) to propose a model of N-glycan 
degradation by B. thetaiotaomicron (Chapter 5).  
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Chapter 2: Materials and Methods 
 
2.1. Molecular biology 
2.1.1. Bacterial strains and vectors 
The bacterial strains and plasmids that were used during this research project are listed in Table 2.1 
and Table 2.2, respectively. 
Table 2.1: Bacterial strains 
Strain  Genotype features Description 
BL21 (DE3) F- dcm ompT hsdS(rB- mB-) gal 
(DE3 [lacI lacUV5-T7 gene 1 ind1 
sam7 nin5]) 
E. coli strain optimised for over-expression of 
recombinant proteins using a T7 promoter. 
(Studier & Moffatt, 1986) 
Tuner (DE3) F– ompT hsdSB (rB– mB–) gal 
dcm lacY1 (DE3)  
This E.coli strain carries a lacY mutation 
optimised for overexpression of recombinant 
proteins using IPTG.(Novagen) 
Top10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
ɸ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara, leu)7697 galU 
galK rpsL (STRR) endA1 nupG λ-  
E. coli strain used for plasmid propagation and 
cloning. (Invitrogen) 
CC118 
λ-pir 
Δ(ara-leu) araD ΔlacX74 galE galK 
phoA20 thi-1 rpsE rpoB argE (Am) 
recA1 λpir  
E. coli strain used in gene deletion plasmid 
propagation. (Herrero et al. 1990) 
S17 
λ-pir 
A pro hsdR RP4-2 (Tc::Mu; 
Km::Tn7)  
( λ pir)  
E. coli strain used in conjugation of pExchange 
plasmid carrying gene deletion. (Skorupski & 
Taylor, 1996) 
B. thetaiotaomicron 
Δtdk 
Δtdk B. thetaiotaomicron VPI-5482 strain lacking a 
thimadine kinase. Used to generate genomic 
mutants through FuDR selection. Provided by Eric 
Martens. 
B. thetaiotaomicron VPI-5482 Distaso (1912), Castellani and Chalmers (1919) 
strain. Provided by Eric Martens. 
B. fragilis NCTC-9343 Veillon and Zuber (1898), Castellani and 
Chalmers (1919) strain. (DSMZ.de) 
B. caccae ATCC-43185 Johnson et al. (1986) strain. (DSMZ.de) 
B. ovatus ATCC-8483 Eggerth and Gagnon (1933) strain. (DSMZ.de) 
B. massiliensis CCUG-48901 Fenner et al. (2005) strain. (DSMZ.de) 
B. finegoldii JCM-13345 Bakir et al. (2006) strain. (DSMZ.de) 
B. vulgatus ATCC-29327 Eggerth and Gagnon (1933) strain. (DSMZ.de) 
B. cellulosilyticus CCUG-44979 Robert et al. (2007) strain. (DSMZ.de) 
B. nordii JCM-12987 Song et al. (2005) strain. (DSMZ.de) 
B. intestinalis JCM-13265 Bakir et al. (2006) strain. (DSMZ.de) 
B. uniformis ATCC-8492 Eggerth and Gagnon (1933) strain. (DSMZ.de) 
B. fluxus JCM-16101 Watanabe et al. (2010) strain. (DSMZ.de) 
B. salyeriae JCM-12988 Song et al. (2005) strain. (DSMZ.de) 
P. merdae ATCC-43184 Johnson et al. (1986) strain. (DSMZ.de) 
B. longum NCTC-11818 Reuter (1963) strain. (DSMZ.de) 
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Table 2.2: Plasmid list 
Plasmid Features Supplier/Reference 
pET28a-b Kanr, T7 promotor, lac, laciq, 
integrated His tag 
Novagen  
 
pExchange-tdk Ampr, ermr, tdk modified suicide 
vector 
Provided by Nicole Koropatkin 
(Koropatkin et al, 2008) 
 
2.1.2. Bacterial growth and selective media 
The list of growth media used in this study is shown in Table 2.3. The media was used alone as 
inoculum broth or poured into plates following the addition of of 2% (w/v) of Bacteriological agar. 
Bacteroides spp. were grown in sterile TYG, MM+carbon source or BHI media whereas E. coli strains 
were grown in sterile Luria-Bertani Broth (LB). When necessary, the selective antibiotics were added 
to the media after sterilisation (Table 2.4). 
Table 2.3: List of media 
Medium Composition Quantity 
(per litre) 
Method 
Luria-Bertani  
(LB) 
Granules, as provided by the 
manufacturer (Sigma-Aldrich) 
25 g Dissolved in MiliQ water and sterilised 
before use 
Tryptone-
Yeast 
Extract-
Glucose 
(TYG) 
Tryptone/Peptone 
Yeast Extract 
Glucose 
Cysteine, free base 
1 M KPO4 pH 7.2 
 0.4 mg/ml FeSO4 
1 mg/ml Vitamin K 
0.8 % CaCl2 
0.25 mg/ml Resazurin 
TYG Salt Solution (MgSO4  
0.5 g/l, NaHCO3 10 g/l, NaCl 2 g/l) 
10 g 
5 g 
2 g 
0.5 g 
100 ml 
1 ml 
1 ml 
1 ml 
4 ml 
40 ml 
Dissolved in MiliQ water and sterilised 
before use 
Minimal 
Media 
Bacteroides 
(MM+0.5 % 
target 
Glycan) 
NH4SO4 
Na2CO3 
Cysteine, free base 
1 M KPO4 pH 7.2 
0.4 mg/ml FeSO4 
1 mg/ml Vitamin K 
0.01 mg/ml Vitamin B12 
0.25 mg/ml Resazurin 
MM Salt Solution (NaCl  
18 g/l,CaCl2 0.53 g/l, MgCl2 0.4 
g/l, MnCl2 0.2 g/l, CoCl2 0.2 g/l) 
1 g 
1 g 
0.5 g 
100 ml 
10 ml 
1 ml 
0.5 ml 
4 ml 
50 ml 
Dissolved in MiliQ water and sterilised 
before use 
Brain-Heart 
Infusion  
(BHI) 
Powder, as provided by the 
manufacturer (Sigma Aldrich) 
37.5 g Dissolved in MiliQ water and sterilised 
before use 
His-Heme Hematin 
0.42 g/l Histidine-HCl  
pH 8.0 
1.2 g 
1 l 
Used to as a supplement to TYG, MM 
and BHI media. 1:1000 dilution after 
media has been sterilised 
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Table 2.4: List of antibiotics 
Antibiotics Working concentration Storage 
Ampicillin 50 µg/ml -20 °C 
Kanamycin 50 µg/ml -20 °C 
Gentamycin 200 µg/ml Prepared when necessary 
Erythromycin 25 µg/ml Prepared when necessary 
5-fluoro-2'-deoxyuridine (FUdR) 200 µg/ml Prepared when necessary 
 
2.1.3. Sterilization 
Astell Hearson 2000 Series Autoclave or a Prestige© Medical Series 2100 Clinical Autoclave were 
used at 121 °C for 1 h to sterilise all solutions and glassware before use. In addition, where 
applicable, solutions were filtered using sterile 0.22 μm Milipore filter discs (Stupor® Acrodisc® 3.2 
Gelman Sciences) and sterile syringes (Plastipak®, Becton Dickinson). 
 
2.1.4. Chemicals, carbohydrates and commercial kits 
All experiments were done using double distilled water as a solvent unless noted otherwise. 
Millipore Milli-RO 10 Plus Water Purification System was used to produce purified MQ H2O (18.2Ω). 
The chemicals, media, commercial kits and substrates were mainly purchased from Sigma Aldrich, 
Megazyme, Carbosynth, Dextra or BDH Laboratories Ltd., with special exceptions listed in the text.  
 
2.1.5. Storage information 
Stocks of plasmid DNA, cDNA and genomic DNA were stored at -20 °C long-term and -4 °C short-
term. Stocks of RNA were stored at -80 °C short-term.  Bacterial strain stocks were stored in 25 % 
(v/v) glycerol at -80 °C.  
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2.1.6. Centrifugation 
Beckman J2-21 centrifuge was used to harvest large-scale cultures of bacterial cells by centrifugation 
in 500ml Nalgene bottles at 5000 rpm for 10 minutes using JA-10 rotor (at 4 °C). Whereas JA25-50 
rotor was used to harvest cell lysate at 25000 rpm for 30 minutes (at 4 °C). Hettich Mikro 220R 
Refrigerated benchtop centrifuge was used to spin small-scale samples (1-10 mL) at speeds up to 
6000 rpm, in 25 ml universal (Sterilin) tubes. Eppendorf tubes (up to 2mL) were centrifuged using a 
Heraeus Pico 21 benchtop microcentrifuge at speeds up to 14,000 rpm.  
 
2.1.7. Transformation of competent E.coli 
Stocks of chemically competent E.coli strains were produced by Mr. Carl Morland and stored at -80 
°C long-term (Cohen et al., 1972). A 100 μl aliquot of required E. coli strain was thawed on ice before 
1-5 μl (200 ng) of plasmid DNA or ligation reaction was added. Reaction was incubated on ice for 30 
minutes before the cells were heat-shocked at 42 °C for 1 minute and incubated on ice for further 2-
5 minutes. 200 μl of fresh LB media was then added and the mixture was incubated at 37 °C, with 
shaking, for up to 1 hour (1h for ligation reactions). Cells were then harvested by centrifugation, re-
suspended in 100 μl of fresh LB media and plated onto LB plates containing an appropriate antibiotic 
and incubated for 16 hours lid-down at 37 °C, aerobically.  
 
 2.1.8.   DNA extraction and quantification  
Plasmid DNA was propagated by transforming a required plasmid into Top10 competent E.coli cells 
as described previously. A single colony was then inoculated into 5mL LB with an appropriate 
antibiotic and incubated at 37 °C overnight, with shaking. The cultures were harvested by 
centrifugation, as outlined previously, and plasmid DNA was purified using a QIAspin Prep kit 
(QIAGEN) as per manufacturer’s instructions. 
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Genomic DNA was extracted using GenElute ™ Bacterial Genomic DNA kit (Sigma-Aldrich) following 
the manufacturer’s protocol. 
NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific) was used to determine DNA 
concentration by measuring the absorbance at 260nm and 280nm. The 260/280 absorbance ratio 
was used to estimate the sample purity. Pure DNA samples have a ratio of ~ 1.8.  
 
2.1.9. Polymerase chain reaction  
The polymerase chain reaction (PCR) technique was used to amplify the target DNA following a 
variant of a protocol first developed by Mullis and Faloona in 1987.  KOD Hot-Start Polymerase Kit 
(Novagen) was used to catalyse the synthesis of new complementary DNA strands based on either 
plasmid DNA or genomic DNA template using a BioRad PHC-3 ThermoCycler. 
For a standard PCR, primers were constructed to target specific DNA regions with the forward 
primer complimentary to the 5’ end of the forward strand and the reverse primer complimentary to 
the 5’ end of the reverse strand. The primers were constructed 15-30 bases in length, with ~50% GC 
content and with a melting temperature (Tm) of >45 °C. Primer parameters were calculated using an 
OligoCalc online tool (Kibbe, 2007). Where required, restriction sites were added to the 5’ ends of 
the primers and additional sequence of 6 nucleotides upstream of the restriction site for efficient 
cutting of the PCR products by the restriction endonucleases. Primers were synthesized by Eurofins 
Genomics (MWG) and resuspended in PCR-grade water to a 100pmol/μl working concentration.  
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 2.1.9.1. Standard PCR conditions 
Standard PCR reaction mix was prepared as shown in Table 2.5 using the KOD Hot-Start DNA 
Polymerase Kit (Novagen). Master mixture was kept on ice until use.  
Table 2.5: Standard PCR reaction mix composition 
Reagent  Volume (μl) 
KOD Buffer (10x) 5 
dNTPs (2mM) 5 
MgSO4 (25mM) 2.5 
Forward Primer (100 μM) 2.5 
Reverse Primer (100 μM) 2.5 
Template DNA  1 
KOD DNA polymerase (1 U/μl) 0.5 
PCR-grade dH2O Up to 50 
 
The standard PCR program used on the thermocycler is shown in Table 2.6. 
 
Table 2.6: Standard PCR program    
                     Initial denaturation 95 °C 60 seconds  
                        Denaturation 95 °C 30 seconds  
   35                Annealing 55 °C 30 seconds  
  cycles           Elongation 68 °C 60 seconds  
                        Final extension 68 °C 600 seconds  
                        Storage   4 °C ∞ 
 
 
After the amplification, DNA product was analysed using agarose gel electrophoresis. If the product 
yield was low or no product of right size was detected, PCR reaction parameters, such as annealing 
and elongation time, were adjusted. In some cases, dimethyl sulfoxide (DMSO) was added to the 
reaction mix (3 μl).  
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2.1.9.2. Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyse the DNA/RNA nucleic acid samples. 1 % (w/v) 
agarose gel was used routinely throughout the study. Solution was prepared by mixing 0.5g of 
agarose powder (Sigma-Aldrich) in 50 ml of 1 x TBE buffer (2mM EDTA, 89mM Tris Base, 89mM 
Boring Acid) and dissolving it completely by boiling. The solution was cooled to around <50 °C and 
0.5 μg/ml of ethidium bromide was added before being poured to the pre-assembled mini-gel 
system mould tank (Applied Biosystems). The gel was let to set for approximately 30 minutes before 
being used. 
For DNA sample loading, agarose gel was submerged in 1 x TBE buffer. DNA samples were mixed 
with 5 μl of 10 x of loading dye (10 x TBE, 50% glycerol, 0.25% Bromophenol blue) and loaded into 
the gel wells. Hyperladder I (Bioline) was used as DNA standard marker. The size of DNA fragments 
was estimated by comparing their electrophoretic migration with that of known standards. The 
samples in the gel were separated by size by running them at 70 V for 45-60 minutes (LKB Bromma 
2197 Power Supply).  
Bio-Rad Gel Doc EZ Imager was used to visualise the DNA bands on the gel following the 
electrophoresis. Images were printed using Mitsubishi Video Copy Processor and thermal paper.  
 
2.1.10. Site-directed mutagenesis (SDM) 
Site-directed mutagenesis was used to generate single amino acid mutants in this study. Forward 
and Reverse synthetic primers designed with a desired amino acid mutation were used to mutate a 
double-stranded recombinant plasmid carrying the wild-type protein. The primers were made 12bp 
in length and complementary to the DNA template, apart from one mutated amino acid. Same PCR 
mix was used for site-directed mutagenesis as described previously with a specially-designed SDM 
thermocycler program (Table 2.7). 
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Table 2.7: Standard PCR program for SDM    
                     Initial denaturation 95 °C 60 seconds  
                        Denaturation 95 °C 30 seconds  
   20                Annealing 55 °C 60 seconds  
  cycles           Elongation 68 °C 60 seconds per 1kb  
                        Final extension 68 °C 600 seconds  
                        Storage   4 °C ∞  
 
Following the PCR amplification, the reaction mix was allowed to cool before 1µl of DpnI restriction 
endonuclease (Thermo Fisher Scientific 10 U/µl) and 3µl of 10 x Tango Buffer were added. DpnI 
recognises the GA_^TC sequence of methylated DNA, leaving the un-methylated PCR product 
undigested. The DpnI digestion reaction was incubated at 37 °C for 2 hours and 5 μl of digested PCR 
product was transformed into chemically competent E.coli cells. 
 
2.1.11. Restriction digestion and purification of DNA  
Restriction digestion of up to 1000ng of DNA was done following a standard protocol provided by 
the manufacturer. Briefly, appropriate 10 x reaction buffer was mixed with the DNA and 1 μl of 
required restriction endonuclease was added to the reaction (Thermo Fisher Scientific). The final 
reaction volume was made up to 40 μl using Ultra-Pure water (Sigma-Aldrich) and incubated at 37 °C 
for 1 hour.  
QIAquick PCR Purification kit (QIAGEN) was used following the manufacturer’s instructions to purify 
the digested DNA and all PCR products.  
Vector DNA was purified using QIAquick Gel Extraction kit (QIAGEN) following the manufacturer’s 
protocol. Briefly, following the vector digestion by restriction endonucleases, the DNA product was 
run on a 1 % (w/v) high purity Seachem Gold Agarose gel using the agarose gel electrophoresis as 
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described previously. The required DNA band was cut from the gel using a scalpel and UV 
transilluminator before being purified using the gel extraction kit.  
2.1.12. Ligation of insert and vector DNA 
Digested vector DNA and inserted DNA were ligated using Rapid DNA ligation kit (Thermo Fisher 
Scientific) following protocol outlined in Table 2.8. In each reaction, insert to vector molar ratio of 
3:1 was calculated and used.  
 
Table 2.8: Ligation reaction mix 
Reagent Amount per reaction 
Digested Insert DNA 20 ng of DNA 
Digested Vector DNA Calculated to 3:1 ratio 
5 x Ligation Buffer 4 μl 
T4 DNA ligase 1 μl 
PCR-grade H2O Up to 20 μl 
 
 
2.1.13. Sewing PCR 
‘Sewing’ PCR, otherwise known as PCR overlap extensions, was used generate plasmid DNA for 
homologous recombination used to mutate the genome of Bacteroides thetaiotaomicron. This 
method was used to generate knock-out mutants. pExchange tdk plasmid and E. coli CC118 λ pir 
strain was used for cloning. Primers were routinely designed with either BamHI and Xbal sites or SalI 
and SpeI sites.   
To remove a gene, four primers flanking 1,000 bp upstream (Flank 1) and downstream (Flank 2) of 
the gene were designed (Figure 2.1). In order to produce a mutant lacking the gene, 20 bp of 
mutation extension of flank 1 primer was designed to be complementary to one of the opposite 
flank.  
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Figure 2.1: Graphical representation of the sewing PCR concept. 
A) 1000 bp of upstream Flank 1 and 1000 bp of downstream Flank 2 were amplified using two separate PCR 
reactions. The primer 2 and primer 3 carried a complementary mutation extension sequence. B) The flank 1 
and flank 2 are ‘sewn’ together and amplified using primer 1 and primer 4 during a third PCR reaction. C) The 
final PCR product carried a desired mutation and 1000bp flanking regions. Figure was adapted from Amy 
Glenwright thesis. 
 
 
The first step was to produce 1000 bp of upstream and 1000 bp of downstream flank by amplifying 
them in two separate PCR reactions with 2 sets of primers: primer 1 and 2 for flank 1 and primer 3 
and 4 for flank 2. The second step was to ‘sew’ the two flanks together at the complementary 
mutation extension and amplify the product in a third PCR reaction using primer 1 and primer 4. The 
final step was to purify the 2000 bp PCR product carrying a desired mutation and insert it into 
pExchange-tdk vector using the ligation protocol described previously. The plasmid was then 
transformed into CC118 λ pir E. coli strain and purified for further use. 
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2.1.14. Automated DNA sequencing 
Value Read service by MWG-Eurofins Genomics was used to sequence DNA. MWG-Eurofins 
Genomics uses ABI sequencers. Pre-paid single value-read labels were provided by the company. For 
each sample, two labelled tubes containing 7 μl of 50-100 ng of DNA were sent for sequencing in 
both forward and reverse direction using either specifically designed primers or primers provided by 
the company (T7 prom and T7 term). T7 promoter sequence – TAATACGACTCACTATAGGG, T7 
terminator sequence – CTAGTTATTGCTCAGCGGT. 
 
2.1.15. RNA extraction and sequencing 
Wild type B. thetaiotaomicron was grown anaerobically overnight at 37°C in 5ml of TyG media. The 
overnight cultures were then inoculated into 5ml of Minimal Media containing either 50mg of N-
glycan or 25 mg of glucose as a carbon sources. The bacterial cultures were then grown to mid-
exponential stage (O.D. of ~0.4 for N-glycan and ~0.6 for glucose).  The cells were harvested by 
centrifugation using the RNAProtect Bacterial Reagent (QIAGEN) to stabilize and protect the 
bacterial cultures from the degradation of RNA transcripts and induction of genes. RNA was then 
extracted using the commercially available RNeasy Mini kit (QIAGEN), following the manufacturer’s 
instructions. The concentration and purity of RNA was estimated by measuring the absorbance at 
260nm and 280 nm respectively using a NanoDrop 2000 UV-Vis spectrophotometer (Thermo Fisher 
Scientific Inc, USA).  To estimate RNA purity, the ratio of the absorbance contributed by the nucleic 
acid to the absorbance of the contaminants is determined. Typically, a requirement for A260/A280 
ratios are between 1.8 and 2.2. RNA quality was also analysed using the agarose gel electrophoresis. 
Intact RNA is represented by 16S rRNA band and example is shown in Figure 2.2. The extracted RNA 
was then frozen and stored at -80°C until required.  
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Figure 2.2. Agarose gel visualisation of RNA samples. This agarose gel shows an example of purified 
RNA samples. HyperladderTM I (HLI) DNA ladder was run to compare the band sizes. Bands at the top 
of the gel in wells 7, 8 and 9 labelled DNA represent DNA contamination present in the RNA samples 
and requirement for DNAse treatment.  
 
 
The extracted RNA was sent to the Oxford Genomics Centre or The Earlham Institute for sequencing. 
The sequencing was done using the High-performance Illumina HiSeq4000 75bp system, 1 PE lane 
(240 million reads per lane). The data was aligned to the reference and quality-checked before being 
returned to us. 
 
2.1.16. cDNA synthesis 
RNA was converted to the cDNA using the QuantiTect Reverse Transcriptase Kit (QIAGEN) following 
the manufacturer’s instructions. The kit is optimised for use in real-time PCR, removing integrated 
genomic DNA and allowing for reliable quantification of gene targets from mRNA transcripts.  
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2.1.17. Quantitative Polymerase Chain Reaction (qPCR)  
Quantitative Polymerase Chain Reaction (qPCR) was used to investigate the upregulation of specific 
genes during the mid-exponential growth phase of B. thetaiotaomicron using specially designed 
primers and cDNA templates.  
cDNA was obtained using a protocol described above. The qPCR primers were designed by taking the 
nucleic acid sequence of the gene of interest and using the GenScript Real-time PCR (TaqMan) 
Primer Design software available on Genscript website to design the primers. 3 sets of primers were 
designed with the amplicon size range between 100-200 bp, and Primer Tm temperatures between 
55-60 °C. The designed primers were synthesized by MWG-Eurofins Genomics and resuspended in 
PCR-grade water to a 100 pmol/μl working concentration. The primers were checked using the wild 
type Bt DNA and standard PCR reaction. Results were visualised on an agarose gel and 100-200 bp 
PCR products were expected (Figure 2.3). 
 
Figure 2.3: An example of agarose gel showing the products amplified by the qPCR primers. Single 
bands of 100-200 bp in size showed that primers are working and can be used in qPCR. 2 bands of DNA are 
visible on lane 1 and suggesting that this primer could not be used. 
 
SYBR Green I kit (Roche) was used in this study. It contains a dye that absorbs light at 497 nm and 
emits light at 520 nm when inserted into double stranded DNA. During each amplification step of 
qPCR, emitted light at 520 nm is measured. The more amplification occurs; the more intensity of 
light is released.  
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For a standard qPCR, a 10 µl of a reaction mix was prepared (Table 2.9) 
Table 2.9: qPCR reaction mix 
Reagent Volume (µl) 
SYBR Green I Master Mix (Roche) 5 
Forward primer (5 µM) 1 
Reverse primer (5 µM) 1 
Template cDNA (50 ng) 2 
PCR-grade H2O 40 
 
 
Quantitative Polymerase Chain Reaction (qPCR) was done using a program given in Table 2.10 on a 
Roche LightCycler® 96.  
Table 2.10: Standard qPCR program     
                     Initial denaturation 95 °C 600 seconds  
                        Denaturation 95 °C 10 seconds  
   45                Annealing 57 °C 10 seconds  
  cycles           Elongation 72 °C 10 seconds   
                        Light measurement 72 °C -  
 
Upon completion, data set was normalised using the Roche LightCycler® 96 analysis software.  
 
 
2.1.18. Counter-selectable mutagenesis of the B. thetaiotaomicron genome 
A pExchange-tdk plasmid carrying a desired mutation produced during a Sewing PCR described 
previously was transformed into S17 λ pir E. coli cells. From this point, S17 λ pir E. coli strain will be 
referred as a ‘donor’ whereas B. theta Δtdk strain will be referred as the ‘recipient’ (Koropatkin et 
al., 2008).  
The donor and recipient strains were grown overnight in 5 ml of LB and 5ml of TYG broth, 
respectively. Bacterial cells were harvested by centrifugation, donor and recipient cell pellets were 
re-suspended and equally mixed together in 1 ml of TYG (Figure 2.4). The mixture was evenly spread 
on BHI-Heme agar plate and incubated lid side up aerobically for 24 hours at 37°C. Because of such a 
thick layer, a lawn of E. coli cells grew first providing anaerobic conditions underneath for B. 
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thetaiotaomicron cells to grow, subsequently providing required conditions for conjugation between 
the donor E. coli cells and recipient B. thetaiotaomicron cells to occur. The thick lawn of cells was 
then scraped and re-suspended in fresh 5 ml of TYG, with no antibiotic. The 100 μl of this solution 
along with 1:10 and 1:100 of dilutions were plated onto BHI-Heme plates containing erythromycin 
(25 μg/ml) and gentamycin (200 μg/ml). These antibiotics are selective for the recipient B. thetaΔtdk 
strain and pExchange-tdk plasmid, therefore only cells which have gone a single recombination 
should grow. These plated cells were incubated at 37°C anaerobically for up to 3 days, before 10 
colonies were re-streaked onto fresh plates to ensure minimal chance of the contamination by wt B. 
theta. The plates were incubated at same conditions for up to 3 more days before 10 colonies were 
picked and inoculated in 5 ml of TYG each and grown overnight anaerobically at 37°C.  
The cells were harvested by centrifugation and pooled together. The 100 μl of this solution along 
with 1:10 and 1:100 of dilutions were plated onto BHI-Heme agar plates containing FUdR (200 
μg/ml) antibiotic. These plates were then incubated for further 3 days anaerobically at 37°C. The 
FUdR allows for selection for cells which have undergone a second recombination event, eliminating 
pExchange-tdk sequence from the genome. The resistant colonies were re-streaked onto fresh 
plates to reduce contamination with wt B. theta cells.  
10 colonies were then inoculated in 5 ml of TYG each for genomic DNA extraction and glycerol stock 
creation. The purified DNA was then screened for successful mutations using standard PCR and 
primer 1 and primer 4. Agarose gel electrophoresis was used to visualise the products and determine 
if it’s a mutant. Genomic DNA of strains that showed a band of right size following the PCR were sent 
to sequencing.  
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Figure 2.4: Graphical representation of mutagenesis protocol.  
A) The donor E.coli S17 λ pir cells and the recipient B. thetaiotaomicron Δtdk cells were grown overnight in 5ml 
of LB and TYG media, respectively. B) Pellets of both donor and recipient cells were harvested by 
centrifugation and combined equally in 5 ml of TYG media. The mixture was plated onto BHI-heme plates and 
grown aerobically for 24h. C) The thick layer of cells was scrapped off the plate and re-suspended in 5ml of TYG 
media. The mixture was plated onto BHI-heme plates + gentamycin (200 μg/ml) and erythromycin (25 μg/ml) 
and grown for 3 days anaerobically. Resistant colonies were then re-streaked onto new plates and grown for 
further 3 days. D) 10 colonies were picked and inoculated in TYG media. The cells were grown for 16 hours, 
anaerobically (First recombination event). E) The 10 cultures were pooled, harvested by centrifugation and re-
suspended in fresh 5ml of TYG. The mixture was then plated onto BHI + FUdR (200 μg/ml) plates and grown for 
3 days, anaerobically (Second recombination event). Resistant colonies were re-streaked onto fresh plates to 
minimise contamination by wt Bt. F) 10 colonies were picked and grown overnight in TYG media. These 
cultures were used to make glycerol stocks and for DNA extraction. G) A graphical representation of the 
recombination events. pExchange-tdk plasmid carrying mutation enters the genome during the first 
recombination event. The second recombination event eliminated pExchange-tdk from the genome. Image is 
adapted from Glenwright, 2017 (PhD thesis). 
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2.1.19. Automated monitoring of bacterial growth curves 
Bacterial growth curves were monitored using an EpochTM Microplate Spectrophotometer (BioTek 
Instruments). Corning Costar 96-Well Cell Culture Plates (Sigma Aldrich) were used for the growths 
inside an anaerobic cabinet, at 37 °C (Don Whitely Scientific). A set-up of triplicates of 200 μl of 
media + required bacterial culture in each condition was routinely used in this study. Wells filled 
with 200 μl of media without the bacteria were used as a control. EpochTM Microplate 
Spectrophotometer measured the optical density at 600nm of each well every 15 minutes and 
recorded the results. The data was then collected from Gen5 2.05 software and investigated using 
GraphPad Prism 7.0 software.  
 
2.1.20. Expression of recombinant proteins in E.coli 
DNA of the plasmid encoding a protein of choice was transformed into either E.coli Tuner or BL21 
cells using a protocol described previously. A single colony was then inoculated into 5 ml of LB 
media, containing a suitable antibiotic, and incubated at 37 °C for 16 hours, with shaking. 1ml of 
overnight culture was then injected into a 2L baffled flask containing 1 L of sterile LB media and a 
suitable antibiotic. The inoculum was then incubated at 37 °C, with shaking, until the culture reached 
the OD600nm of approximately 0.6 - 0.8. The cells were cooled and protein overexpression was 
induced by adding 1 mM of IPTG and incubating at 16 °C overnight. The cells were then harvested by 
centrifugation as described previously. 
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2.1.21. Immobilised Metal Affinity Chromatography (IMAC) 
In this study, all expressed soluble proteins were carrying a His-tag made of 6 or more histidine 
residues. This allowed proteins to be purified using an immobilised metal affinity chromatography 
(IMAC) where histidine tag bound to a positively-charged transition metal ions (e.g. cobalt or nickel) 
immobilised in the column. In order to elute the bound protein, high concentrations of imidazole 
were used, which disrupts the protein-metal interaction by competing for the binding of the metal 
ions. 
Gravity-flow columns were set up using 5 ml of TALON resin (Clontech Laboratories) which contains 
cobalt ions. The column was then equilibrated using 40 ml of TALON buffer (20 mM Tris, 300 mM 
NaCl, pH 8). 
The cells were grown and harvested as described above. The cell pellets were re-suspended in 10 ml 
of TALON buffer, transferred into sterile 20 ml tubes and stored at -20 °C until required. The cell 
mixture was sonicated on ice for 2-3 minutes using a low intensity setting on a B. Braun Labsonic® U 
Ultrasonic Homogenizer (~42 watts and 0.5 second cycling). The sonicated cells were then 
centrifuged for 30 minutes at 25,000 rpm and supernatant (cell free extract CFE) was collected.  
The supernatant was filtered using a 0.45 μM PTFE syringe filter (Sigma Aldrich) and loaded onto 
buffer-equilibrated TALON column. The flow-through liquid was collected and TALON column was 
washed twice in 20-25 ml of TALON buffer. These fractions were collected. The protein was eluted in 
four fractions: 2 x 5 ml of TALON buffer containing 10 mM of Imidazole followed by 2 x 5 ml of 
TALON buffer containing 100 mM of Imidazole. SDS-PAGE gels were used to visualise the purification 
fractions.  
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2.1.22. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to visualise the 
proteins and determine their purity, quantity and approximate size (Laemmli, 1970). Routinely, 12.5 
% polyacrylamide gels (Acrylogel 3; BDH Electran) were prepared and used with two glass plates (12 
cm x 10 cm) and a special rubber seal.  
The buffers needed for the SDS-PAGE gel preparation and operation are listed in Table 2.11. The 
resolving gel solution was prepared according to the protocol and pipetted in-between the glass 
plates, leaving approximately 2 cm gap from the top, which was filled with water to allow the top of 
gel set in a straight line. The stacking gel solution was then pipetted into the 2 cm gap and a well-
comb was inserted to form the wells. The comb was fixed into plate using a binder clip, do make 
sure there are no air bubbles or gaps formed. The gel was allowed to set at room temperature for 
approximately 30 minutes, well-comb and rubber band were removed before the gel was 
transferred into a gel tank. The tank was filled with the 10 x of SDS-PAGE running buffer. Samples 
pre-mixed with 1:2 of loading dye and boiled for 3 minutes. 20 μl of appropriate molecular weight 
(MW) protein standard was pipetted onto one of the wells, alongside of the cooled samples. A 
current of 35 A per gel was applied and gels were allowed to run for 45-55 minutes until the loading 
buffer has run off the end of the gel.  
Following the gel electrophoresis, InstantBlue stain (Expedeon) was used to stain the gel for 20-30 
min in a 150 rpm orbital shaker to visualise the protein bands. Gels were de-stained using distilled 
water and photographed using a Bio-Rad Gel Doc EZ Imager with Bio-Rad Image Lab software.  
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Table 2.11: SDS-PAGE gel and buffer recipes. 
Component name Reagents used Volume or Concentration 
Resolving gel (12.5%) 
/per gel 
0.75 M Tris/HCl buffer, pH 8.8 + 0.2 % SDS  
40 % Acrylamide (BDH Electran 
acrylamide, 3 % (w/v) bisacrylamide)  
Double distilled H2O  
10 % (w/v) Ammonium persulphate  
  Tetramethylethylenediamine (TEMED) 
2.35 ml 
1.45 ml 
 
0.875 ml 
22.5 μl 
7.5 μl 
Stacking gel  
/per gel 
0.25 M Tris/HCl buffer, pH 6.8 + 0.2 % SDS  
40 % Acrylamide (BDH Electran 
acrylamide, 3 % (w/v) bisacrylamide)  
Double distilled H2O  
10 % (w/v) Ammonium persulphate  
  Tetramethylethylenediamine (TEMED) 
0.938 ml 
0.188 ml 
 
0.75 ml 
15 μl 
5 μl 
SDS-PAGE running 
buffer (1 litre) 
32 mM Tris / 190 mM glycine, pH 8.3  
SDS 
350 ml 
0.1 % (w/v) 
Loading buffer (10 ml) 0.25M Tris/HCl, pH 8.8  
Glycerol  
SDS  
β-mercaptoethanol  
Bromophenol Blue Dye  
 
5 ml 
25 % (w/v) 
10 % (w/v) 
2.5 ml 
0.1 % (v/v) 
 
2.1.23. Buffer exchange 
Following the SDS-PAGE gel visualisation, the TALON + Imidazole fractions containing the required 
soluble protein were buffer-exchanged in small volumes using dialysis tubing with a molecular 
weight cut-off of 12kDa and a required buffer. Sodium Phosphate 20mM pH 7 buffer was routinely 
used in this study. The sample was loaded into the dialysis tubing, sealed with clips and submerged 
into 4 L of dialysis buffer. The sample was dialysed overnight at 4°C, with stirring, to allow for buffer 
exchange to take place. 
 
2.1.24. Concentration of proteins  
Proteins were concentrated using 2 mL of 20 mL Vivaspin (Sartorius) or Amicon Ultra (Merck) 
centrifugal concentrators with 5, 10, 30, 50 or 100 kDa molecular weight cut-off filters as required. 
Heraeus Megafuge 16R (Thermo Fisher Scientific) centrifuge with a swing-out rotor was used to 
concentrate the samples for 20-40min at 10 °C. 
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2.1.25. Size exclusion chromatography 
Proteins that required high purity, such as those used in crystallography, were further purified using 
a size exclusion chromatography. ÄKTA Pure liquid chromatography system (GE Healthcare) was 
used with a HiLoad 16/600 Superdex 200pg 120 ml gel filtration column (GE Healthcare). Prior the 
use, the gel filtration column was equilibrated in the required buffer (usually buffer A) 10mM Tris pH 
8 and B) 10mM Tris, NaCl 1M pH 8) and <5 ml of concentrated protein sample (not dialysed) was 
injected into the machine. The proteins were separated and purified through the column at a flow 
rate of 1.2 ml/min, typically eluting at 80-85 minute time point. 2 ml fractions were collected and 
analysed using the SDS-PAGE gels.  
 
2.1.26. Determination of protein concentration 
NanoDrop 2000 benchtop spectrophotometer (Thermo Fisher Scientific) was used to determine the 
protein concentration. The detector was blanked and 2 μl of purified protein sample was loaded. 
The absorbance at A280-320nm was measured and noted down. The protein concentration was 
calculated using the A = ɛClD equation, where A= absorbance, ɛ = molar extinction coefficient, C 
= molar concentration of the sample, l = length of light path in cm and D = dilution factor. The 
protein extinction coefficient was calculated using the amino acid sequence and the ProtParam 
bioinformatics tool. Alternatively, the NanoDrop 2000 has a function of calculating the concentration 
of a known protein solution in mg/ml when you enter the protein molecular weight (kDa) and 
extinction coefficient.  
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2.2. Bioinformatics tools 
2.2.1. Sequence alignments, homology and phylogenetic trees 
Basic Local Alignment Search Tool (BLAST) by NCBI (National Centre for Biotechnology Information) 
was used to search for amino acid sequences (Altschul et al., 1997), hosted by European 
Bioinformatics Institute (EBI) website (https://www.ebi.ac.uk/). 
Alternatively, KEGG: Kyoto Encyclopedia of Genes and Genomes was used to search for sequences of 
specific genes (http://www.kegg.jp/). 
Amino acid sequences were aligned using the Clustal Omega Multiple Sequence Alignment tool also 
found on EBI website (https://www.ebi.ac.uk/Tools/msa/clustalo/). 
Phylogenetic trees were constructed using the amino acid sequences obtained from Uniprot 
database and phylogeny.fr tool. Phylogeny.fr combines multiple bioinformatics tools, such as 
MUSCLE, CLustalW, T-Coffee, PhyML, TNT, TreeDyn and Drawtree, to construct a robust 
phylogenetic tree and analyse the relationships between a set of amino acid sequences. 
PULDB and Uniprot databases were used to identify homologous PULs in other Bacteroides spp. 
 
2.2.2. Prediction of protein parameters 
SignalP 4.1 bioinformatics tool was used to predict the presence of signal peptides in the amino acid 
sequences and the location of their cleavage site. The server is hosted by DTU Bioinformatics 
website (http://www.cbs.dtu.dk/services/SignalP/). 
ProtParam tool by ExPASy Bioinformatics Resource Portal was used to compute various physical and 
chemical parameters of the proteins based on their amino acid sequence. These parameters include 
the molecular weight and molar extinction coefficient (https://web.expasy.org/protparam/). 
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2.2.3. Genetic analysis tools 
Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to investigate potential loci and 
manually search the genes of interest (http://www.kegg.jp/). 
Carbohydrate-Active enZYmes Database (http://www.cazy.org/) was used to investigate predicted 
enzyme activities and compare them to structurally-related functional and catalytic domains already 
characterised and published.  
Simple Modular Architecture Research Tool (SMART) hosted by European Molecular Biology 
Laboratory (http://smart.embl-heidelberg.de/) was used to investigate the protein domain 
composition. 
The Integrated Microbial Genomes (IMG) website (https://img.jgi.doe.gov/) was used for analysis 
and comprehensive comparison of genes and their domains.  
 
2.3. Biochemistry 
2.3.1. Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry (ITC) was used to investigate and quantify the thermodynamic 
parameters of carbohydrate binding to proteins. MicroCalTM VP Isothermal Titration Calorimeter was 
used to quantify the binding and plot the titration curve along with the MicroCalTM Origin 7.0 
software to calculate the thermodynamic parameters – association constant (Ka), stoichiometry of 
reaction (n) and binding enthalpy (∆H).  
Proteins used for ITC were routinely dialysed in HEPES 50mM pH 7.5 buffer and carbohydrates 
(ligands) were dissolved in same buffer to avoid reading errors. Protein and ligand concentrations 
were adjusted and optimised for each reaction as required, usually 50 M of protein and 10-50mM 
of ligand. Titrations were performed at 307 rpm with 28 injections of 10 μl of ligand into the cell 
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containing the protein every 200 seconds at constant temperature of 25 °C. Protein-ligand binding 
results in either absorbance or release of heat (endothermic or exothermic reaction), the ITC 
machine measures it and plots a titration curve that is used to calculate the thermodynamic 
parameters using a non-linear regression model. Other parameters were calculated using: 
−𝑅𝑇 ln 𝐾𝑎 = 𝛥𝐺 =  𝛥𝐻 − 𝑇𝛥𝑆 
R = gas constant; ΔG = Gibbs energy change; ΔH = enthalpy change; T = absolute temperature in Kelvin; 
ΔS = entropy change 
 
2.3.2. Thin layer chromatography (TLC)  
Thin-layer chromatography (TLC) is a solvent-based chromatography technique used to separate and 
analyse non-volatile mixtures, such as glycans. Due to differences in charge, structure and solubility, 
different glycans migrate with the solvent up the silica-coated foil plate at different rates, allowing 
for separation. Typically, smaller sugars migrate faster than larger complexes.  
Routinely, a solution of 1-butanol/ acetic acid/ water at 2:1:1 ratio was used as a running 
buffer/solvent. It was poured into a glass chromatography tank, sealed shut and left to equilibrate 
for minimum 1 hour prior to use. A silica-coated foil plates (Silicagel 60, 20 cm x 20 cm, Sigma 
Aldrich) were used in this study. The plates were cut into required size with 1 cm gap from the 
bottom for the sample loading, and labelled appropriately using a soft pencil. Samples were loaded 1 
cm apart from each other, 3-9 µl of final volume per sample, along with the appropriate known 
sugar standards. The silica plates with loaded samples were put into the equilibrated running buffer 
and allowed to migrate for approximately 1 hour until solvent reached the top of the plate. For 
analysis of larger sugar mixtures, plates were taken out, dried and put back in for another hour to 
allow better separation of the glycans.  
To visualise the sugars, dried plates were stained with either Orcinol stain (sulphuric acid/ ethanol/ 
water 3:70:20 v/v, orcinol 1 %) or Diphenylamine-aniline-phosphoric acid stain (1.7% w/v 
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Diphenylamine, 1.7% v/v Aniline, 85% v/v Ethyl acetate, 2% Hydrochloric Acid and 11% Phosphoric 
acid). Plates were dried and developed by heating to 100 °C.  
 
2.3.3. High-performance Liquid Chromatography (HPAEC-PAD) 
High-performance liquid chromatography (HPAEC-PAD) was used to assess the activity of enzymes 
against various carbohydrate substrates. The enzyme reactions were set up in either dH2O or 20mM 
NaH2PO4 (pH 7) buffer containing 0.1-0.2% substrate and 1-2μM of enzyme in a final volume of 
200μL. All of the substrates were purchased commercially from Sigma-Aldrich, Dextra, Carbosynth 
and OligoTech. The reactions were incubated for 1h to 16h at 37 Cͦ. The samples were then boiled 
and centrifuged at 13 000 x rpm for 10 min. The supernatants were analysed by HPLC along with the 
known glycan standards to allow for identification.  
The Dionex DX500 ICS3000 system along with the the Dionex CARBOPACTM PA-100 HPLC column 
were routinely used in this study to investigate the degradation of N-glycans. The pulsed 
amperometric detection (PAD) was used to detect the sugars (with settings of E1 = +0.05, E2 = +0.6 
and E3 = -0.6). Figure 2.5 shows the HPLC program commonly used for N-Glycan separation in this 
study. 
 
Figure 2.5: Commonly used HPLC program and buffers. 
A) HPLC program. Buffer A. 100mM NaOH; B) 100mM NaOH, 1M sodium acetate; C) dH2O; D) 500mM NaOH. 
Sugars were eluted with an isocratic flow followed by a gradient of sodium acetate. Following the elution, 
column was washed with 100% of buffer D and equilibrated with 95% of buffer C and 5% of buffer A. B) 
Example of a sialic acid (Neu5Ac) standard elution. GraphPad Prism 7.0 was used to make this graph. 
 
A B 
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2.3.4. Microscale Thermophoresis (MST) 
Microscale Thermophoresis (MST) was used to investigate and quantify the bio-molecular 
interactions between the carbohydrate-binding modules of proteins and N-glycan substrates. The 
technique is based on thermophoresis – a movement of molecules induced by a variety of molecular 
properties, such as change in hydration shell, conformation, size or charge. It is highly sensitive 
technique that uses a temperature gradient induced by an infrared laser to detect and quantify the 
movement of fluorescently labelled molecules, thus allowing to measure the dissociation constants 
and determine thermodynamic parameters of protein-substrate interactions (Jerabek-Willemsen et 
al., 2011). 
In this study, microscale thermophoresis (MST) was done using Monolith NT.115 machine 
(NanoTemper) and Monolith NT.115 Standard Glass Capillaries. The proteins were purified using 
protocol described previously, dialysed in HEPES 50 mM pH 7.5 buffer for 4 hours at room 
temperature, concentrated using 30k cut-off concentrator, desalted using ZEBA desalting columns 
(Sigma Aldrich) and labelled using the Alexa Fluor 647 dye overnight at 4°C. Following the 
incubation, the labelled protein was centrifuged using a 5K cut-off concentrator at 3500 x rpm for 10 
minutes to remove unbound dye. To ensure the purity, the protein was desalted again using ZEBA 
desalting columns. The purity of labelled protein was assessed by measuring the ratio of protein/dye 
using a spectrophotometer. Protein absorbance was measured at 280nm and dye absorbance was 
measured at 650nm (Molar absorbance: 250,000 M-1 cm-1). Optimal ratio is 1:1. The concentration 
of labelled protein was determined, protein sample was split into 10 µL aliquots and flash-frozen at – 
80 °C until use. 
During the MST experiment, dilution series of 16-fold of unlabelled substrate (N-glycan, 6 mM stock) 
was prepared. The concentration of the fluorescently labelled of proteins was kept constant at 100 
nM. 10 µL of ligand was mixed with 10 µL of fluorescently-labelled protein and loaded onto the glass 
capillaries. The samples were then put onto a magnetic rack and loaded into the Monolith NT.115 
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machine. Depending on the fluorescence of the sample, 50-100% of LED power was used and 
fluorescence was measured. The collected data was then analysed using the MO Affinity Analysis 
software and plotted using GraphPad Prism 7.1 to calculate the dissociation constant Kd. Figure 2.6 
shows the principle behind the microscale thermophoresis (MST). 
 
 
Figure 2.6: A graphical representation of the principle behind the Microscale Thermophoresis 
(MST). A) A figure showing a typical thermophoretic curve. During the initial state, fluorescent dye is evenly 
distributed throughout the capillary. Once the laser is shot through the capillary, increase in the heat 
decreases the heat-sensitive fluorescence levels. During the thermophoresis, fluorescently-labelled molecules 
move out of the laser focal point due to gradient created by the heat and reaches the steady state. When the 
laser is turned off, heat-sensitive fluorescent molecules move back to the laser focal point and fluorescence 
increases. B) An example of thrombin-heptamer interaction. The graph displays unbound, intermediate and 
fully bound fluorescently-labelled thrombin molecules (left image). The unbound and fully bound baselines, 
including their concentrations, are used to calculate the affinity (right image). The figure was adapted from 
Monolith NT. 115 online instruction manual.  
A 
B 
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2.3.5. Enzymatic assays  
All enzyme assays, unless otherwise stated, were done using 1 µM of enzyme and 20 mM sodium 
phosphate pH 7 buffer, at 37 °C for 1 h to 16 h. The assays were usually repeated three times, to 
ensure the reproducibility of the result. The enzyme assay products were investigated using either 
TLC, HPLC (described previously) or mass spectrometry.  
For catalytic activity assays, 100 mM sodium phosphate pH 7.5 buffer was routinely used. Both the 
substrate mixture and enzyme were pre-warmed to 37 °C prior initiation of the reaction. The assays 
were also performed in technical triplicates. The enzyme assay results were plotted in GraphPad 
Prism 7.1 and used to calculate slopes or Michaelis-Menten kinetics model was used to estimate KM 
and calculate kcat using the formulas:  
                                                          V0 =  
Vmax [S]
Km+[S] 
       or      V0 =  
kcat 
Km 
× [𝑆] × [𝐸] 
V0= initial velocity; Vmax = rate of reaction when enzyme is saturated with substrate; Km= substrate 
concentration at which reaction rate is 1/Vmax; [S] = substrate concentration; kcat= number of substrate 
molecules catalysed per molecule of enzyme; [E] = enzyme concentration.  
 
 
 
 2.3.5.1. Colorimetric p-Nitrophenyl Phosphate (pNP) assays 
p-Nitrophenyl (pNP)-linked substrates were used to analyse and measure the activity of various 
glycoside hydrolases. Initially, pNP-linked substrates were dissolved in dH2O (to the final reaction 
concentration of 1mM) and mixed with the enzyme of interest (1 µM final concentration) and 
incubated at 37 Cͦ for 1hour. If the enzyme showed activity on the linked substrate, the colour of the 
reaction turned yellow. 
To measure the rate of the substrate hydrolysis, a final concentration of 0.1-1 mM of the substrate 
was dissolved in 20mM NaH2PO4 pH 7.5 buffer and dH2O. The reactions were set up in 600 μL quartz 
cuvettes and incubated at 37 fͦor 2-5 minutes. Various known concentrations of enzyme were added 
to the cuvettes and substrate release was monitored using Pharmacia Ultrospec 4000 
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spectrophotometer at 420 nm. The data was fitted into Michaelis-Menten kinetics model using 
GraphPad Prism 7.1 and enzyme kinetic parameters were calculated using method described above. 
p-Nitrophenol extinction coefficient is 18,000 M-1 cm-1. 
 
 2.3.5.2. Commercial monosaccharide release detection kits 
The commercially available kits by Megazyme were used to monitor the galactose or mannose 
release. D-Mannose/D-Fructose/D-Glucose kit and L-Arabinose/D-Galactose detection kits were 
used in this study. Both of these linked-assay kits utilise dehydrogenases to catalyse the oxidation of 
sugars and conversion of NAD+ into NADH in 1:1 molar ratio. The reactions were set up following the 
manufacturer’s protocol in 600 μL quartz cuvettes. 20mM NaH2PO4 pH 7.5 buffer was also used in 
these experiments. The reactions were monitored using Pharmacia Ultrospec 4000 
spectrophotometer at 340 nm, a wavelength NADH absorbs at. GraphPad Prism 7.1 and Michaelis-
Menten model were also used to calculate the enzyme kinetic parameters. NADH extinction 
coefficient is 6230 M-1 cm-1.  
 
2.3.5.3. Enzyme kinetics measurement using HPLC 
High-performance liquid chromatography (HPLC; HPAEC-PAD) was used to monitor enzyme catalytic 
activity on N-glycan substrates. Enzyme assays were set up in 20 mM sodium phosphate buffer, pH 
7.5 with 1 µM of final enzyme concentration and 10 mg/ml of final N-glycan concentration. These 
enzyme reactions were incubated at 37 °C for up to 16 h. 30 µl of reaction were taken at required 
time points (e.g. 0 min; 5 min; 10 min; 20 min; 40 min; 60 min and 16h), boiled and centrifuged at 
13,000 x rpm for 10 minutes before being loaded onto HPLC vials in 10-fold dilution in MiliQ water. 
Samples were analysed using the same method described previously (2.3.3). Data was collected 
using ChromeleonTM Chromatography Management System (Dionex) by measuring the peak 
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area*min. Known standards were used to determine which peaks correspond to which 
monosaccharides. To ensure the HPLC detection sensitivity remained constant, 0.05mM glucose 
standards were run in-between the samples and peak areas were measured.  
In some cases, known concentrations of required monosaccharides were also assayed on HPLC, peak 
areas were measured and the standard curve was plotted using the GraphPad Prism 7.1. This 
allowed to determine and calculate the concentration of monosaccharides released off N-glycans by 
enzymes tested.  
 
2.3.6. Acid Hydrolysis of Carbohydrates 
Acid hydrolysis of various N-glycans was done to determine their approximate composition. 
Required N-glycan was hydrolysed using 100 mM HCl at 100 °C for 1 h. Following the incubation, the 
sample was cooled down and neutralised by addition of NaOH. Samples were analysed using TLC and 
HPLC against known sugar standards. 
 
2.3.7. Preparation and purification of N-glycans 
Heavily N-glycosylated proteins, such as bovine serum fetuin and bovine serum alpha1-acid 
glycoprotein were used as sources for N-glycan purification. PNGaseF from Elizabethkingia 
meningoseptica (Sigma Aldrich) was used to cleave whole N-glycans off protein backbone. It acts by 
hydrolysing the bond between the reducing-end GlcNAc residue of an N-glycan structure and an 
asparagine residue of the protein backbone. 20mg/ml of N-glycoprotein was dissolved in 50mM 
NaH2PO4 pH7.5 buffer and 10U final concentration of PNGaseF was added. The reaction was 
incubated at 37 °C for 16h to ensure all of the N-glycan has been cleaved off. Sample was then run 
on SDS-PAGE (1:50 dilution) alongside with undigested N-glycoprotein to check deglycosylation was 
successful. The sample was then boiled to inactivate PNGaseF, centrifuged at 13,000 x rpm for 30 
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minutes and supernatant containing the N-glycans was collected. The supernatant was then further 
concentrated using 5K cut-off centrifugal concentrator at 3500 x rpm for 10 minutes to ensure no 
protein is left over. The N-glycan purity was checked on SDS-PAGE and TLC before the sample was 
freeze-dried using the Christ Alpha 1-2 Freeze Drier at -60 °C. N-glycans were then stored at -20 °C 
until required. 
Trypsin from porcine pancreas (Sigma Aldrich) was used to digest glycoproteins according to the 
manufacturer’s instructions.  
 
2.3.8. Mass spectrometry and HPLC analysis of procainamide-labelled N-Glycans (Ludger) 
Enzyme assays of 1 µM final concentration of required enzymes and 10mg/ml final of required N-
glycoprotein were set up in 20mM NaH2PO4 pH 7 buffer and incubated at 37 °C for 1 - 16 h, as 
required. The samples were then boiled for 10 minutes to inactivate the enzymes and labelled with 
fluorescent procainamide label (Ludger) according to the manufacturer’s protocol. 
 The samples were then sent to Paulina Urbanowicz who works for our industrial partner, Ludger 
Ltd., a glycotechnology company. Procainamide-labelled N-glycans were analysed using LC-ESI-MS 
(liquid chromatography - electrospray ionization- mass spectrometry), a highly-sensitive technique 
that combines physical separation capabilities of Ultra-High Performance Liquid Chromatography 
with the subsequent mass spectrometry analysis.  Mass spectrometry data analysis software 
COMPASS was used to analyse the data and determine the N-glycan structures present in the 
samples.  
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2.3.9. Western Blot 
Western blot was used to detect specific proteins in the B. thetaiotaomicron cell samples. Samples 
were run on SDS-PAGE gel, alongside of MagicMark XP Western Protein Standard (Thermo Fisher 
Scientific), using a protocol described previously. The proteins run out on the gel were then 
transferred onto Amersham Protran 0.45 Nitrocellulose membrane (GE Healthcare) using the Mini 
Trans-Blot system (Bio-Rad) and a chilled transfer buffer (Table 2.12). The blotting was done for 90 
minutes at 80 V, using a freezing block and a magnetic stirrer to keep the transfer buffer cool. 
Blocking buffer was prepared as listed in Table 2.12 and the membrane was blocked overnight at 4 
°C, with shaking. Primary Anti-Flag antibody (Custom made, Eurogentec) was then diluted 1:2000 in 
10 ml of antibody buffer and incubated with the membrane for 1 hour at room temperature, with 
shaking. The membrane was then washed three times with the wash buffer (Table 2.12). Secondary 
Anti-Flag Goat Anti-Rabbit-HRP antibody (SC-2004, Santa Cruz) was diluted 1:5000 in 10 ml of 
antibody buffer and incubated with the membrane for 1 hour at room temperature, with shaking. 
The membrane was washed three times again. 
The membrane was then developed using 3 mL of 1:1 mixture of chemi-luminescence Clarity 
Western ECL reagents (Bio-rad) and visualised using ChemiDoc XRS+ System (Bio-Rad). 
Table 2.12: Western blot buffers 
Buffer name Reagents Amount used Concentration 
Transfer Buffer 
(1 litre) 
Tris-HCl 
Glycine 
Methanol 
SDS 
dH2O 
3 g 
14.3 g 
300 ml  
0.5 g 
200 ml 
25 mM 
192 mM 
30 % 
1.7 mM 
- 
Blocking Buffer 
(10 ml) 
1 x PBS tablet (Oxoid) 
Milk powder 
Tween20 
10 ml 
0.5 g 
50 μl 
- 
5 % 
0.5 % 
Antibody Buffer 
(10 ml) 
1 x PBS (Oxoid) 
Milk powder 
10 ml 
0.5 g 
- 
5 % 
Wash Buffer 
(50 ml) 
1 x PBS (Oxoid) 
Tween20 
50 ml 
250 μl 
- 
0.5 % 
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2.3.9.1 Cellular Localization 
3 x 5 ml cultures of Bacteroides thetaiotaomicron were cultured in minimal media on 10 mg/ml of 
bovine serum alpha1-acid glycoprotein as a sole carbon source. The bacterial cultures were allowed 
to grow to mid-exponential growth phase (OD600nm of 0.6) and were harvested by centrifugation at 
3,500 x rpm for 5 minutes. The supernatant was discarded, the bacterial cells were washed twice in 
5 ml of Phosphate Buffered Saline (PBS) and re-suspended in 2 ml of the same buffer. The cell 
mixture was then split into four 0.5 ml fractions. 2 mg/ml of Proteinase K solution was added to 3 of 
these fractions and 1 was left undigested as a control. Proteinase K is a protease that digests all 
proteins that are present on a cell surface, leaving intracellular proteins intact. The samples were 
incubated at 37 °C for 16 hours, with shaking. After the incubation the samples were centrifuged at 
3,500 x rpm for 10 minutes and supernatant was discarded. The cell pellets were re-suspended in 0.5 
ml of PBS and Proteinase K was inactivated by the addition of 200 μl of trichloroacetic acid (TCA). 
The solution was incubated for 30 minutes on ice. After the incubation, the precipitated proteins 
were centrifuged at 3,500 x rpm for 10 minutes and washed four times in 1 ml of ice-cold acetone. 
Following the wash, the cell pellets were re-suspended in 0.5 ml of PBS buffer and ran on SDS-page 
gel. Western blot protocol, as described previously, was used to detect whether proteins of interest 
are located on a cell surface or inside of the cell. If the protein is located outside of the cell, 
Proteinase K treatment would have digested it and no protein band would be visible on the Western 
Blot.  
 
2.3.9.2 Protein expression levels 
Similar method as described above was to investigate the specific protein expression levels. 3 x 5 ml 
cultures of B. thetaiotaomicron were grown in minimal media on 1% of bovine serum alpha1-acid 
glycoprotein and 3 x 5 ml cultures were grown on 0.5% of glucose as sole carbon sources. The cells 
were grown to mid-exponential growth phase (OD600nm of 0.6) and harvested by centrifugation. The 
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cells were re-suspended in 1 ml of PBS and run on SDS-PAGE gel. Western blot was run using the 
protocol described previously. Protein expression levels were compared between the B. theta cells 
grown on glucose as sole carbon source to those on alpha1-acid glycoprotein, which is heavily N-
glycosylated. Thicker bands visualised by the Western Blot corresponded to higher expression levels. 
 
2.3.9.3. Determination of protein is secreted outside of the cell 
Same growth protocol as described in section 2.3.9.3 was used to grow the bacterial cells, but 
instead of discarding the growth supernatant, it was concentrated to the same volume as whole cells 
and run on SDS-PAGE gel alongside of the cell pellets. Western blot was done according to the 
protocol described previously. If the protein is secreted outside of the cell, bands corresponding to 
the protein of interest would be detected in the supernatant sample.  
 
2.3.10. Whole Cell Assays 
B. thetaiotaomicron was inoculated in 4 x 5 ml of minimal media containing 2% of α1-acid 
glycoprotein as a sole carbon source and grown to the mid-exponential growth phase. When the 
cells reached the OD600nm of approximately 0.6, they were gently harvested using centrifugation at 
3,500 x rpm for 5 minutes. The supernatant was collected and the cell pellet was washed in PBS.  
Whole cell assays were used to investigate the catalytic activity of enzymes and their cellular 
localization. B. thetaiotaomicron is an obligate anaerobe, thus in the presence of oxygen, cells retain 
structural integrity but are metabolically inactive. Whereas cell-surface proteins which are not ATP-
dependent, such as carbohydrate-active enzymes, remain functionally active and can be 
investigated.  
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The washed bacterial cells were re-suspended in PBS and split into four fractions. A fraction of whole 
cells was incubated with 2% of α1-acid glycoprotein in PBS in a ratio of 1:1. One fraction was left 
untreated, one was boiled for 10 minutes as a control and one fraction was sonicated. Supernatant 
was incubated with 2% of α1-acid glycoprotein. To stop these reactions, samples were centrifuged in 
order to remove the cells and the supernatant was boiled for 10 minutes. These samples were 
analysed using the thin-layer chromatography (TLC).   
 
2.3.11. Supernatant Analysis 
In order to investigate whether B. thetaiotaomicron can utilise all of the N-glycans present on the 
bovine serum α1-acid glycoprotein, the cells were grown in minimal media containing 1 % of α1-acid 
glycoprotein as a sole carbon source for 24 hours. The cells were then centrifuged at 3,500 x rpm for 
5 minutes and supernatant was collected. The supernatant was analysed by TLC and HPLC for traces 
of undigested N-glycans.  
 
2.4. Crystallography  
2.4.1. Protein crystallisation trial setup  
Soluble proteins for crystallography trials were purified using TALON IMAC columns, following 
protocol described in section 2.1.  Proteins were then concentrated using 30K cut-off concentrator 
at 3,500 rpm for 20-30 minutes and further purified using size exclusion chromatography (SEC) 
(section 2.1). SEC fractions were collected and analysed by SDS-PAGE before pooling fractions 
containing purest protein and concentrating to approximately 30 mg/ml. When required, protein 
was mixed with a substrate of choice for co-crystallisation. 
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 Initial protein crystallisation screens were set up using the sitting-drop vapour-diffusion method and 
MRC 96-well crystallisation plates (Molecular Dimensions). Pre-prepared crystallography screening 
plates were used. These included Index screen from Hampton Research and Structure, JCSG+, 
Morpheus and PACT screens from Molecular Dimensions. Mosquito Crystal Nanolitre dispensing 
robot (TTP Labtech) was used to set up crystal plates by dispensing 200 nl + 200 nl and 200 nl + 100 
nl of protein and crystal screen solution, respectively. Once plates were set up, they were sealed and 
incubated at 20 °C.  
 
2.4.2. Crystal screen optimisation 
The screen conditions that crystals formed in were optimised and set up using hanging-drop vapour 
diffusion method (Figure 2.7) and VDX 24-well hanging drop plates (Molecular Dimensions). 
Modified original screen conditions with varied precipitant and salt concentrations were set up using 
1 μl of protein + 1 μl of crystal screen solution along with 1 μl of protein + 2 μl of crystal screen 
solution. As before, the plates were sealed and incubated at 20 °C. 
 
 
 
Figure 2.7: Graphical representation of hanging-drop crystallisation plate set up.  
The well containing the crystallisation solution and a hanging-drop of protein + crystallisation solution mix was 
sealed using vacuum grease and a glass coverslip. Figure was adapted from Sarah Shapiro’s thesis. 
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2.4.3. Crystal structure solving and visualization 
With the assistance of Dr. Arnaud Beslé, the crystals were harvested using cryo-protected suitably 
sized loops (Hampton) and flash frozen in liquid nitrogen. In-house screening of crystal diffraction 
was done using Rigaku MSC microfocus generator and Raxis IV++ image plate detector. Most 
suitable crystals, chosen by their resolution and diffraction pattern were taken for data collection at 
Diamond Light Source (DLS, Didcot, Oxfordshire, UK). 
The structure of BT0459 (GH20-family enzyme) was solved using a molecular replacement by Dr. 
Arnaud Beslé.  
Protein structures were manipulated and visualised using WinCoot and PyMOL softwares. 
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Chapter 3: Complex N-Glycan metabolism by members of the 
human gut microbiota 
3.1. Introduction and motivation for the research 
 
The last two decades of human microbiome research has produced a tremendous amount of data 
that collectively reveals the significant impact the gut microbiota has on human metabolism, 
physiology and overall health (Sender et al., 2016). Previous studies have shown that B. 
thetaiotaomicron is one of the few endogenous gut microbes that is capable of growing on host-
derived mucins in the absence of dietary carbohydrate input. Mucins are heavily O-glycosylated 
proteins that provide structural and functional basis for the mucus layer (Martens et al., 2008). 
However, little interest has been focused towards the understanding of the underlying processes of 
dietary and host-derived N-glycan degradation by the gut microbiota. Glycosylation patterns of N-
glycoproteins are complex and diverse, thus would require an extensive metabolic machinery to fully 
degrade and utilize. The gut microbiota produces numerous enzymes that allow degradation of 
various carbohydrate structures, but little information is available on mechanisms gut microbes 
employ to degrade N-glycan structures found on various dietary and host-derived glycoconjugates. 
Understanding the precise mechanisms employed by gut microbiota to degrade these highly 
complex glycans is important for boosting our comprehension of how it benefits human health. 
3.2. Objectives 
 
i. To investigate the capacity of gut Bacteroidetes to utilise complex N-glycans 
ii. To investigate potential cooperation of multiple polysaccharide utilization loci (PULs) 
required for N-glycan degradation 
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3.3. Results 
3.3.1. Prominent members of gut microbiota can utilize N-glycans as sole carbon sources 
 
In a study done by Martens et al. (2009), a dominant member of human gut microbiota, B. 
thetaiotaomicron was shown to be capable of growing by utilising porcine gastric mucin III (PGMIII) 
as a sole carbon source, in vitro. PGMIII is a large, heavily O-glycosylated mucin present in the mucus 
layer of the gut. In this study, bacterial growth assays were set up to find out whether prominent 
members of human gut microbiota, including wild type Bacteroides thetaiotaomicron, are also 
capable of utilising heavily N-glycosylated proteins as sole carbon sources. α1-Acid Glycoprotein (α1-
AGP), one of the major plasma proteins found in mammals, was chosen as an N-glycan substrate. 
The bacteria were grown in minimal media+hematin containing either 2% of bovine α1-Acid 
Glycoprotein (α1-AGP) or 1% of N-Acetylglucosamine (GlcNAc) as sole carbon sources following 
protocols described in Sections 2.1.2 and 2.1.19. The growths assays were performed twice in 
triplicate to minimise the risk of any errors and contamination. These data show that several 
members of gut microbiota can utilise α1-Acid Glycoprotein (Figure 3.1). Compared to growth on N-
Acetylglucosamine, some bacteria displayed a longer lag phase while growing using α1-Acid 
Glycoprotein, suggesting they may not be specialised in N-glycan degradation. These include B. 
ovatus, B. nordii, B. salyeriae, B. fluxus, B. langum and B. uniformis. In comparison, some bacteria, 
such as B. cellulosilyticus, B. intestinalis and P. merdae, could not utilise α1-Acid Glycoprotein at all.  
Finally, this data allowed us to identify bacterial species that are capable of efficiently utilizing 
complex N-glycan structures found on α1-Acid Glycoprotein. These include wild type B. 
thetaiotaomicron, B. fragilis, B. massiliensis and B. uniformis. 
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Figure 3.1: Growth curves of gut Bacteroidetes on α1-Acid glycoprotein and GlcNAc. The bacterial 
growth assays on minimal media+hematin containing 2% bovine α1-Acid Glycoprotein (α1-AGP) and 1% N-
Acetylglucosamine (GlcNAc) were monitored by measuring the optical density at 600nm using an automated 
plate reader, anaerobically at 37 °C. The growth assays were initiated by inoculating the media+substrate with 
10µl of a required bacterium culture grown on 1% GlcNAc overnight, anaerobically at 37 °C. The bacterial 
growth assays were performed twice in triplicate and the mean data presented. The error bars indicate the 
standard deviation from the mean. 
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3.3.2. N-glycan utilization by B. thetaiotaomicron 
 
Wild type Bacteroides thetaiotaomicron, one of the prominent members of the human gut 
microbiota, was chosen as a model organism to study the N-glycan degradation by commensal gut 
microbes further because it is easy to cultivate and manipulate. In order to investigate whether B. 
thetaiotaomicron displays the same N-glycan utilisation pattern as was seen when it was grown on 
bovine α1-AGP (see Section 3.1.3.1), other commercially available heavily N-glycosylated proteins 
were acquired (Sigma Aldrich). These include bovine fetal serum fetuin and human blood transferrin. 
 Wild type B. thetaiotaomicron was grown in minimal media+hematin containing an appropriate 
concentration of N-glycoprotein substrate or 1% glucose as a control, in triplicates, following a 
protocol described in Section 2.1.2 (Figure 3.2). Glycosylation patterns of these N-glycoproteins are 
very different and may vary in every commercially-produced batch, therefore different N-
glycoprotein concentrations ranging from 0.5% to 4% were assayed to find optimal growth 
conditions. Transferrin was digested using trypsin, a protease found in the digestive system, in order 
to mimic the state of some dietary N-glycoproteins gut microbiota would see. Fetuin was treated 
with PNGaseF to cleave only the N-glycans off the protein backbone. PNGaseF is unable to cleave O-
glycans, so using this enzyme enabled us to investigate only the N-glycan utilisation by the 
bacterium. Only the N-glycan fraction was used for the growths. Growths were monitored 
automatically using an EpochTM Microplate Spectrophotometer, measuring optical density of the 
cultures at 600 nm every 15 minutes (see Section 2.1.19).  The results confirmed that B. 
thetaiotaomicron can efficiently utilise N-glycans. B. thetaiotaomicron displayed a tri-phasic growth 
pattern when grown on N-glycans derived from bovine fetal serum fetuin, suggesting that multiple 
polysaccharide utilization loci (PULs) may be activated during the utilization.   
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Figure 3.2: Comparing the growth curves of wild type B. thetaiotaomicron on selected N-
glycoproteins. The bacterium was cultured in minimal media containing either 1% glucose, 4% trypsin-
digested transferrin, 2% α1-Acid Glycoprotein or 2% PNGaseF-derived N-glycans from Fetuin. Growth data for 
each condition was measured using an automated plate reader. The bacterial growth measurements were 
performed in triplicate. The error bars indicate the standard deviation from the mean.  
 
 
B. thetaiotaomicron can utilise all N-glycan sources relatively well compared to the glucose control. 
Although it grows to a lower optical density on N-glycans compared to the glucose, it should be 
pointed out that N-glycans can have very complex structures that could require the activity of 
multiple binding proteins and degrading enzymes to fully degrade and utilize, thus N-Glycans are 
much more metabolically taxing to utilize than simple sugars such as glucose.  
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The α1-AGP was chosen as a model N-glycoprotein substrate to further investigate the N-glycan 
degradation due to its commercial availability and high bi-antennary N-glycan structure content. 
In order to investigate whether wild type B. thetaiotaomicron is utilising the N-glycans as a sole 
carbon source and does not require to degrade the protein fraction to sustain growth, larger-scale 
growth assays were set up. B. thetaiotaomicron was grown in minimal media+hematin containing 
2% of native bovine α1-AGP, 1 % glucose as control and 2% of PNGaseF-digested protein-only 
fraction of bovine α1-AGP (see Section 2.1.2). Optical density at 600 nm was measured every hour 
and a sample of the culture was collected. The samples were assayed using SDS-PAGE gel to visualise 
protein de-glycosylation and thin-layer chromatography (TLC) to visualise the N-glycan degradation 
products. A separate PNGaseF-digestion assay was set up to confirm that the fully N-glycosylated 
bovine α1-AGP is 41-44 kDa in size whereas fully de-glycosylated bovine α1-AGP is 23 kDa in size 
(data not shown, see Section 2.3.7). The growth results show B. thetaiotaomicron is utilising N-
glycans without digesting the protein fraction (Figure 3.3). De-glycosylation of the bovine α1-AGP 
was initially observed on the SDS-PAGE gel (Figure 3.3-B). A change in size from fully N-glycosylated 
~41 kDa protein to fully de-glycosylated ~23 kDa protein band was noted, suggesting it was not due 
to proteolytic activity. The observed degradation of the glycoprotein and the appearance of 
differently-sized bands could be representative of variably N-glycosylated protein. No growth was 
observed in protein-only fraction, confirming that B. thetaiotaomicron is utilising only the N-glycan 
fraction of α1-AGP for the growth. N-glycan degradation was further observed on the TLC plate 
where based on the appearance of the sialic acid band, the N-glycan degradation was observed over 
time (Figure 3.3-C). B. thetaiotaomicron releases free sialic acid, but does not possess Nan operon 
required to process it, presumably in order to access the carbohydrate structures that the sialic acids 
cap (Juge et al., 2016).  
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Figure 3.3: Investigating the N-Glycan degradation by the wild type Bacteroides thetaiotaomicron. 
A) Wild type B. thetaiotaomicron was cultured in minimal media+hematin containing 2% bovine α1-Acid 
Glycoprotein, 2% bovine α1-Acid Glycoprotein protein-only fraction or 1% Glucose as a control. Bacteria cultures 
were incubated for 24 hours, samples were collected and optical density (600 nm) was measured every hour. B) 
α1-Acid Glycoprotein de-glycosylation was investigated using SDS-PAGE gel. Full-size bovine α1-Acid Glycoprotein 
is 41-43kDa in size and is labelled with an asterisk (*). A band of ~23 kDa represents a fully de-glycosylated bovine 
α1-Acid Glycoprotein (labelled ⱡ). C) α1-Acid Glycoprotein N-glycan degradation was visualised using a thin-layer 
chromatography (TLC). Gradual degradation of N-Glycans and sialic acid release was observed. 1mM of sialic 
acid (Neu5Ac) standard was used to identify the band. The band of a predicted de-sialylated N-glycan structure 
is labelled. 
 
A 
B 
C 
* 
ⱡ 
 85 
 
To investigate the α1-AGP degradation by B. thetaiotaomicron further, the composition of the 
glycans in the spent media was analysed using High-Performance Liquid Chromatography (HPAEC-
PAD) (see Section 2.3.3). The supernatants of the wild type B. thetaiotaomicron growth on MM-α1-
AGP (2% w/v) were collected at mid-exponential (after 8 h) and stationary (after 24 h) phases. The 
peak corresponding to the sialic acid (Neu5Ac) was identified by running a Neu5Ac standard 
alongside of these samples. Based on the appearance of various new peaks compared to the control 
MM+α1AGP sample, the results suggest that B. thetaiotaomicron is utilising N-glycans found on 
bovine α1-Acid Glycoprotein, leaving the sialic acid untouched (Figure 3.4). The precise N-glycan 
structures present in these samples could not be identified using this technique. 
 
Figure 3.4: High-Performance Liquid Chromatography showing the deglycosylation of bovine α1-
Acid Glycoprotein by the wild type Bacteroides thetaiotaomicron. Control is a sample of MM+AAG 
collected before inoculation. Mid-exponential and after-growth samples show glycans present in the media 
during growth, products of surface degradation or secretion. Labelled peaks are suspected N-glycan structures. 
1:10 dilutions of the samples were loaded. 1mM of sialic acid (Neu5Ac) standard was used.  
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3.3.3. RNA-seq data identifies genes upregulated by B. thetaiotaomicron in response to 
N-glycans 
 
RNA seq was used to investigate genes upregulated during the growth of the wild type B. 
thetaiotaomicron on various N-glycoproteins as sole carbon sources compared to the glucose 
control. N-glycans present on the hen egg N-glycopeptide (Ludger) have been analysed and were 
found to contain only the complex sialylated bi-antennary N-glycan structures whereas bovine fetuin 
is decorated by a wide range of complex sialylated N-glycan structures (Aich et al., 2013). N-glycan 
structures present on bovine α1-Acid Glycoprotein were identified using mass spectrometry and 
contain mainly complex sialylated biantennary N-glycan structures. The graphical representation of 
these structures is displayed in Figure 3.5. Mass spectrometry data will be discussed in more detail 
in Section 3.1.3.6. 
 
Figure 3.5: N-glycan structures found on glycoproteins used for RNAseq. Bovine α1-Acid Glycoprotein 
and N-glycopeptide derived from hen egg contain mainly bi-antennary complex N-glycan structures whereas 
bovine fetuin has mixture of complex N-glycans. Examples of bi-antennary and tri-antennary sialylated 
complex N-glycan structures found on bovine fetuin are displayed. Figure was made using the information 
obtained from mass spectrometry analysis, Ludger Ltd. and Aich et al., 2013. 
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Wild type B. thetaiotaomicron was inoculated in minimal media+hematin containing either 1 % 
glucose, 2% of trypsin-digested bovine α1-AGP, 2% of N-glycopeptide derived from the hen egg 
(Ludger) or 2% of N-glycans derived from bovine Fetuin prepared following the protocol described in 
Section 2.3.7. Cultures were grown to mid-exponential phase (~OD600nm 0.6), the cells were 
harvested and RNA was extracted using QIAGEN RNeasy kit following a protocol described in Section 
2.1.15. The RNA was sequenced by the Earlham Institute using the Illumina HiSeq4000 system. 
Unfortunately, when the results came back and were analysed, we found a significant Serratia 
species contamination present in glucose and N-glycans (Fetuin) samples. It was decided to repeat 
the RNA sequencing using the RNA derived from the wild type B. thetaiotaomicron grown on 2% 
bovine α1-AGP and 1 % glucose as control. The extracted RNA was instead sent to Oxford Genomics 
Centre, who offered a better quote and completion time-scale. To be consistent, the RNA was also 
sequenced using the Illumina HiSeq4000 system.  
The RNA sequencing data analysis was done with the help of John Casement (Bioinformatics Support 
Unit, NU). Briefly, reads were aligned against the Bacteroides thetaiotaomicron VPI-5482 genome 
using the bioinformatics tool Bowtie2. Genome annotation was obtained from the Ensembl 
database. Counts of reads aligning to the genomic features were obtained and differential 
expression analysis was done using R package DESeq2. The Benjamini-Hochberg p-values were 
obtained and adjusted using the same R package. The analysed RNA seq data is listed in 
Supplemental Table 3.1. The analysis of the results from both sequencing batches showed that 
Serratia spp. contamination present in the first batch did not show any significant influence over the 
gene upregulation, however for the purpose of clarity, contamination-free RNA sequencing data 
would be used for the publication.  
RNA sequencing data analysis results were initially visualised using a Venn diagram. Venn diagram 
enabled identification of 66 common genes upregulated in B. thetaiotaomicron when it was grown 
on hen egg N-glycopeptide, bovine fetuin N-glycans and bovine α1-AGP compared to the glucose 
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control (Figure 3.6). Only the genes upregulated 2-fold or higher with the Benjamini-Hochberg 
adjusted p-values being less than 0.01 are classed as significant and thus, only these were included 
in the Venn diagram (Supplemental Table 3.1). Differences in upregulation patterns may be due to 
different N-glycan structures present on these N-glycoproteins.  
Figure 3.6: Venn diagram showing the upregulation of genes by B. thetaiotaomicron in response to 
N-glycoproteins. 66 common genes were found to be upregulated in all three conditions. 22 common genes 
were upregulated when B. thetaiotaomicron was grown on N-glycopeptide (hen egg) and N-glycans (fetuin). 23 
common genes were upregulated when it was grown on N-glycans (hen egg) and α1-Acid Glycoprotein. 68 
common genes were upregulated when B. thetaiotaomicron was grown on α1-Acid Glycoprotein and N-glycans 
(Fetuin). Venn diagram was done using a ‘VennDiagram’ R package and only includes genes upregulated 2-fold 
or higher, with p-values less than 0.01. 
 
The genes upregulated when B. thetaiotaomicron was grown on α1-Acid Glycoprotein were chosen 
for initial investigation because these samples contained no Serratia spp. contamination. The genes 
encoding CAZYmes and predicted glycan binding/import proteins were manually identified 
(Supplemental Table 3.1). The gene list was expanded to include genes upregulated less than 2-fold 
that were in the same gene clusters (predicted PULs) as the highly upregulated genes. The heatmap 
of the gene upregulation was made using the GraphPad Prism 7.0 software (Figure 3.7.1). The key 
gene clusters (predicted PULs) that are upregulated by N-glycans were identified. These include 
BT0455-0461, BT0506-0507, BT1032-1052 and BT4404-4407. 
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Figure 3.7.1: RNA sequencing data identifying the apparatus B. thetaiotaomicron uses to utilise the 
N-glycans present on bovine α1-Acid Glycoprotein. The white/red heatmap shows gene expression at the 
basal level whereas the green/red heatmap shows the fold change in gene upregulation compared to the 
glucose. The data identified key gene clusters that are upregulated by α1-Acid Glycoprotein N-glycans: BT0455-
0461, BT0506-0507, BT1032-1052 and BT04404-4407. Error bars and statistical information can be found in 
Supplemental table 3.1. 
 
 
 
BT0455-0461 
BT4404-4407 
BT0506-0507 
BT1032-1051 
IDENTIFIED GENE CLUSTERS 
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The genetic composition of BT0455-0461, BT0506-0507, BT1032-1052 and BT4407-4407 loci is 
displayed in Figure 3.7.2.  BT0455-0461 locus encodes a GH33 sialidase BT0455, three GH20 β-
hexosaminidases BT0456, BT0459, BT0460, putative esterase BT0457, GH2 mannosidase BT0458 and 
GH2 galactosidase BT0461. BT0506-0507 locus encodes predicted a GH20 β-hexosaminidase BT0506 
and a regulator BT0507. BT4404-4407 locus encodes SusC/D/E and a GH18-family enzyme. BT1032-
1052 locus encodes three predicted GH18-family enzymes, three SusC/D/E pairs, two surface glycan 
binding proteins (SGBPs), GH130 mannosyl phosphorylase, GH20 β-hexosaminidase BT1052 and a 
GH92 α-mannosidase BT1032 that was previously shown to be involved in high-mannose N-glycan 
degradation (Dr. Fiona Cuskin, unpublished data). The characterization of the enzymes encoded by 
BT0455-0461 and BT0506-0507 loci will be the main focus of this thesis. The BT1032-1051 and 
BT4404-4407 systems were explored by Dr. Lucy Crouch and will not be described in detail in this 
thesis. 
 
Figure 3.7.2: Genetic composition of the key PULs required for N-glycan utilisation by B. 
thetaiotaomicron. The composition BT0455-0461, BT0506-0507, BT1032-1052 loci is displayed. The 
information acquired from the Uniprot and Kyoto Encyclopedia of Genes and Genomes (Kegg) was used to 
make this figure. 
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To further investigate the upregulation of B.theta0455-0461 cluster of genes, a heatmap of gene 
expression levels induced by bovine α1-AGP, hen egg N-glycopeptide and bovine fetuin N-glycans 
was made (Figure 3.8).  
 
Figure 3.8: A heatmap showing basal gene expression levels of B.theta0455-0461 locus. The heatmap 
was made plotting basal gene expression counts, averaged from triplicates. Error bars and further statistical 
information can be found in Supplemental table 3.1.  
 
 
These data suggest that the genes from the B.theta0455-0461 locus are highly expressed at the basal 
level. Very high basal expression and upregulation levels of BT0459GH20 were observed. Combined, 
these data indicate that this locus is important for B. thetaiotaomicron utilisation of N-glycans. 
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3.3.4. Analysis of gene expression levels by quantitative RT-PCR 
 
To validate upregulation of the genes identified by the RNA seq data analysis when wild type B. 
thetaiotaomicron was grown on various N-glycoproteins, quantitative RT-PCR (qPCR) analysis was 
carried out. Messenger RNA derived from the wild type B. thetaiotaomicron grown on various N-
glycoproteins and glucose as sole carbon sources was converted to cDNA following a protocol 
described in Section 2.1.16. The qPCR primers, based on the genes of interest, were designed using a 
GenScript tool (Supplemental table 3.2).  
q-PCR was set up following a protocol described in Section 2.1.17 using the primers for B.theta0455-
0461 genes and B.theta1032-1051 genes, PUL that contains an endo-β-N-acetylglucosaminidase 
BT1044GH18 required to cleave the N-glycan structures off the protein backbone (Dr. Lucy Crouch, 
unpublished data).  The results suggest that B. thetaiotaomicron begins N-glycan degradation by 
upregulating B.theta1032-1051 PUL, specifically BT1044GH18 encoding the enzyme that cleaves the core 
N-glycan chitobiose (GlcNAc-β1,4-GlcNAc-Asn) bond, releasing the N-glycan structures from the 
protein backbone (Figure 3.9). This gene is very highly upregulated in mid-exponential phase. 
Because the fetuin N-glycan structures were already cleaved off the protein backbone by the 
PNGaseF, neither BT1044GH18 not any other genes from this locus were upregulated. On the other 
hand, B.theta0455-0461 genes are upregulated at much lower rate, however considering the RNA seq 
data analysis results that show high basal expression levels of these genes, the data seems to be 
consistent. BT0459GH20 is the highest upregulated gene of this locus, suggesting its importance for N-
glycan degradation. It is important to note that the upregulation differences observed in BT0455, 
BT459 and BT0461 compared to the rest of the screened genes could be due to the presence of 
gene-specific regulatory factors or due to the mRNA stability/mRNA decay. 
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Figure 3.9: qPCR analysis of genes encoding CAZYmes upregulated during growth of B. 
thetaiotaomicron on N-glycans. Wild type Bt cells were grown on each of the substrates to the mid-
exponential phase (OD 0.4-0.6) and harvested. RNA was extracted and quality-checked before converting it 
into the cDNA. N-glycans used in this experiment include native α1-AGP, trypsinised α1-AGP, PNGase-F-cleaved 
bovine fetuin N-glycans and hen egg N-glycopeptide. Upregulation levels are shown as fold-change relative to 
MM-Glucose. Data for each gene and growth condition was obtained in triplicates, twice. The error bars 
indicate the standard deviation.  
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3.4. Discussion 
The ability to metabolise a diverse range of extremely complex glycan structures present in the 
human gut by numerous members of Bacteroidetes, including B. thetaiotaomicron, has been linked 
to the huge repertoire of enzymes, each specialised in degrading specific glycan structures (Ndeh et 
al., 2018). This ability to metabolise highly complex glycan structures was observed in this chapter 
when several prominent members of the human gut microbiota were screened for their ability to 
utilise complex N-glycans as a sole carbon source. The capacity to efficiently metabolise the complex 
biantennary N-glycan structures present on the bovine α1-Acid Glycoprotein was observed in wild 
type B. thetaiotaomicron, B. fragilis, B. massiliensis and B. uniformis (Figure 3.1). This is surprising 
considering the availability of N-glycan sources in the human gut in a form of dietary and host-
derived N-glycoconjugates is relatively high (Tailford et al., 2015). The ability to efficiently utilize 
host-derived N-glycans could be a metabolically taxing but a favourable trait in the gut that gives 
these microbes a metabolic advantage in times of starvation. 
 A more thorough investigation has revealed that a prominent member of a human gut microbiota, 
B. thetaiotaomicron, is capable of utilizing a diverse range of N-glycan structures decorating various 
N-glycoproteins, such as transferrin, fetuin and α1-AGP (Figure 3.2). Although N-glycan degradation 
appears to be metabolically taxing, it was observed that this microbe only utilizes the N-glycan 
fraction of the bovine α1-AGP and does not require the protein fraction for the growth (Figure 3.3). 
Considering how complex N-glycan structures can be (e.g. biantennary, triantennary, tetraantennary 
and bisecting), these results indicated that Bt must possess an extensive repertoire of specialised 
enzymes capable of accommodating and degrading such highly complex glycan structures. 
Transcriptomic data analysis helped to identify this complex N-glycan utilization apparatus of Bt 
(Figure 3.7.1). Based on the high gene upregulation data, the key enzymes were identified to belong 
to the BT0455-0461, BT0506-0507, BT1032-1051 and BT4404-4407 loci (Figure 3.7.2). A further 
analysis of the upregulation data identified seven enzymes encoded by the B.theta0455-0461 and 
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BT0506-BT0507 loci that were upregulated when the wild type Bt was grown on three different 
sources of N-glycans, suggesting their importance for the complex N-glycan degradation by this 
bacterium (Figure 3.8). Based on the information obtained from CAZy database, the upregulated 
genes encode the sialidase BT0455GH33, four β-hexosaminidases BT0456GH20, BT0459GH20, BT0460GH20 
and BT0506GH20, β-mannosidase BT0458GH2 and β-galactosidase BT0461GH2. The observed very high 
basal expression levels of these genes indicates their importance to the N-glycan metabolism and 
proliferation of Bt in the mucus layer of the gut. Interestingly, the systemic analysis of the gut 
metatranscriptome and gut metagenome studies identified a significant number of microbial 
transcripts (41%) was not differentially upregulated in comparison to their genomic abundance. A 
huge number of gene families were found to be consistently upregulated at a low fold at the 
transcriptional level but highly abundant metagenomically (Franzosa et al., 2014). These findings 
could explain such a low upregulation fold displayed by some of the key genes in the RNA seq data. 
qPCR analysis validated the RNA-seq data analysis results. The high-upregulation levels of genes 
from BT0455-0461 locus and key genes of BT1032-1051 were consistent with the RNA-seq data and 
indicated their importance for the complex N-glycan metabolism by Bt. The significant change 
observed in the upregulation data of BT0455 could be explained by the abundance and importance 
of the sialic acid utilization by the human gut microbiota in vivo. The data also suggested that the N-
glycan degradation by Bt may be initiated by a predicted endo-glycosidase BT1044GH18 enzyme that 
could release the N-glycan structures off the protein backbone. However, full characterisation is 
required to confirm this hypothesis. 
Combined, these data suggested that the complex N-glycan utilisation is a metabolically taxing and a 
niche trait present only in dominant members of Bacteroidetes. In B.t, complex N-glycan 
degradation appears to depend on a cooperative activity of numerous enzymes encoded by four 
discrete loci. However, in order to fully understand this pathway, the full biochemical 
characterisation of the key enzymes is required. 
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Chapter 4: Characterization of the key members of N-glycan 
utilization apparatus in B. thetaiotaomicron 
4.1. Introduction and motivation for the research 
Bacteroides thetaiotaomicron, a Gram-negative symbiotic commensal gut microbe, is capable of 
utilizing a variety of dietary and host-derived glycans as sole carbon and energy sources. In order to 
degrade complex glycan structures, B. thetaiotaomicron encodes a range of enzymes that are known 
as carbohydrate-active enzymes (CAZymes) (www.cazy.org). These include glycoside hydrolases 
(GHs), polysaccharide lyases (PLs), glycosyl transferases (GLs) and carbohydrate esterases (CEs). 
As discussed in Chapter 3, BT0455-0461 and BT0506-0507 loci are upregulated when B. 
thetaiotaomicron is grown on N-glycoproteins as sole carbon sources, compared to the glucose 
control. Interestingly, BT0455-0461 does not fit classical PUL model due to the lack of SusC/D pair, 
SGBP and a regulator. Numerous CAZymes are encoded by these loci, including a sialidase 
BT0455GH33, galactosidase BT0461GH2, four hexosaminidases BT0456GH20, BT0459GH20, BT0460GH20 and 
BT0506GH20, esterase BT0457CE and a mannosidase BT0458GH2 (Figure 4.1). 
 
Figure 4.1: Overview of enzymes encoded by the BT0455-0461 and BT0506-0507 loci. The collective 
information obtained from KEGG, IMG and Uniprot databases was used to make this figure (see Section 2.2). 
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In theory, combined cooperative activity of these enzymes would enable degradation of a typical N-
glycan structure. In nature, complex N-glycans structures are commonly heavily sialylated and would 
require an activity of a sialidase to degrade. Sialidases are a huge group of specialised enzymes 
produced by both prokaryotes and eukaryotes that catalyse the cleavage of glycosidic linkages of 
terminal sialic acid caps of complex carbohydrates found on glycoconjugates (Park et al., 2013). The 
majority of bacterial sialidases are grouped together based on the similarities between their amino 
acid sequences and are classified into the glycoside hydrolase (GH) family 33 (GH33) of the CAZy 
classification. The only sialidase produced by B. thetaiotaomicron, BT0455GH33, was upregulated 
when it was grown on N-glycans indicating it is necessary for the degradation of these structures.   
Acetylation of sialic acids, such as Neu9Ac, can hinder the activity of the sialidases. Thus, the de-
acetylation of O- and N-linked acetylated glycan structures by carbohydrate esterases is a common 
occurrence in nature. Currently characterized carbohydrate esterases are grouped into 16 CAZy 
families. These include sialate-O-acetylesterases that are a broad-acting group of esterases that are 
classified into the SGNH superfamily of hydrolases, a distinct class of α/β hydrolases (Rangarajan et 
al, 2011). BT0457CE is a putative sialic acid esterase that is potentially required to boost the catalytic 
efficiency of the sialidase BT0455GH33. 
Desialylation of a typical complex N-glycan structure would expose galactose linkages that would 
require an activity of a galactosidase, such as a predicted β-galactosidase BT0461GH2, to cleave. 
Enzymes with β-galactosidase activity are grouped into the glycoside hydrolase A (GH-A) superfamily 
of glycoside hydrolases that is further subdivided into the GH1, GH2, GH35 and GH42 subfamilies 
(Talens-Perales et al., 2016). β-galactosidases were shown to catalyse the hydrolysis of terminal, 
non-reducing D-galactosyl bonds found on various glycan structures, through disaccharides to 
oligosaccharides, including O- and N-glycans (Panesar et al., 2010). 
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Removal of caps from a typical complex N-glycan structure would reveal numerous GlcNAc linkages 
that would require several specialised β-hexosaminidases to remove. Four predicted β-
hexosaminidases, BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20, were upregulated when B. 
thetaiotaomicron was grown on N-glycoproteins. The enzymes classified into the glycoside hydrolase 
(GH) family number 20 (GH20) of CAZy classification are a large group of specialised enzymes that 
are found in both eukaryotes and prokaryotes. The group is mainly comprised of exo-acting β-
hexosaminidases such as β-N-acetylglucosaminidases and β-N-acetylgalactosamindases that cleave 
D-GlcNAc and D-GalNAc monosaccharides from the terminal ends of carbohydrates, respectively. 
Members of the GH20 family of enzymes are involved in various important biological processes, 
catalysing the hydrolysis of the D-GlcNAc/D-GalNAc linkages in glycoconjugates and 
glycosaminoglycans (Val-Cid et al., 2015). 
Once various GlcNAc linkages are removed from the typical complex N-glycan structure, an N-glycan 
core tetrassacharide (Man-α1,6(Man-α1,3)Man-β1,4-GlcNAc-) is exposed. Degradation of this 
structure would require a cooperative activity of several specialised mannosidases, such as a β1,4-
mannosidase BT0458GH2 that was upregulated when Bt is grown on complex N-glycans. 
Mannosidases are a large group of enzymes that are specialised in catalysing the hydrolysis of the 
glycosidic mannose linkages found in complex carbohydrates. They are grouped into α-
mannosidases and β-mannosidases. Majority of β-mannosidases are classified into the glycoside 
hydrolase (GH) family number 2 (GH2) of the CAZy classification, along with β-galactosidases and β-
glucuronidases. To date, it is known that B. thetaiotaomicron produces 33 GH2-family enzymes, 5 of 
which are annotated as β-mannosidases.  Like the rest of GH2 family of enzymes, β-mannosidases 
are retaining enzymes that follow a double-displacement Koshland mechanism (CAZypedia.org, GH2 
family).  
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However, it is important to characterise these enzymes to determine their substrate specificities 
that would allow us to fully understand how these enzymes are employed by B. thetaiotaomicron to 
degrade complex N-glycan. 
 
4.2. Research objectives 
i. To functionally characterize enzymes involved in N-glycan degradation 
 
ii. To investigate potential cooperation of multiple polysaccharide utilization loci (PULs) 
required for N-glycan degradation 
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4.3. Results 
4.3.1. Protein cloning, expression and purification 
Genes encoding the BT0455GH33, BT0456GH20, BT0457CE, BT0458GH2, BT0459GH20, BT0460GH20 and 
BT0461GH2 have been amplified and cloned into pET28a derivative E.coli prokaryotic expression 
vector by the Nzytech. BT0506GH20 was cloned into pET28a plasmid following a protocol described in 
Sections 2.1.11-13. In both cases, the encoded soluble recombinant proteins contained an N-
terminal His-tag sequence for easy purification (MGSSHHHHHHSSGPQQGLR). Chemically competent 
E.coli Tuner cells were routinely used for the recombinant protein expression following a protocol 
described in Section 2.1.20. Protein overexpression was induced using 1 mM of IPTG and overnight 
incubation at 16 °C. Cells were harvested by centrifugation and supernatant containing the soluble 
recombinant protein was collected. Purification of N-terminal His-tagged recombinant proteins was 
done using an immobilised metal affinity chromatography (IMAC) following a protocol described in 
Section 2.1.21. The purified protein concentration was determined by measuring the absorbance at 
280 nm (A280nm) and calculating it using the molecular weight and extinction coefficient (see 
Section 2.1.26). Collected purified protein fractions were analysed by SDS-PAGE (Figure 4.2). Elution 
fractions containing the protein were combined and dialysed against the buffer using 12kDa cut-off 
membrane tube (see Section 2.1.23). Dialysed proteins were concentrated and used for enzyme 
assays. The theoretical molecular weights of the recombinant proteins are displayed in Figure 4.2. 
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Figure 4.2: SDS-PAGE gel showing the fractions of purified BT0455-0461 and BT0506 proteins.  
12.5% polyacrylamide gel was used for the SDS-PAGE analysis. Mw is a wide-range molecular marker (Sigma 
Aldrich). FT is a supernatant flow-through. W is fraction collected following a wash with Talon buffer. Lane 1 
and 2 show protein fractions eluted using 10 mM imidazole whereas lane 3 and 4 show protein fractions 
eluted using 100 mM imidazole. The theoretical molecular weight of the proteins is displayed in kDa.  
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4.3.2. BT0455: Characterisation of the sialidase 
4.3.2.1. Introduction 
Sialic acid is usually found on the terminating branches of complex carbohydrates decorating 
mucins, O-glycoproteins and N-glycoproteins (Juge et al., 2016). On N-glycoproteins, terminal sialic 
acid residues usually form α2-3/6 glycosidic linkages. B. thetaiotaomicron, a dominant member of 
human GI tract, possesses a single sialidase - BT0455. Because BT0455GH33, also referred to as BTSA, 
is the only sialidase found in B. thetaiotaomicron to-date, the basic substrate specificity and 
structure of it has already been determined (Park et al., 2013). It is a hydrolytic sialidase that has a 
wide substrate specificity and can cleave α2-3, α2-6 and α2-8-linked terminal sialic acid linkages of 
tested substrates such as pNP-Neu5Ac, 3’-sialyllactose, 6’-sialyllactose and colominic acid. As 
mentioned previously, B. thetaiotaomicron can release free sialic acid but it lacks the operon to 
utilize it. Perhaps it removes the sialic acid caps in order to access the underlying carbohydrate 
structures. Interestingly, BT0455GH33 was shown to be upregulated when B. thetaiotaomicron was 
grown on porcine gastric mucin (PGMIII) (Martens et al., 2008). BT0455GH33 was also shown to be a 
key enzyme required for sialic acid release in vivo in a mouse gut model (Bjursell et al., 2006; Ng et 
al., 2013) 
As was previously shown in Chapter 3 (Figure 3.7.1), BT0455GH33 is upregulated when B. 
thetaiotaomicron is grown on N-glycoproteins as sole carbon sources, compared to the glucose 
control. Although it is the only sialidase encoded by the B. thetaiotaomicron, the knowledge of its 
activity against N-glycans is lacking. Thus, the aim of this chapter was to investigate the ability of 
BT0455GH33 to target and catalyse the cleavage of terminal sialic acids capping N-glycoproteins. 
 
4.3.2.2. Sequence comparison of BT0455GH33 to other characterised sialidases 
In order to investigate the sequence similarities and differences between BT0455GH33 and other 
structurally and biochemically characterized GH33 sialidases listed on CAZy database, a phylogenetic 
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tree was constructed using the amino acid sequences obtained from Uniprot database and 
phylogeny.fr tool (Figure 4.3). 
 
Figure 4.3: Phylogenetic tree of characterized CAZy GH33-family sialidases. Sialidases from these 
species are included in the tree: B. thetaiotaomicron, B. fragilis, B. longum, C. canimorsus, C. perfringens, A. 
viscosus, C. septicum, C. diphteriae, F. tularensis, H. pylori, L. pneumophilia, M. viridifaciens, P. sordellii, P. 
gingivalis, R. gnavus, S. typhimurium, S. intermedius, S. pneumoniae, T. forsythia, T. denticola, T. pyogenes and 
V. cholerae. Sialidases were selected using the CAZy list of characterized GH33-family enzymes. The 
phylogenetic tree was constructed using the DynTree layout.  
 
 
The phylogenetic tree shows that BT0455GH33 is clustered on the same branch as other Bacteroides 
spp. sialidases, such as NanH from B. fragilis (BF_1729) and B. vulgatus (BVU_4143). Interestingly, it 
also appears to be very similar to the NanH from Tannerella forsythia (BFO_2207), a sialidase from A. 
muciniphila (Amuc_1835) and a sialidase from C. canimorsus (Ccan_045790). These similarities 
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suggest that these sialidases that could be structurally and functionally related to BT0455GH33. 
Interestingly, NanH from B. fragilis and NanH from T. forsythia have been previously shown to be 
involved in sialylated N-glycan degradation (Cao et al., 2014; Roy et al., 2011). Combined, the 
phylogenetic analysis results suggest that BT0455GH33 along with the other homologous sialidases 
could share the same substrate specificity as NanH from B. fragilis and NanH from T. forsythia.  
To further investigate the similarities of BT0455GH33 to the sialidases produced by other Bacteroides 
spp., the sequences of BT0455GH33, BVU_4143GH33 and BF_1729GH33 were aligned using the Clustal 
Omega Multiple Sequence Alignment tool and visualised using the ESPript 3.0 tool. The results are 
displayed in Figure 4.4. Based on conserved residues highlighted in red, it shows that these sialidases 
are approximately 70% homologous to one another.  The sequence alignment also shows that 
BT0455GH33, BVU4143GH33 and BF1729GH33 contain the conserved features of a typical GH33-family 
sialidase, such as RIP/RLP motif (Arg-Ile/Leu-Phe), repetitive Asp-boxes (Ser/Thr-X-Asp-X-Gly-X-Thr-
Trp/Phe) and catalytic residues, tyrosine (Y) and glutamic acid (E). 
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Figure 4.4: Alignment of the sialidases from Bacteroides species. RIP motif (Arg-Ile-Pro) contains 
arginine required for the catalytic activity of the GH33-family sialidase. Asp-box I, II, III and IV motifs maintain 
structural integrity and characteristics of a typical sialidase by folding into well-defined β-hairpins. Sequences 
were aligned using Clustal Omega tool and visualised using ESPript 3.0 tool. Fully (100%) conserved amino 
acids are displayed in red. 
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4.3.2.3. Defining N-glycan specificity of BT0455GH33  
As was previously shown in the RNA seq and qPCR data analysis, the sialidase BT0455GH33 is 
upregulated when B. thetaiotaomicron is grown on N-glycoproteins as sole carbon sources, 
compared to the glucose control (Figure 3.8 And Figure 3.9, respectively). To investigate the 
enzymatic BT0455GH33 activity against sialylated N-glycan substrates, enzyme assays were set up 
following a protocol described in Section 2.3.5. BT0455GH33 was mixed with various commercially 
available N-glycoproteins. Because deglycosylation of an N-glycoprotein with a single enzyme may 
not be sufficient enough to see a noticeable change in a protein band size, BT0461GH2, a GH2-family 
β-galactosidase that is present in the same B.theta0455-0461 locus, was added into the mixture. The 
activity of BT0461GH2 will be discussed later in this thesis. The enzyme assays were incubated in 
sodium phosphate 20mM (pH 7) buffer for 1 hour at 37 °C and products visualised using SDS-PAGE. 
Deglycosylation of the glycoprotein can be observed by a decrease in glycoprotein band size. The 
results show that these enzymes are active versus bovine fetuin, but show no activity against bovine 
lactoferrin, bovine immunoglobulin G (IgG) and human transferrin (Figure 4.5). These results could 
be explained by the presence of differentially siallylated N-glycan structures on these glycoproteins. 
Representative glycan structures present on bovine fetuin are Neu5Ac-α2,3-Gal-β1,4-GlcNAc, 
Neu5Ac-α2,3-Gal-β1,3-(Neu5Ac-α2,6)-GalNAc and Neu5Ac-α2,3-Gal-β1,3-GalNAc, with N-glycans 
contributing to a 79% of a total glycan mass (Wu et al., 2016). Whereas lactoferrin, transferrin and 
IgG predominantly contains Neu5Ac-α2,6-Gal-β1,4-GlcNAc structures (Park et al., 2013; Barboza et 
al., 2012).  However, it is important to point out that these results may also be due to the 
inaccessibility of sialic acid to BT0455GH33 (e.g. due to high levels of sialic acid acetylation) or due to 
insufficient amount of glycosylated structures present on these commercially-acquired N-
glycoproteins.  
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Figure 4.5: SDS-PAGE gel showing the degradation of N-glycoproteins by BT0455GH33 and 
BT0461GH2. The enzyme assays were set up by mixing 1µM of required enzymes with 1mg/ml of each of the 
glycoproteins in sodium phosphate 20mM (pH 7) buffer and incubating for 1 hour at 37 °C. 1:20 dilutions of 
the enzyme assay products were loaded onto the SDS-PAGE gels. Degradation is observed by the decrease in 
glycoprotein band size in reaction lane compared to the control (highlighted in a red box). Mw is a wide-range 
molecular marker (Sigma Aldrich). Esial is BT0455GH33; R is the reaction mixture; Egal is BT0461GH2 and C is N-
glycoprotein control.  
 
 
To further investigate the BT0455GH33 enzymatic activity against various sialylated substrates and to 
observe the sialic acid release, enzyme assays were set up and products were visualised using the 
thin-layer chromatography (TLC) following a protocol described in Section 2.3.2. Speculating that the 
release of the N-glycan structures from the protein backbone would affect the BT0455GH33 activity, 
some of the N-glycoproteins were de-glycosylated using the Peptide-N-glycosidase F (PNGaseF) 
treatment that hydrolyses the bond between the reducing-end GlcNAc residue of an N-glycan 
structure and the asparagine residue of the protein backbone. Commercially-available PNGaseF from 
E. meningtoseptica (Sigma Aldrich) that can remove oligomannose, hybrid and complex N-glycans 
structures was used to cleave the N-glycans off the protein backbone of bovine α1-AGP and human 
transferrin following a protocol described in Section 2.3.7. BT0455GH33 enzyme assays were set up 
against various substrates following a protocol described in Section 2.3.5 and incubated for 1 hour at 
37 °C. The reaction products were visualised using the TLC (Figure 4.6). Based on the sialic acid 
release, the results show that BT0455GH33 is active against all substrates tested: bovine submaxillary 
mucin (BSM), bovine α1-AGP, PNGaseF-digested bovine α1-AGP, PNGaseF-digested human 
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transferrin and bovine fetuin. BSM is a heavily sialylated mucin (up to 17%) that contains different 
forms of sialic acid –neuraminic acid, KDO and KDN (Bhavanandan et al., 1998). As evident by the 
multiple sialic acid bands visible on the TLC, BT0455GH33 is a broad-acting enzyme that can tackle 
different forms of sialic acid (Figure 4.6).  No difference in BT0455GH33 activity against PNGaseF-
digested and native bovine α1-AGP was observed. Interestingly, BT0455GH33 was active against the 
PNGaseF-liberated N-glycans from human transferrin whereas it was previously shown to be inactive 
against a native form of the human transferrin (see Figure 4.5). 
 
Figure 4.6: Screening for BT0455 activity against N-glycoproteins. C – N-glycoprotein control; +Esial – N-
glycoprotein + BT0455GH33. S.A. stands for Neu5Ac sialic acid control. Thin-layer chromatography (TLC) plates 
were stained using the DPA stain.  
 
 
To visualise the sialic acid release in more detail, the enzyme assays were set up and products were 
visualised using the High-Performance Liquid Chromatography (HPLC/HPAEC-PAD) following a 
protocol described in Section 2.3.3. Known monosaccharide standards, such as sialic acid, were run 
alongside of the enzyme assay samples in order to accurately identify the different peaks. Due to the 
structural differences of the N-glycoproteins, different elution programs and HPLC columns were 
used, resulting in the differentiation in the peak elution pattern.  The appearance of peaks 
representative of N-Acetyl-Neuraminic acid (Neu5Ac) was observed after incubating BT0455GH33 with 
bovine fetuin, PNGaseF-digested bovine fetuin, human transferrin and PNGase-F-digested bovine α1-
AGP (Figure 4.7). These results confirm that BT0455GH33 is a broad-acting sialidase that can uncap 
both bovine and human sialylated N-glycans. Based on the detection and elution pattern, the 
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multiple unidentified peaks present in PNGaseF-cleaved fetuin and α1-AGP samples could be 
representative of differentially de-sialylated N-glycan structures. However, without known N-glycan 
standards it is impossible to identify. 
 
 
Figure 4.7: BT0455GH33 releases sialic acid from N-Glycoproteins. HPAEC-PAD chromatograms showing 
the release of sialic acid. 10mg/ml of N-glycoproteins were incubated with 1µM of BT0455GH33 enzyme in 
20mM sodium phosphate (pH 7) for 1 hour at 37°C. 1:10 dilution was loaded onto the HPAEC-PAD. The final 
concentration of sialic acid standard (Neu5Ac) run is 1mM. A. Desialylation of Fetuin. B. Desialylation of 
PNGaseF-cleaved Fetuin. C. Desialylation of Transferrin. D. Desialylation of PNGaseF-cleaved α1-Acid 
glycoprotein (α1-AGP).  
 
To investigate the de-sialylation of N-glycan structures in more depth, the enzyme assay products 
were visualised using the U-HPLC combined with the mass spectrometry (LC-ESI-MS) analysis. The 
enzyme assay products were labelled with procainamide and sent for analyses using the equipment 
provided by our industrial partner Ludger following a protocol described in Section 2.3.8. Bovine α1-
AGP was chosen as a model N-glycan substrate. BT1044 is a GH18-family endo-β-N-
acetylglucosaminidase that was previously shown to be highly upregulated in the RNA seq data 
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(Figure 3.7.1) (www.cazy.org). BT1044GH18 acts as an endo-β-N-acetylglucosaminidase, hydrolysing 
the bond between the chitobiose (GlcNAc-β1,4-GlcNAc) of the core of complex N-glycan to release 
the glycan from the protein (Dr. Lucy Crouch, unpublished data). Because Bt does not produce a 
PNGaseF-like enzyme and would not normally see PNGaseF-cleaved N-glycan structures, BT1044GH18 
was used to pre-treat bovine α1-AGP and cleave the N-glycans off the protein backbone prior the 
incubation with BT0455GH33. The labelled enzyme assay products were analysed using combined U-
HPLC and mass spectrometry, which allowed to accurately determine the mass of each peak and 
predict the N-glycan structure it corresponds to. The results are displayed in Figure 4.8 and show 
that BT0455GH33 is capable of cleaving two different forms of sialic acid – N-Glycolyl-neuraminic acid 
(NeuGc) and N-Acetyl-Neuraminic acid (NeuAc). Human N-glycoproteins only contain NeuAc. These 
results suggest that BT0455GH33 is a broad-acting sialidase capable of removing all α2-3/6-linked sialic 
acid caps off N-glycan structures released from bovine α1-AGP protein backbone by the endo-β-N-
acetylglucosaminidase BT1044GH18.  
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Figure 4.8: De-sialylation of bovine α1-AGP N-glycan structures by BT0455GH33. 
A. HPLC analyses of α1-AGP degradation by BT1044GH18 and BT0455GH33. Figure B and Figure C show N-glycan 
structures corresponding to each peak that were constructed using the mass spectrometry data. D. Examples 
of mass spectrometry peaks with calculated masses [M/Z] and corresponding sugar structures.  
 
 
MS data and predicted structure for each peak shown in Figure 4.8 are displayed in Table 4.1 
Table 4.1: Mass spectrometry data of GH18-cleaved bovine α1-AGP degradation by BT0455GH33. 
 
Retention time (min) corresponds to the peaks in the HPLC chromatograms.  
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Overall, the data presented in this section strongly supports the claim that the sialidase BT0455GH33 is 
a broad-acting enzyme that has an N-glycan specificity. BT0455GH33 was found to be capable of taking 
all α2-3/6-linked sialic acid caps off transferrin, fetuin and α1-AGP, including Neu5Ac and Neu5Gc. 
BT0455GH33 was also capable of liberating different forms of sialic acid off bovine submaxillary mucin 
(BSM).  
 
4.3.3. BT0457: Characterization of a sialic acid esterase 
 
4.3.3.1. Introduction 
Sialic acids are acetylated monosaccharides that are usually found capping the terminal branches of 
glycoconjugates, such as N-glycans, O-glycans and gangliosides. Since they are typically found on the 
terminal ends of glycan chains, they are a perfect target for the utilization by the gut microbes. 
However, acetylation of the sialic acids, such as Neu5Ac and Neu9Ac, can hinder the efficiency of the 
sialidase activity. Carbohydrate esterases (CEs) are enzymes that cleave acetyl groups off 
carbohydrate groups capping complex glycan structures, such as conjugated sialic acid caps. 
 B. thetaiotaomicron encodes BT0457 that, based on the amino acid sequence similarity and the 
domain composition, is predicted to be a sialic acid-specific 9-O-acetylesterase. The aim of this 
section was to investigate the activity of BT0457CE esterase. 
 
4.3.3.2. Bioinformatics analysis of BT0457CE 
In order to compare the BT0457CE to other known esterases, sequence similarity database (SSDB) 
tool hosted by Kyoto Encyclopedia of Genes and Genomes (KEGG) database resource was used to 
generate a dendrogram of top 50 best orthologue matches to BT0457CE (Figure 4.9). KEGG SSDB 
contains all known information about the amino acid sequence similarities between proteins in 
organisms that have been completely sequenced. The results displayed in Figure 4.9 show that this 
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type of esterase is widespread among the different species of bacteria, suggesting their importance 
in sialylated glycan utilization. The results also show that BT0457CE is clustered together with 
esterases encoded by other members of Bacteroides species. 
 
Figure 4.9: A dendrogram showing the taxonomic relationship of BT0457 to 50 orthologous 
esterase-coding genes. KEGG SSDB tool was used to perform a sequence similarity search on BT0457CE and 
visualise the results by producing a dendrogram of 50 best matches. Dendogram was produced using Smith-
Waterman similarity score to identify the best hits. 
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Based on the dendrogram displayed in Figure 4.9, B. vulgatus esterase BVU4140CE appears to be 
closely related to BT0457CE. Genome comparison showed that this esterase is predicted to be a part 
of B. vulgatus BVU4133-4145 PUL that is very similar to BT0455-0461 in B. thetaiotaomicron. 
BVU4133-4145 encodes a predicted sialic acid esterase BVU4140CE, sialidase BVU4143GH33 and three 
GH20-family hexosaminidases. Furthermore, the sialidase BVU4143GH33 was previously shown to be 
homologous to BT0455GH33 (Figure 4.4). Previously characterised sialic acid-specific 9-O-
acetylesterase (NanS) from T. forsythia was also chosen for structural comparison (Phansopa et al., 
2015). To investigate the similarities of BT0457CE to BVU4140CE and NanS from T. forsythia, the 
sequences were aligned using the Clustal Omega Multiple Sequence Alignment tool and visualised 
using the ESPript 3.0 tool. The results are displayed in Figure 4.10. Based on the fully conserved 
residues, these sialate-O-acetylesterases appear to be closely related and have a sequence similarity 
of over 60%.  SGNH family of esterases are defined by the presence of four blocks of conserved 
amino acid sequences. Block I contains the G-D/N-S motif, which contains the nucleophilic serine 
residue. Block II contains the glycine (G), which is conserved among all members of SGNH family of 
hydrolases. Block III contains the conserved asparagine (N) residue and Block IV contains two 
conserved catalytic residues, aspartic acid (D) and histidine (H) (Rangarajan et al., 2011).  
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Figure 4.10: Amino acid sequence alignments of confirmed and putative sialate O-acetylesterases 
from T. forsythia (NanS), B. thetaiotaomicron (BT_0457) and B. vulgatus (BVU_4140). Conserved 
amino acid blocks are displayed where block I contains G-D/N-S motif, block II contains the glycine (G), block III 
contains asparagine (N) and block IV contains aspartic acid (D) and histidine (H). Blocks are further divided in 
Type I, II and III according to the conserved SGNH residues present. Residues highlighted in red boxes are 100% 
conserved. Amino acid residues framed in blue boxes are 70% or more identical based on their 
physicochemical properties. 
 
 
The conserved residues of these four blocks are characteristic of the SGNH family of hydrolases.  
Sialate-O-acetylesterases BT0457CE, BVU4140CE and NanS from T. forsythia have type I and type II of 
SGNH conserved residues which indicates they possess two structural domains (Figure 4.11). The 
domain representative of the type I of SGNH family of hydrolases is displayed as Lipase_GDSL_2 by 
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PFAM database. Meanwhile, DUF303 domain is predicted to belong to the type II domain of the 
SGNH family hydrolases (Phansopa et al., 2015). The results show that all three sialate-O-
acetylesterases have an identical domain composition, suggesting they could have very similar 
enzymatic activities and target same sialylated glycan structures. 
 
Figure 4.11: Domain architecture of BT0457, NanS and BVU4140 esterases. SMART tool was used to 
visualise the domain composition. Predicted signal sequence is shown in red. Pfam domains are displayed in 
grey boxes. Amino acid sequence length is displayed below the illustrated domains.  
 
In order to investigate and compare the amino acid sequence and domain composition of BT0457CE 
to other esterases in B.thetaiotaomicron,  Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database resource was used to identify paralogous protein-coding genes. The sequences were 
aligned using the Clustal Omega Multiple Sequence Alignment tool and visualised using the ESPript 
3.0 tool. The results show that the amino acid sequence of BT0457CE is not closely related to any 
other esterases produced by B.thetaiotaomicron, but all enzymes seem to share blocks of fully 
conserved residues highlighted in red in the Figure 4.12. One of these conserved amino acid blocks 
contains conserved residues of Block III (Type II) that belong to the predicted type II SGNH family of 
hydrolases.  
It is better illustrated in the Figure 4.13 showing the PFAM domain composition. The results show 
that BT0457CE is the only esterase to contain the domain of the type I of SGNH family of hydrolases, 
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named Lipase_GDSL_2 in Pfam. Interestingly, majority of them seem to contain DUF303 domain, 
predicted to be representative of the type II domain of the SGNH family of hydrolases. 
 
 
Figure 4.12: Amino sequence alignments of confirmed and putative esterases from B. 
thetaiotaomicron paralogous to BT0457. KEGG database was used to identify the paralogues. The figure 
shows the alignment of sequences between 467 and 740 amino acids. Amino acids highlighted in red boxes are 
fully conserved. Amino acid residues framed in blue boxes are 70% or more identical based on their 
physicochemical properties 
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Figure 4.13: Domain composition of B. thetaiotaomicron esterases paralogous to BT0457. Predicted 
signal peptide sequence is displayed in red. Pfam domains are shown in grey boxes. Amino acid sequence 
length is displayed below the domains. 
 
4.3.3.3. Screening for substrate specificity of BT0457CE 
RNA seq data analysis displayed in Figure 3.7.1 shows that the esterase BT0457CE is upregulated 
when B. thetaiotaomicron is grown on N-glycoproteins as sole carbon sources, compared to the 
glucose control. To further investigate the activity of the predicted sialic acid-specific 9-O-
acetylesterase BT0457CE against sialylated carbohydrates, enzyme assays were set up following a 
protocol described in Section 2.3.5. To initially assess the BT0457CE enzyme activity, colorimetric 
assays with para-Nitrophenol (pNP)-linked acetate were set up. If the enzyme showed activity on the 
linked substrate, the colour of the reaction turned yellow. The results showed that BT0457CE is active 
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against pNP-acetate. However, when it was attempted to obtain the kinetic parameters of BT0457CE 
activity against the pNP-acetate following a protocol described in Section 2.3.5.1, it displayed a really 
low enzymatic efficiency and thus, the rate of substrate hydrolysis could not be measured. This may 
be due to the fact that pNP-acetate is synthetic and not a true substrate for BT0457CE.  
To visualise the de-acetylation of the sialic acid by BT0457CE in more detail, the enzyme assays 
against Bovine Submaxillary Mucin (BSM) were set up in sodium phosphate 20mM (pH 7) and 
incubated overnight at 37 °C. The enzyme assay products were visualised using the HPAEC-PAD 
following a protocol described in Section 2.3.3. Bovine Submaxillary Mucin (BSM) was chosen 
because it is heavily sialylated by a number of different variants of sialic acids (Zauner et al., 2012). A 
known N-Acetylneuraminic acid standard (Neu5Ac) was run alongside of the enzyme assay samples 
in order to accurately identify this sialic acid peak. Neu9Ac was not available to purchase 
commercially at the time of this experiment, thus could not be used. The results show that N-
Acetylneuraminic acid (Neu5Ac), cleaved by BT0455GH33 from the bovine submaxillary mucin (BSM), 
is not a substrate for the BT0457CE esterase (Figure 4.14). Based on the change in peak intensity, the 
results suggest that the treatment with BT0457CE enables the sialidase BT0455GH33 to cleave more 
Neu5Ac from the BSM glycans. The peaks labelled 1, 2, 3 and 4 could not be identified but based on 
the intensity of the peak labelled number 2, it could represent a form of a de-acetylated sialic acid. 
These peaks could also represent different de-sialylated forms of O- or N-linked glycan structures 
present on BSM. 
Due to high sequence similarity to T. forsythia NanS and no detected activity on Neu5Ac, the overall 
results indicate that BT0457CE could be a sialic acid-specific 9-O-acetylesterase. However, due to 
time constraints, more in-depth analyses could not be done to confirm this claim.  
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Figure 4.14: De-acetylation of sialic acid released from Bovine Submaxillary Mucin (BSM). HPLC 
analyses of bovine submaxillary mucin (BSM) degradation by BT0455GH33 and BT0457CE are shown. 1mM of 
sialic acid standard was used (Neu5Ac). Peaks labelled 1-4 could not be identified using known carbohydrate 
standards.  
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4.3.4. BT0461: Characterization of a galactosidase activity 
4.3.4.1. Introduction 
The complete degradation of N-glycan structures depends a cooperative activity of multiple 
carbohydrate-active enzymes. One of the key enzymes required is a β-galactosidase. B. 
thetaiotaomicron possesses a number of β-galactosidases but according to the CAZy database, only 
five have been characterized to date. BT0461 is a GH2-family β-galactosidase that is predicted to 
target terminal β1-3/6- and/or β1-4- D-galactosyl bonds. BT0461GH2, like the sialidase BT0455GH33, 
was found to be upregulated when B. thetaiotaomicron was grown on porcine gastric mucin (PGMIII) 
but its precise substrate specificity remains unknown (Martens et al., 2008). 
As previously shown in Figure 3.8, BT0461GH2, along with the other genes from the BT0455-0461 
locus, is upregulated when B. thetaiotaomicron is grown on N-glycoproteins as a sole carbon source. 
Thus, the aim of this chapter was to investigate and characterise the substrate specificity of 
BT0461GH2. 
 
4.3.4.2. Bioinformatics analysis of BT0461GH2 
To investigate the similarities of BT0461GH2 to other characterised β-galactosidases, the amino acid 
sequence of BT0461GH2 was used as a query for BLASTP and KEGG search to identify the homologous 
proteins. The identified putative β-galactosidase orthologues and suspected paralogues were used 
for phylogenetic and bioinformatics analysis.  
Initially, the sequence similarity database (SSDB) tool hosted on KEGG database was used to 
generate a dendrogram of top 50 best matches to BT0461GH2 (Figure 4.15). The results show that 
BT0461GH2 type of GH2 β-galactosidase is widespread and has homologs in a variety of species of 
commensal and pathogenic bacteria. The orthologues of BT0461GH2 β-galactosidase found in other 
Bacteroides species are highlighted in Cluster 1 and Cluster 2, suggesting they may have different 
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substrate specificities. Because the closest biochemically and structurally related characterised GH2 
β-galactosidase to BT0461GH2 was identified as LacZ in E.coli, which shares only 24% homology, 
substrate preferences of BT0461GH2 remain to be identified. 
 
Figure 4.15: A dendrogram showing the taxonomic relationship of BT0461GH2 to its 50 best 
orthologous β-galactosidase-coding genes. KEGG SSDB tool was used to perform a sequence similarity 
search on BT0461GH2 and visualise the results by producing a dendrogram of best orthologues. Smith-
Waterman similarity score was used to identify the best hits. 
 
To investigate the sequence similarities of BT0461GH2 to closely related β-galactosidases further, 
BVU4134GH2 and Ccan01450GH2 putative β-galactosidases were chosen for the comparison and PFAM 
domain composition was obtained using the protein sequences and Simple Modular Architecture 
Tool (SMART). It was found that the amino acid sequence of BT0461GH2 is 60% and 78% homologous 
to BVU4134GH2 and Ccan01450GH2, respectively, and these enzymes share a very similar domain 
composition (Figure 4.16). BT0461GH2 appears to have an identical domain composition to the 
BVU4134GH2, further supporting the previously discussed claim that B. vulgatus BVU4133-4145 PUL is 
very similar to BT0455-0461 locus in B. thetaiotaomicron. Ccan01450GH2 shares Glyco_hydro_2, 
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Glyco_hydro_2C and DUF4982 PFAM domains with BT0461GH2 and BVU4134GH2. These domains are 
characteristic of a typical GH2-family β-galactosidase (CAZypedia.org, GH2 family). In overall, based 
on these results it appears to be safe to hypothesise that these enzymes could have similar substrate 
specificities. 
 
Figure 4.16: Domain composition of GH2-family β-galactosidases. PFAM domain composition of β-
galactosidases from B. thetaiotaomicron (BT0461GH2), B. vulgatus (BVU4134GH2) and C. canimorsus 
(Ccan01450GH2) are displayed in grey boxes. Predicted signal peptide sequence is displayed in red. Amino acid 
sequence length is displayed below the domains. DUF stands for domain of unknown function. 
 
 
 
4.3.4.3. Defining the substrate specificity of BT0461GH2 
To initially assess BT0461GH2 enzyme activity, assays with para-Nitrophenol (pNP)-linked substrates 
were set up following a protocol described in Section 2.3.5.1 using 1 mM of pNP-substrates and 
incubation for 30 min at 37 °C . As predicted by the bioinformatics analyses (see Section 4.3.4.2), 
BT0461GH2 was only active against p-nitrophenyl-β-D-galactopyranoside (pNP-β-Gal) and showed no 
activity against p-nitrophenyl-α-D-galactopyranoside (pNP-α-Gal), p-nitrophenyl-β-D-
mannopyranoside (pNP-β-Man) nor p-nitrophenyl-β-D-glucopyranoside (pNP-β-Glc), confirming it is 
a β-galactosidase. To further investigate the BT0461GH2 specificity, enzyme assays against various 
disaccharide structures were set up following a protocol described in Section 2.3.5. The assays were 
incubated for 16 hours at 37 °C and reaction products were visualised using the TLC.  
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The positive results were identified by the release of galactose monosaccharide and showed that β-
galactosidase BT0461GH2 is active against all galactose disaccharides that have β1,4 linkages (Figure 
4.17). These include β1,4-Galactobiose, Gal-β1,4-GlcNAc (LacNAc) and Gal-β1,4-Glucose (Lactose). 
BT0461GH2 showed no activity against β1,6-Galactobiose, suggesting it may have a β1,4-linkage 
specificity. 
 
Figure 4.17: Screening for the enzyme activity of BT0461GH2 against simple disaccharides. 1µM of 
BT0461GH2 was incubated with 1-2mM of disaccharides. C – disaccharide control; +Egal – substrate incubated 
with BT0461GH2. Gal is 1mM Galactose standard. Thin-layer chromatography (TLC) plates were stained using 
the DPA stain.  
 
 
To determine the substrate preference of the retaining β-galactosidase BT0461GH2, the catalytic 
activity of the enzyme against different β1,4-linked disaccharides was measured at 340nm using D-
Galactose detection kit (Megazyme) following the manufacturer’s instructions (see Section 2.3.5.2). 
BT0461GH2 activity against p-nitrophenyl-β-D-galactopyranoside (pNP-β-Gal) was measured at 320nm 
following a protocol described in Section 2.3.5.1. The kinetic parameters and respective kinetic 
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curves for each disaccharide are shown in Figure 4.18. The enzyme kinetics results show that 
BT0461GH2 displays the highest activity against the pNP-β-Gal, however it is a synthetic substrate and 
not found in nature. Based on the kcat/KM values, BT0461GH2 shows a 2-fold preference for Gal-β1,4-
GlcNAc over Gal-β1,4-Gal. Gal-β1,4-GlcNAc is a structure commonly found in N-glycan structures. 
Although BT0461GH2 is active on lactose (Gal-β 1,4-Glc), based on low kcat/KM value, it does not 
appear to be a preferred substrate.  
 
Figure 4.18: Activity of BT0461GH2 vs disaccharide substrates.  All reactions were performed at 37 °C 
using 20 mM NaH2PO4 (pH 7.5) buffer. Reaction rates were measured at 320 nm (for pNP-Gal) and 340 nm for 
disaccharides and plotted in GraphPad Prism 7.0 software using non-regression analysis (see Section 2.3.5). 
The standard errors were generated from biological triplicates. 
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To investigate whether BT0461GH2 can catalyse the hydrolysis of the Gal-β1,4-GlcNAc(α1,3-Fuc) 
trisaccharide, where fucose could potentially interfere with the BT0461GH2 activity, enzyme assays 
against Lacto-N-fucopentaose III were set up following the same protocol used above (see Section 
2.3.2). An α-fucosidase BT1625GH29 was incubated together with the BT0461GH2 to investigate if it has 
any effect. Based on the RNA-seq data, BT1625GH29 is also upregulated when B. thetaiotaomicron is 
grown on N-glycoproteins as sole carbon sources (Supplemental table 3.1). Based on the 
disappearance of the band representative of a released galactose monosaccharide, the results 
showed that β-galactosidase BT0461GH2 is unable to take the galactose off when the fucose is linked 
onto the GlcNAc (Figure 4.19). However, once the fucose is released by the fucosidase BT1625GH29, 
β-galactosidase BT0461GH2 can hydrolyse the Gal-β1,4-GlcNAc linkage.  
 
Figure 4.19: BT0461GH2 activity against Lacto-N-fucopentaose III. 1µM of enzymes were incubated with 
1mM of pentasaccharide. C – substrate control; +Egal – substrate + BT0461. +Efuc – substrate + BT1625GH29. Gal 
is 1mM Galactose standard. TLC plates were stained using the DPA stain. DPA could not stain fucose. Arrow 
indicates the galactose product. 
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To investigate BT0461GH2 activity on N-glycan substrates, enzyme assay against bovine α1-Acid 
glycoprotein and bovine fetuin was set up. Considering the majority of N-glycans are capped by 
terminal sialic acids, the sialidase BT0455GH33 was also included in the fetuin assay. Enzyme activity 
assays of 1 µM of sialidase BT0455GH33 and 1 µM of β-galactosidase BT0461GH2 against 10mg/ml of N-
glycoproteins were set up following a protocol described in Section 2.3.5. The enzyme assays were 
incubated in sodium phosphate 20mM (pH 7) buffer for 1 hour at 37 °C and visualised using the SDS-
PAGE gel and TLC (see Section 2.3.2; Section 2.1.22). The results suggest that BT0461GH2 is an exo-
glycosidase that cannot cleave sialylated galactose residues off the α1-AGP N-glycan structures 
(Figure 4.20). BT0461GH2 requires the pre-treatment with the sialidase BT0455GH33 to remove the 
sialic acid caps off the sialylated α1-AGP and fetuin N-glycans before it can cleave galactose caps off. 
Thus, the sequential release of sialic acid and galactose by BT0455GH33 and BT0461GH2, respectively, 
was observed (Figure 4.20-A and B). Deglycosylation of bovine fetuin N-glycans by BT0455GH33 and 
BT0461GH2 was also observed by a decrease in N-glycoprotein size from ~64 kDa to ~55 kDa (Figure 
4.20-C). 
 
Figure 4.20: N-glycan degradation by the sialidase BT0455GH33 and β-galactosidase BT0461GH2.  
A) α1-acid glycoprotein degradation. B) Bovine fetuin degradation. TLC plates showing sialic acid and galactose 
release by BT0455GH33 and BT0461GH2, respectively. Esial is BT0455; Egal is BT0461; S.A. is 2mM sialic acid 
(Neu5Ac) standard; Gal is 1mM galactose standard. DPA stain was used to stain the TLC plates. Arrow indicates 
the galactose product.  C) SDS-PAGE showing Fetuin N-glycoprotein degradation by BT0455GH33 and BT0461GH2 
(highlighted in red box). Mw is a wide-range molecular marker (Sigma Aldrich). RFet is the reaction mixture and 
CFet is control. 1:20 dilutions of the assays were loaded. Degradation is observed by the decrease in N-
glycoprotein band size in reaction lane compared to the control.  
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To further investigate the enzymatic BT0461GH2 activity against complex de-sialylated N-glycan 
structures, enzyme assays against native, PNGaseF- and GH18-digested bovine α1-AGP were set up 
following a protocol described in Section 2.3.2. The products were visualised using TLC (see Section 
2.3.5). The results displayed in Figure 4.21-A show that there is no difference in the enzymatic 
activity of β-galactosidase BT0461GH2 on N-glycans released from protein backbone by either 
PNGaseF or GH18 (BT1044) enzymes. The β-galactosidase BT0461GH2 is active on all forms of N-
glycans. The PNGaseF and GH18-cleaved N-glycan structures are highlighted in red boxes. The 
examples of differences of these structures are displayed in Figure 4.21-B.   
 
Figure 4.21: Degradation of desialylated bovine α1-AGP N-glycan structures by β-galactosidase 
BT0461GH2. A) Degradation products visualised on a TLC plate. Esial is BT0455GH33; Egal is BT0461GH2; C is 
substrate control. N-glycan structures are highlighted in red boxes. Thin-layer chromatography (TLC) plate was 
stained using the DPA stain. S.A. is 2mM sialic acid (Neu5Ac) standard; Gal is 1mM galactose standard. B) 
Examples of PNGaseF-cleaved and GH18-cleaved complex N-glycan structures are based on most abundant N-
glycan structure found on α1-AGP, identified using mass spectrometry data (see Figure 4.8). 
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To investigate the galactose release in more detail, the enzyme assays were set up and products 
were visualised using different optimised HPAEC-PAD programs (Section 2.3.3). As was previously 
observed, BT0461GH2 shows no activity on N-glycans that are capped by the sialic acids, thus the 
substrates used in this assay were de-sialylated using the sialidase BT0455GH33 (Figure 4.20). Based 
on the appearance of a peak identified using a standard as a galactose monosaccharide, the results 
show that β-galactosidase BT0461GH2 can cleave galactose off de-sialylated bovine fetuin and human 
transferrin N-glycoproteins (Figure 4.22). Combined, these results suggest that BT0461GH2 is an exo-
glycosidase and N-glycoprotein de-glycosylation by BT0455GH33 and BT0461GH2 is a sequential 
process. 
 
 
 
 
 
 
 
A 
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Figure 4.22: BT0461GH2 releases galactose from de-sialylated N-Glycoproteins. HPAEC-PAD 
chromatograms showing the release of galactose. A. Galactose release by BT0461GH2 from de-sialylated bovine 
Fetuin. B. Galactose release by BT0461GH2 from de-sialylated human Transferrin. 10mg/ml of each of N-
glycoproteins was incubated with 1µM of BT0455GH33 and BT0461GH2 enzymes in 20mM sodium phosphate (pH 
7) buffer. 1:10 dilution was loaded onto the HPAEC-PAD.  
 
To investigate the de-glycosylation of N-glycan structures in more depth, the enzyme assay products 
were visualised using the U-HPLC combined with the mass spectrometry (LC-ESI-MS) analysis, which 
allows for accurate calculation of the mass of each peak and prediction of the N-glycan structure it 
corresponds to. The results displayed in Figure 4.23 show that BT0461GH2 is an exo-glycosidase 
capable of taking majority of terminal β1,4-galactose caps off N-glycan structures pre-treated with 
endo-β-N-acetylglucosaminidase BT1044GH18 and the sialidase BT0455GH33. It was observed that 
BT0461GH2 leaves some galactose caps in-tact on the complex bi-antennary N-glycan structure 
(Figure 4.23-III). It is important to note that these N-glycan structures were assembled based on the 
mass spectrometry data and thus, they may contain different galactose linkages that BT0461GH2 
cannot target. 
 
B 
 131 
 
 
 
 
Figure 4.23: Degradation of bovine α1-AGP N-glycan by BT0461GH2.  
Top panel: U-HPLC analyses of bovine α1-AGP degradation by BT1044GH18, BT0455GH33 and BT0461GH2. Bottom 
panel: Figure I, II and III show N-glycan structures corresponding to each peak that were constructed using the 
mass spectrometry data (See Table 4.1). 
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4.3.4.4. Generating the BT0461GH2 catalytic mutant 
One of the signature characteristics of the GH2-family β-galactosidases is the presence of the 
conserved catalytic residue – Glutamic acid (Glu; E). Bioinformatics analysis (see Section 4.3.4.2) and 
comparison of BT0461GH2 to the homologous GH2-family β-galactosidases from other Bacteroides 
species let us identify the catalytic residue of BT0461GH2 as Glu512 found in the sequence LGSETAS 
(Figure 4.24-A). The catalytic mutant E512Q of BT0461GH2 was generated using site-direct 
mutagenesis following a protocol described in Section 2.1.10 (Figure 4.24-B). The primers used to 
generate the mutant are displayed in Supplemental table 3.2. Mutating negatively-charged glutamic 
acid (E) into a polar glutamine (Q) allowed us to retain the structural integrity of the protein but 
rendered it catalytically inactive. 
 
Figure 4.24: Generating a BT0461GH2 catalytic mutant. A) Amino acid sequence alignment of BT0461GH2 
to the homologous GH2-family β-galactosidases. The sequence alignment was done using Clustal Omega and 
visualised using the Espript 3.0 too. Amino acid residues displayed in red boxes are fully conserved. Catalytic 
residue is highlighted in the black box and labelled with an asterisk (*). B) Agarose gel showing the PCR 
products of the site-directed mutagenesis. M is a high fidelity genomic DNA marker. Lane 1 shows a successful 
site-directed mutagenesis product that was sent to sequence.  
 
The generated BT0461GH2 E512Q catalytic mutant was tested against a variety of β1,4-linked 
substrates and was found to be inactive (data not shown).  
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To understand the structural basis of the substrate specificity displayed by BT0461GH2, the crystal 
trial of the BT0461GH2 E512Q catalytic mutant was set up in order to obtain a crystal of a ligand-
bound form of the protein. The BT0461GH2 E512Q catalytic mutant was expressed and purified using 
the gel filtration following a protocol described in Section 2.1.25. The protein fractions collected 
from the gel filtration purification were visualised using the SDS-PAGE and combined (Figure 4.25).  
 
Figure 4.25: Purification of the BT0461GH2 E512Q catalytic mutant. A) SDS-PAGE gel of purified 
BT0461GH2 E512Q mutant. These fractions were pooled and concentrated. B) A graphical representation of the 
gel filtration procedure. Blue peaks highlighted in a black box represent the eluted protein fractions (displayed 
in red numbers) that were collected.   
 
 
The purified protein was concentrated to 30mg/ml and co-crystallised with Gal-β1,4-GlcNAc using an 
automated MosquitoR nano-dispensing robot and sitting-drop vapour diffusion method following a 
protocol described in Section 2.4.1. The conditions of crystal screens (Molecular Dimensions) in 
which crystals formed were optimised. The BT0461GH2 E512Q mutant was co-crystallised with Gal-
β1,4-GlcNAc using the hanging-drop vapour diffusion method following a protocol described in 
Section 2.4.2. Numerous crystals were obtained throughout the duration of 2 months. The crystals 
that formed in 15% PEG3350, 50mM sodium nitrate, 0.1M Bis-Tris propane (pH 7.5) condition were 
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harvested (Figure 4.26). The crystals were collected and analysed by Dr. Arnaud Baslé. 
Unfortunately, none of the crystals diffracted and due to the time constraints, the crystal screens 
could not be repeated.  
 
Figure 4.26: An image of the BT0461GH2 E512Q crystals. Crystals formed in 15% PEG3350, 50mM sodium 
nitrate, 0.1M Bis-Tris propane (pH 7.5) buffer using hanging-drop vapour diffusion method. 
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4.3.5. The four GH20s: Characterization and comparison of BT0456GH20, 
BT0459GH20, BT0460GH20 and BT0506GH20 
4.3.5.1. Introduction 
In the gastrointestinal tract (GI), D-GlcNAc and D-GalNAc residues are found in structural chains of 
carbohydrates decorating glycoconjugates, such as mucins, O-glycoproteins and N-glycoproteins. On 
N-glycoproteins, D-GlcNAc residues are usually found forming β1-2/4/6 and bisecting β1-4 glycosidic 
linkages (Stanley et al., 2009). The enzymes that cleave GlcNAc and GalNAc monosaccharides from 
the non-reducing end of glycans are grouped into glycoside hydrolase (GH) family 20 (GH20) of the 
CAZy classification. B. thetaiotaomicron, a prominent member of human gut microbiota, encodes 
numerous GH20-family β-N-acetylhexosaminidases, each specialised in cleaving specific glycosidic 
bonds. Four of these enzymes - BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20, were shown to 
be upregulated when B. thetaiotaomicron was grown on N-glycoproteins as sole carbon sources, 
compared to the glucose control (Figure 3.7.1). Despite the potential importance of N-glycan 
degradation to the host health (e.g. degradation of N-glycans present on secretory IgA), the 
knowledge of de-glycosylation pathways is lacking, particularly how commensal gut microbes can 
tackle different D-GlcNAc linkages found on complex N-glycan structures. Thus, the aim of this 
section was to characterize the activities of BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20, and 
investigate their involvement in complex N-glycan degradation. 
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4.3.5.2. Bioinformatics analysis and comparison of the four GH20s 
To compare the sequence similarities of the four GH20s to the other known N-acetyl-β-
hexosaminidases, the amino acid sequences of BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 
were obtained using the UniProt database and queried against BLASTP and KEGG search to identify 
the homologous proteins. The identified putative β-hexosaminidase homologs were used for 
phylogenetic and bioinformatics analysis.  
Initially, the sequence similarity database (SSDB) tool hosted by Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database was used to identify orthologues of BT0456GH20, BT0459GH20, BT0460GH20 
and BT0506GH20. The orthologues were found in a range of species of bacteria, including members of 
gut microbiota and other Bacteroides species. Closest related orthologues were selected for 
phylogenetic analysis. Based on the CAZy search, none of these enzymes have been characterised 
yet with an exception of BF_1730 (nanA), BF_1734 (nanB) and BF_1735 (nanM) that were shown to 
be involved in sialylated glycoconjugate utilisation in B. fragilis (Nakayama-Imaohji et al., 2012).  
In order to explore the sequence similarities between the BT0456GH20, BT0459GH20, BT0460GH20 and 
BT0506GH20, a phylogenetic tree was constructed using a phylogeny.fr tool. The taxonomic 
relationships between the enzymes displayed in the phylogenetic tree in Figure 4.27 indicate that 
the four GH20s encoded by the B. thetaiotaomicron could be functionally quite different. The 
enzymes in each cluster could be specialised in targeting different glycosidic linkages, e.g. ones 
found on complex N-glycans such as β1,2/4/6 or bisecting GlcNAc-β1,4- linkages. 
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Figure 4.27: Phylogenetic tree of β-hexosaminidases encoded by the members of gut microbiota. 
Species included in the tree: B. thetaiotaomicron, B. fragilis, B. vulgatus, A. muciniphila, B. xylanisolvens, B. 
ovatus, B. hellcogenes and A. finegoldii. BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 are highlighted in 
red. The phylogenetic tree was constructed using the DynTree layout.  
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To investigate the taxonomic relationship of the four GH20s further, the BT0460GH20 amino acid 
sequence was used as a query on a KEGG database to identify paralogous genes in B. 
thetaiotaomicron. The taxonomic relationship of 15 identified genes was visualised using a 
dendrogram (Figure 4.28). The results confirmed that the four GH20s are not functionally related 
and suggest they may have different substrate or linkage specificities. 
 
 
Figure 4.28: A dendrogram showing the relationship of BT0460GH20 β-hexosaminidase to 
paralogues encoded by B. thetaiotaomicron. The four GH20s are labelled with a red asterisk (*). KEGG 
SSDB tool was used to perform a sequence similarity search. The dendrogram was generated using the best 
matches identified by a Smith-Waterman similarity score.  
 
To explore the similarities of the BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 β-
hexosaminidases further, the amino acid sequences were aligned and compared. The results show 
that amino acid sequence of BT0459GH20 is 40% identical to BT0460GH20, 36% identical to BT0506GH20 
and 22% identical to BT0456GH20 whereas BT0460GH20 is 33% identical to BT0506GH20 and 22% 
identical to BT0456GH20 (Figure 4.29). Meanwhile, the amino acid sequence of BT0456GH20 is 24% 
identical to BT0506GH20.  The sequence alignment shows that the four GH20s have the characteristic 
catalytic residues of the GH20 retaining family of β-hexosaminidases, the D-E pair of amino acids 
that is usually preceded by the H-x-G-G motif (CAZypedia.org, GH20 family). Interestingly, 
BT0456GH20 has a H-I-G-T motif instead which may be involved in its substrate specificity. 
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Figure 4.29: Amino acid sequence alignments of the four β-hexosaminidases: BT0456GH20, 
BT0459GH20, BT0460GH20 and BT0506GH20. Fully conserved amino acid residues are highlighted in solid red 
boxes. Amino acid residues framed in blue are 70% or more similar based on their physicochemical properties. 
Catalytic residue pair D-E is labelled with an asterisk (*).  
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The PFAM domain composition of BT0456GH20, BT0459GH20, BT0460GH20 and BT0460GH20 β-
hexosaminidases is displayed in Figure 4.30.  Despite having quite low sequence similarity scores 
displayed in Figure 4.29, the four β-hexosaminidases have very similar PFAM domain architectures. 
It is not surprising, considering multiple protein sequences can belong to a single PFAM domain 
family. All four of the GH20-family enzymes contain the non-catalytic Glyco_hydro_20b and catalytic 
Glyco_hydro_20 domains. Interestingly, BT0456GH20 appears to have a truncated version of a 
Glyco_hydro_20 domain, which may play a role in its activity. BT0459GH20 and BT0460GH20 also 
contain a predicted CBM domain labelled F5_F8_type_C (Pfam) whereas BT0506GH20 contains a 
predicted CBM domain labelled PA14 (Pfam). BT0459GH20 and BT0506GH20 also contain a predicted 
linker domain labelled as CHB_Hex_C_1 by Pfam.  
 
 
Figure 4.30: Domain composition of the GH20-family β-hexosaminidases. PFAM domain composition 
of β-hexosaminidases BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 from B. thetaiotaomicron are 
displayed in grey boxes. Predicted signal peptide sequence is displayed in red. Amino acid sequence length is 
displayed below the domains.  
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4.3.5.3. Defining the BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 substrate 
specificity 
To initially investigate the activities of the four GH20 enzymes, assays with para-Nitrophenol (pNP)-
linked substrates were performed. Data showed that BT0456GH20, BT0459GH20, BT0460GH20 and 
BT0506GH20 were all active against pNP-β-GlcNAc and pNP-β-GalNAc, confirming they are β-
hexosaminidases. To gain more insight into the substrate specificities of the four GH20s further, 
enzyme assays against various defined disaccharides were performed and visualised using thin-layer 
chromatography (TLC) (see Section 2.3.2). The tested disaccharides include GlcNAc-β1,2-Man, 
GlcNAc-β1,3-Man, GlcNAc-β1,3-Gal, GalNAc-β1,3-Gal and GlcNAc-β1,4-GlcNAc.  
Based on the observed release of monosaccharides, the initial results showed that all four β-
hexosaminidases are active against most of the disaccharides tested but displayed a variation in 
their enzymatic efficiencies (Figure 4.31). BT0459GH20 appeared to be the most active enzyme of the 
four, completely degrading all tested disaccharides into monosaccharides within 1 hour of 
incubation at 37°C. Meanwhile, BT0456GH20 and BT0460GH20 displayed only a partial degradation of 
the disaccharides after 1 hour of incubation whereas BT0506GH20 appears to be the least efficient 
enzyme, showing no activity against any of the disaccharides after 1h of incubation. Furthermore, 
only partial degradation of the tested disaccharides was observed by BT0506 after 16 hours of 
incubation. BT0506GH20 showed no activity against GlcNAc-β1,4-GlcNAc (chitobiose). These results 
suggest an importance of a +2 subsite for this enzyme. In overall, these results indicate that 
BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 β-hexosaminidases have different glycosidic 
linkage specificities. Based on the inefficiency observed in GlcNAc-β1,4-GlcNAc (chitobiose) 
degradation by BT0456GH20, BT0460GH20 and BT0506GH20, these enzymes may have a preference for a 
different aldohexaose, such as mannose, over D-GlcNAc in the +1 subsite.  
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Figure 4.31: Screening for the enzyme activity of BT0456GH20, BT0459GH20, BT0460GH20 and 
BT0506GH20 against simple disaccharides. 1µM of enzymes was incubated with 1mM of disaccharides. C – 
disaccharide control; +E – substrate incubated with the enzyme. Red highlight indicates an active enzyme. 
1mM of N-Acetyl-Glucosamine (GlcNAc), mannose (Man), N-acetyl-galactosamine (GalNAc) and galactose (Gal) 
standards were used. TLC plates were stained using the DPA stain. Monosaccharide products are labelled with 
arrows. 
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Interestingly, assays of BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 against chito-
oligosaccharides revealed that BT0459GH20 appears to be the only enzyme that can fully degrade 
chitobiose, chitotriose, chitotetrose and chitopentose during 1 hour of incubation at 37°C (Figure 
4.32). Due to a presence of a band representative of a chitobiose, it was observed that neither 
BT0456GH20, BT0460GH20 nor BT0506GH20 showed any activity against this disaccharide after 1 hour of 
incubation. Based on these results, all four GH20s seem to prefer chitotriose, chitotetrose and 
chitopentose, suggesting they may have a preference for oligosaccharide structures over 
disaccharides. Furthermore, none of the enzymes showed any activity on de-acetylated chito-
oligosaccharides, indicating the importance of the acetyl group for their activity (data not shown). 
  
 
 
Figure 4.32: Investigating the enzyme activities of BT0456GH20, BT0459GH20, BT0460GH20 and 
BT0506GH20 against chito-oligosaccharides. 1µM of enzymes was incubated with 1mM of substrates. C – 
substrate control. Red highlight indicates enzyme was active. 1mM of N-Acetyl-Glucosamine (GlcNAc) standard 
was used. TLC plates were stained with DPA stain. GlcNAc products are labelled with arrows. 
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To investigate whether BT0459GH20, BT0456GH20, BT0460GH20 and BT0506GH20 have the ability to cleave 
the Gal-β1,4-GlcNAc (LacNAc) disaccharide off, which would be indicative of an endo-glycosidase 
activity, enzyme assays against Lacto-N-neotetraose were set up following a protocol described in 
Section 2.3.2. The enzyme assays were incubated for 16 hours at 37 °C. The results displayed in 
Figure 4.33 show that none of the enzymes can hydrolyse LacNAc linkages, suggesting they are exo-
glycosidases.  
 
Figure 4.33: Screening for the activity of BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 
against Lacto-N-neotetraose. 1µM of enzymes was incubated with 1mM of substrate. C –substrate control. 
1mM of galactose (Gal) and N-Acetyl-Glucosamine (GlcNAc) standards were used. TLC plates were stained 
using the DPA stain.  
 
To determine the substrate preference of the four retaining β-hexosaminidases BT0456GH20, 
BT0459GH20, BT0460GH20 and BT0506GH20, the catalytic activities of the enzymes against defined 
disaccharides were measured at 340nm using a D-Mannose/D-Galactose detection kit (Megazyme) 
following the manufacturer’s instructions (see Section 2.3.5.2). The enzyme kinetics results showed 
that all four glycosidases displayed the highest activity against the pNP-β-GlcNAc and pNP-β-GalNAc, 
however these are synthetic substrates that are not found in nature (Figure 4.34). Based on the 
kcat/KM, BT0460GH20 and BT0506GH20 show a preference for GlcNAc-β1,2-Man disaccharide over the 
rest of the substrates tested. This disaccharide is commonly found in complex N-glycan structures. 
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Interestingly, BT0459GH20 shows a 2-fold preference for a synthetic GlcNAc-β1,3-Man disaccharide 
over GlcNAc-β1,2-Man. 
 
 
 147 
 
 
 
Figure 4.34: Graphical representation of the enzyme activity of BT0456GH20, BT0459GH20, BT0460GH20 
and BT0506GH20.  A) BT0456GH20 kinetic parameters. B) BT0459GH20 kinetic parameters. C) BT0460GH20 kinetic 
parameters. D) BT0506GH20 kinetic parameters. All reactions were performed at 37 °C in 20 mM NaH2PO4 (pH 
7.5). Rates were measured at 320 nm for pNP-linked substrates and at 340 nm for the disaccharides. The 
results were plotted in GraphPad Prism 7.0 software using non-regression analysis (see Section 2.3.5). The 
standard errors were generated from biological triplicates. For some substrates, labelled “–“ on the table, no 
kinetic parameters could be obtained. 
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4.3.5.4. Investigating the BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 activities 
against N-glycans 
 
To further explore the BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 substrate specificities, 
enzyme assays were set up against complex N-glycoproteins, such as bovine α1-AGP and bovine 
fetuin. These N-glycoproteins were chosen because they contain different complex N-glycan 
structures (Figure 3.6).  
Speculating that the GH18-liberated N-glycan structures are the likely targets for the GH20-family 
enzymes because B. thetaiotaomicron encodes numerous GH18 glycosidases but does not produce a 
PNGaseF-like enzyme, enzyme assays against native α1-AGP, GH18-digested α1-AGP and PNGAseF-
digested bovine fetuin were set up following a protocol described in Section 2.3.2.  The products 
were visualised using the TLC (Figure 4.35) (see Section 2.3.5). D-GlcNAc migrates very closely to the 
galactose on the TLC plate, thus a very the faint band is visible after the staining with the DPA 
(labelled with black arrows). Despite problems with the staining, the results show that all four GH20-
family enzymes appear to be active on all N-glycoproteins tested. Compared to BT0459GH20, 
BT0460GH20 and BT0506GH20, BT0456GH20 appears to release the least of D-GlcNAc off the native α1-
AGP (Figure 4.35-A).  
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Figure 4.35: Degradation of N-glycan structures by the β-hexosaminidases BT0456GH20, BT0459GH20, 
BT0460GH20 and BT0506GH20. A) Native bovine α1-AGP. Arrows indicate a band representative of a GlcNAc 
product. B) GH18-digested bovine α1-AGP. C) PNGaseF-digested bovine fetuin. Esial is BT0455; Egal is BT0461; C 
is control. TLC plate was stained using the DPA stain. GlcNAc is 1mM N-Acetyl-Glucosamine standard. S.A. is 
2mM sialic acid (Neu5Ac) standard; Gal is 1mM galactose standard.  
 
 
To investigate the N-glycan degradation by BT0456GH20, BT0459GH20 and BT0460GH20 glycosidases in 
more detail, the enzyme assays against de-sialylated and de-galactosylated N-glycoproteins were 
performed and the products were visualised using two different HPAEC-PAD programs (Section 
2.3.3). At the time these assays were set up, BT0506GH20 had not been cloned. Based on the 
appearance of a peak representative of a GlcNAc, these results show that all three BT0456GH20, 
BT0459GH20 and BT0460GH20 enzymes release GlcNAc from native and PNGAseF-digested bovine 
fetuin pre-treated with the sialidase BT0455GH20 and galactosidase BT0461GH20 (Figure 4.36). Based 
on the size of the peak in Panel A when all three GH20s were incubated with native fetuin, more 
GlcNAc release is observed than in individual GH20 assays, suggesting that each of the BT0456GH20, 
BT0459GH20 and BT0460GH20 enzymes may target different GlcNAc linkages. Similar pattern was 
observed in Panel B. GH20 treatment of the PNGaseF-liberated fetuin N-glycans revealed a range of 
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peaks that, based on their absence in Panel A, correspond to different N-glycan products (Figure 
4.36-B). However, due to the lack of N-glycan standards, they could not be identified. These results 
indicate that BT0456GH20, BT0459GH20 and BT0460GH20 could target different GlcNAc linkages present 
on tetra-antennary bovine fetuin N-glycans, such as β1,2/4/6 and bisecting β1,4- linkage. Judging by 
the size of a GlcNAc peak, a notable difference in BT0456GH20 activity on native fetuin compared to 
PNGaseF-cleaved fetuin N-glycans was observed, indicating a preference for N-glycan structures 
liberated from protein backbones (Figure 4.36-A and B). Interestingly, no such difference in activity 
was observed in BT0459GH20 and BT0460GH20 assays. Combined, these results support the suggestion 
that the N-glycan de-glycosylation by the B.theta0455-0461 enzymes is a sequential process 
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Figure 4.36: Exploring the activity of BT0456GH20, BT0459GH20 and BT0460GH20 against bovine fetuin. 
HPAEC-PAD chromatograms showing the release of N-Acetylglucosamine (GlcNAc). N-glycoproteins were pre-
treated with the sialidase BT0455GH33 and galactosidase BT0461GH2 because GH20s were previously confirmed 
to be exo-glycosidases. A) Activity on native bovine fetuin. B) Activity on PNGaseF-digested bovine fetuin.  
10mg/ml of N-glycoproteins were incubated with 1µM of enzymes in 20mM sodium phosphate (pH 7) buffer 
for 16 h at 37°C. 1:10 dilution was loaded onto the HPAEC-PAD. The concentration of monosaccharide 
standards used is 1mM. Predicted N-glycan elution peaks are highlighted in red box. The difference in size of 
galactose and GlcNAc elution peaks is due to detection response difference. Two different elution programs 
were used due to the requirement of the N-glycan peak separation of PNGaseF-digested sample.  
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To investigate the degradation of N-glycan structures in more detail, the GH20 enzyme assays 
against α1-AGP were performed and products were visualised using the U-HPLC combined with the 
LC-ESI-MS analysis (see Section 2.3.8). The results displayed in Figure 4.37 show a sequential 
degradation of α1-AGP N-glycans by BT1044GH18, BT0455GH33, BT0461GH2 and the three GH20s. Once 
again, BT0506GH20 had not been cloned at this stage. Based on no change observed between the 
peaks present in +GH18+GH33+GH2 sample (Figure 4.37-C) and the BT0456-treated sample, these 
results indicate that BT0456GH20 does not appear to display any activity against biantennary N-
glycans present on α1-AGP. Meanwhile, BT0459GH20 and BT0460GH20 appear to have similar substrate 
specificities, with BT0459GH20 producing more end-product. Judging by the mass spectrometry results 
displayed in Figure 4.37-B, endo-β-N-acetylglucosaminidase BT1044GH18 cleaves predominantly 
sialylated biantennary complex N-glycan structures off α1-AGP. These structures mainly contain 
GlcNAc-β1,2-Man linkages, thus explaining similar activities off BT0459GH20 and BT0460GH20. These 
results also suggest that BT0456GH20 cannot target GlcNAc-β1,2-Man linkages of N-glycan structures, 
explaining low upregulation data observed in the RNA seq analysis on α1-AGP (Figure 3.8).  
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Figure 4.37: Degradation of α1-AGP N-glycans.  Top panel: HPLC analyses of α1-AGP degradation by 
BT1044GH18, BT0455GH33, BT0461GH2, BT0456GH20, BT0459GH20 and BT0460GH20. Based on the height of sialic acid 
peaks, loss of HPLC detection sensitivity was observed in some of the samples. Bottom panel: Figures A, B, C 
and D show N-glycan structures corresponding to each U-HPLC peak that were constructed using the mass 
spectrometry data (See Table 4.1 for details).  
 
 
To increase our understanding of the roles of BT0456GH20, BT0459GH20 and BT0460GH20 in N-glycan 
breakdown, enzyme assays against NGA4 N-glycan were set up. NGA4 is a complex N-glycan 
structure found on several mammalian glycoproteins, including human α1-AGP (Ludger). It contains 
GlcNAc-β1,2/4/6-Man linkages. The assay was incubated for 16h at 37°C, products were labelled 
with procainamide and visualised using U-HPLC and mass spectrometry (see Section 2.3.8). The 
results displayed in Figure 4.38 show that BT0456GH20 can cleave two GlcNAc linkages off the NGA4 
structure, however the precise linkages could not be determined. Considering previously obtained 
data (Figure 4.37), these results suggest that BT0456GH20 cannot target GlcNAc-β1,2-Man linkages of 
complex N-glycan structures. In comparison, BT0459GH20 can hydrolyse all GlcNAc-β1,2/4/6-Man 
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linkages present on the NGA4 structure, confirming it is a broad-acting enzyme. Whereas a partial 
degradation of the NGA4 N-glycan structure was observed following the incubation with BT0460GH20. 
The results suggest that BT0460GH20 can cleave all GlcNAc linkages off NGA4 N-glycan structure much 
like BT0459GH20, but at significantly lower efficiency. Interestingly, it also leaves an N-glycan structure 
with one GlcNAc linkage still in-tact, supporting a potential importance of a +2 binding sub-site. 
 
Figure 4.38: Investigating the activity of BT0456GH20, BT0459GH20 and BT0460GH20 against complex N-
glycan structure NGA4. U-HPLC chromatograms of NGA4 (GlcNAc4Man3GlcNAc2) degradation are 
displayed. The predicted N-glycan structures corresponding to the 1, 2 and 3 of HPLC peaks have been 
constructed using the mass spectrometry data. NGA4 N-glycan was purchased from and enzyme assay 
products were analysed by Ludger Ltd. 
 
 
To quantitatively assess the BT0459GH20, BT0460GH20 and BT0506GH20 degradation of the bovine α1-
AGP N-glycan structures, relative rates of GlcNAc release were measured by setting up timed 
enzyme assays following a protocol described in Section 2.3.3. BT0456GH20 showed no detectable 
activity against bovine α1-AGP, so it could not be assessed in this experiment. To stay consistent, the 
α1-AGP was pre-treated with BT1044GH18, BT0455GH33 and BT0461GH2 prior to incubating with the 
GH20 enzymes. Based on the appearance of a peak representative of the N-glycan tetrasaccharide, 
these results show BT0459GH20 and BT0506GH20 are the most effective enzymes against the GlcNAc 
linkages present on α1-AGP N-glycans, capable of removing all GlcNAc caps within 40 minutes of 
incubation (Figure 4.39). In comparison, BT0460GH20 appeared to be relatively inefficient. Consistent 
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with previously observed results (Figure 4.38), BT0460GH20 leaves N-glycan structure with one GlcNAc 
linkage still present after 16 hours of incubation, suggesting it cannot access it.  
 
 
Figure 4.39: Investigating the efficiency of N-glycan degradation by BT0459GH20, BT0460GH20 and 
BT0506GH20. HPAEC-PAD chromatograms showing the timed degradation of N-glycans by the three GH20s. 
10mg/ml of N-glycoprotein was incubated with 1µM of each of enzymes in 20mM sodium phosphate (pH 7) 
buffer for up to 16 h at 37°C. Samples were diluted 1:10 before loading. Elution peaks representative of the N-
glycan tetrasaccharide (Man3GlcNAc1) and N-glycan pentasaccharide (GlcNAc1Man3GlcNAc1) products are 
labelled with arrows. 
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The products of the bovine α1-AGP N-glycan degradation by the BT0459GH20, BT0460GH20 and 
BT0506GH20 after 1 hour of incubation at 37 °C are displayed in Figure 4.40. Control is 10mg/ml of 
liberated α1-AGP N-glycan mixture pre-treated with BT0455GH33 and BT0461GH2 enzymes. Based on 
the disappearance of the peaks representative of complex N-glycan structures that contain exposed 
GlcNAc linkages, these results show that BT0459GH20 and BT0506GH20 catalyse the hydrolysis of all 
exposed GlcNAc linkages. Consistent with previous results, BT0460GH20 appears to cleave only one of 
the GlcNAc linkages present on the biantennary N-glycan structures. Interestingly, the data also 
suggests that BT0460GH20 prefers the PNGaseF-cleaved N-glycan over the GH18-cleaved N-glycan 
structure, a structure it would not normally see. None of the enzymes appear to have any activity on 
Gal-β1,4-GlcNAc (LacNAc) linkages, further confirming that they are exo-glycosidases. 
 
 
Figure 4.40: The degradation of bovine α1-AGP N-glycans by BT0459GH20, BT0460GH20 and 
BT0506GH20. Enzyme assays were set up using 10mg/ml of substrate and 1µM of each of enzymes. The 
reaction was incubated for 1 hour, inactivated and products were labelled with procainamide before being 
analysed using U-HPLC and mass spectrometry. The N-glycan structures corresponding to the U-HPLC peaks 
have been constructed using the mass spectrometry data (Ludger) and are labelled with arrows.  
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To explore the catalytic efficiency of the BT0459GH20, BT0460GH20 and BT0506GH20 β-hexosaminidases 
in more detail, the complex GH18-digested N-glycan degradation and the appearance of the N-
glycan core tetrasaccharide (Manα1-3(Manα1-6)Manβ1-4GlcNAc) product was monitored. GH18-
digested N-glycan mixture was chosen because B. thetaiotaomicron does not produce a PNGaseF-
like enzyme. Considering that GH20s were previously confirmed to be exo-glycosidases, N-glycan 
mixture was also pre-treated with the BT0455GH33 and BT0461GH2 enzymes. The N-glycan core 
tetrasaccharide peak was identified using the mass spectrometry data. The amount of 
tetrasaccharide produced by each enzyme was estimated based on the peak area (nC*min) obtained 
in the HPAEC-PAD chromatogram using the Chromeleon software. The results were plotted using 
GraphPad Prism 7.0 software and analysed (Figure 4.41). When incubated with the N-glycans 
derived from bovine α1-AGP, BT0459GH20 and BT0506GH20 displayed similar enzymatic efficiency and 
over time generated a higher amount of tetrasaccharide (Manα1-3(Manα1-6)Manβ1-4GlcNAc) 
compared to the BT0460GH20. Instead, BT0460GH20 was found to generate a high amount of an N-
glycan pentasaccharide (GlcNAcβ1-2Manα1-3(Manα1-6)Manβ1-4GlcNAc)(Figure 4.41-B). These 
results are consistent with the degradation pattern of BT0459GH20, BT0460GH20 and BT0506GH20 
observed in Figures 4.38, 4.39 and 4.40.  
 
Figure 4.41: Monitoring the N-glycan core tetrasaccharide production by BT0459GH20, BT0460GH20 
and BT0506GH20. A) The production of N-glycan core tetrasaccharide (Manα1-3(Manα1-6)Manβ1-4GlcNAc) 
over time. Peak area (nC*min) corresponding to the N-glycan core tetrasaccharide was recorded and plotted. 
Peaks corresponding to these structures are labelled with arrows. B) HPAEC-PAD chromatograms showing the 
N-glycan degradation products generated by BT0459GH20, BT0460GH20 and BT0506GH20 after 18 hours of 
incubation. The experiment was repeated three times and same pattern of degradation was observed. 
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To clarify the linkage specificity of BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20, enzyme 
assays against known structures of N-glycans available commercially at our industrial partner Ludger 
Ltd were set up following a protocol described in Section 2.3.8. The procainamide-labelled products 
were visualised using the U-HPLC combined with the mass spectrometry (LC-ESI-MS) analysis to 
accurately identify the N-glycan structures. The results displayed in Figure 4.42 suggest that 
BT0459GH20, BT0460GH20 and BT0506GH20 have an overlapping complex N-glycan specificities and can 
fully deglycosylate A2, A3 and A4 N-glycan structures. Based on the changes in the size of the peaks 
representative of N-glycan structures, BT0456GH20 seems to display the lowest efficiency, struggling 
to cleave GlcNAc-β1,2-Man linkages of A2 and A3 N-glycan structures. BT0456GH20 can hydrolyse the 
GlcNAc-β1,4-Man linkage of A3 N-glycan structure but shows no activity on A4 N-glycan structure. 
These results are consistent with the previous findings that BT0456GH20 is not specialised in 
targetting GlcNAc-β1,2-Man linkages (Figures 4.37 and 4.38). Interestingly, BT0460GH20 seems to 
prefer bisecting GlcNAc linkages on IgG N-glycans whereas BT0506GH20 cannot target them at all. 
Meanwhile, BT0456GH20 and BT0459GH20 show a trace activity against bisecting GlcNAc, although the 
activity of BT0459GH20 against it seems to be impaired by the presence of core fucose on IgG N-
glycans (Figure 4.42-D). Consistent with the previously obtained results, these data show that 
BT0459GH20 is a very efficient, broad-acting β-hexosaminidase. 
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Figure 4.42: Degradation of known N-glycan structures by BT0456GH20, BT0459GH20, BT0460GH20 and 
BT0506GH20. A) A2 N-glycan (GlcNAc2Man3GlcNAc2) degradation. B) A3 N-gycan (GlcNAc3Man3GlcNAc2) 
degradation. C) A4 N-glycan (GlcNAc4Man3GlcNAc2) degradation. D) IgG N-glycan (GlcNAc3Man3GlcNAc2Fuc1)  
degradation. IgG was pre-treated with sialidase BT0455GH33 and galactosidase BT0461GH2.  
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4.3.5.5. Crystallography and structure analysis  
4.3.5.5.1. Generating catalytic mutants of the four GH20s  
One of the key characteristics of the GH20-family β-hexosaminidases is the presence of the 
conserved catalytic residue pair – D-E that is usually preceded by the H-x-G-G motif. Amino acid 
sequence alignment of the four GH20-family enzymes allowed us to identify the conserved catalytic 
residues of BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 (Figure 4.43). Interestingly, 
BT0456GH20 appears to have a H-I-G-T motif instead of H-x-G-G motif seen in other GH20s, suggesting 
it may have an effect on the catalytic activity of this enzyme. Aspartic acid (D) marked with an 
asterisk (*) was successfully mutated to generate a catalytic mutant.  
 
Figure 4.43: Identifying catalytic residues of BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 β-
hexosaminidases. The sequence alignment was done using Clustal Omega and visualised using the Espript 
3.0. Amino acid residues displayed in red boxes are fully conserved. Amino acid residues framed in blue are 
70% or more similar based on their physicochemical properties. Catalytic residue is highlighted with an asterisk 
(*).  
 
 
The catalytic mutants D332N of BT0459, D328N of BT0460 and D347N of BT0506 were generated by 
site-direct mutagenesis following a protocol described in Section 2.1.10 and sequenced (Figure 4.44-
A). The primers used to generate these mutants are displayed in Supplemental table 3.2. The 
attempt to generate the BT0456GH20 catalytic mutant was unsuccessful. The mutant enzymes were 
expressed and purified following a protocol described in Section 2.1.25. The protein fractions 
collected from the gel filtration purification were visualised using SDS-PAGE and combined (Figure 
4.44-B). The purified mutant enzymes were tested and showed no activity against pNP-β-GlcNAc 
(data not shown). An E333A mutant of BT0459 and E329A mutant of BT0460 were also generated. 
Surprisingly, after testing them against pNP-β-GlcNAc, it was discovered that they retained their 
catalytic activity (data not shown).  
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Figure 4.44: Generating catalytic mutants of BT0459GH20, BT0460GH20 and BT0506GH20. A) Agarose gel 
showing the PCR products of the site-directed mutagenesis. M is a high-fidelity genomic DNA marker. Site-
directed mutagenesis products highlighted in red were sent for sequencing. B) SDS-PAGE analysis of purified 
protein fractions. Mw is a wide-range molecular weight marker (Sigma). 
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4.3.5.5.2. Generating catalytic mutant crystals 
Initially, it was attempted to generate the GH20 catalytic mutant crystals in a bound form with a 
ligand. The purified BT0459D332N, BT0460D328N and BT0506D347N proteins were concentrated to 
30mg/ml and co-crystallised with either 100mM GlcNAc-β1,2-Man or high-concentration of complex 
N-glycan derived from bovine α1-AGP. This N-glycan substrate was produced by digestion with 
BT1044GH18, BT0455GH33 and BT0461GH2 enzymes (see Section 2.3.7). Equal volume (100 nL) of protein 
and crystal screen solutions (Molecular Dynamics) were mixed using a sitting-drop vapour-diffusion 
method and the automated MosquitoR nanodrop dispensing robot (see Section 2.4.1.) Crystals were 
grown at 20 °C. Initial hit conditions were optimised and proteins were co-crystallised with either 
GlcNAc-β1,2-Man or the N-glycan mixture using the hanging-drop vapour diffusion method following 
a protocol described in Section 2.4.2. Numerous crystals of BT0459D332N, BT0460D328N and 
BT0506D347N catalytic mutants were obtained from various conditions over the months. The Figure 
4.45 illustrates a BT0459D332N crystal obtained by this approach. The crystal collection and analysis 
was done by Dr. Arnaud Baslé (ICaMB, NU). Unfortunately, none of the crystals diffracted and no 
data could be obtained. It was also attempted to soak BT0459D332N apo crystals in a high 
concentration of N-glycan mixture derived from α1-AGP using the same method as described above. 
Unfortunately, it was not successful and due to time constraints it could not be repeated. 
 
Figure 4.45: Examples of BT0459D332N crystals. Crystals were obtained by co-crystallization of BT0459D332N 
mutant with GlcNAc-β1,2-Man substrate. Crystals formed in 15% (w/v) PEG3350, 75mM sodium acetate, 0.1M 
of Bis-Tris (pH 7.5).  
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4.3.5.5.3. BT0459GH20 crystal structure 
After the attempt to obtain the crystals of the GH20 catalytic mutants in a bound form with a ligand 
failed, it was decided to generate the crystal structures of the wild type BT0456GH20, BT0459GH20, 
BT0460GH20 and BT0506GH20 proteins. The purified wild type proteins were concentrated and initial 
crystal screens (Molecular Dimensions) were set up using a Mosquito crystallisation robot (TTP 
Labtech) and sitting-drop crystallisation technique following a protocol described in Section 2.4.1. 
Initial hits were optimised and set up using the hanging-drop vapour diffusion method following a 
protocol described in Section 2.4.2. Only high-quality BT0459GH20 crystals were obtained after 10 
days in 10% (w/v) PEG3350, 0.1M sodium acetate and 100mM Bis-Tris (pH 7.5) (Figure 4.46). Due to 
time constraints, crystals of the other GH20s could not be obtained. 
 
Figure 4.46: Generating BT0459GH20 crystal. A) SDS-PAGE gel showing the purification of BT0459GH20 
protein expressed in E.coli Tuner cells. The fractions were combined and concentrated to 30mg/ml. B) 
BT0459GH20 crystals formed in 10% (w/v) PEG3350, 0.1M sodium acetate and 100mM Bis-Tris buffer (pH 7.5). 
 
 
 
 
 
 
 166 
 
The crystals were harvested and the data sets were collected by Dr. Arnaud Baslé at the Diamond 
Light Source (DLS). The structure of the wild type BT0459GH20 was solved by molecular replacement 
to a resolution of 2.4 Å. BT0459GH20 protein is 87kDa in size and consists of four domains. The 
BT0459GH20 structure presented a C-Terminal putative CBM (F5/8 type C) domain comprised of a β-
sandwich fold connected to the β-stranded linker domain (CHB_HEX_C1) followed by a GH20 domain 
that folds into (β/α)8-barrel topology and GH20b domain comprised of an β-sandwich fold and two 
α-helix strands (Figure 4.47).  
 
Figure 4.47: Wild type BT0459GH20 crystal structure. X-ray structure of BT0459GH20 was coloured 
according to the domain composition. The structure was rotated 180 degrees between the two images. 
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Because co-crystallisation of BT0459D332N catalytic mutant with an N-glycan or GlcNAc-β1,2-Man 
ligand failed, it was decided to investigate the structural similarities of the wild type BT0459GH20 to a 
structure of an exo-β-D-N-acetylglucosaminidase StrH from S. pneumoniae that was previously 
shown to target N-glycans (Pulvinage et al., 2011). Protein structure comparison server (DALI) and 
literature review was used to identify this enzyme. StrH is one of the virulence factors of 
S.pneumoniae required for effective human compex N-glycan utilisation. Because StrH is a much 
larger enzyme and contains two catalytic domains – GH20a and GH20b, the BT0459GH20 only shares 
21% sequence similarity to StrH. These GH20a and GH20b domains enable StrH to recognise GlcNAc 
residues on a range of complex N-glycan structures, such as bi-antennary, tetra-antennary and 
bisecting (Pulvinage et al., 2011). To compare the similarities, the BT0459GH20 crystal structure was 
overlaid with the GH20a and GH20b domains of StrH (PDB ID: 2YLA). The catalytic cores of both of 
the GH20a and GH20b domains are structurally very similar to the GH20 domain of BT0459GH20 
(Figure 4.48). Furthermore, the GlcNAc-bound -1 subsite of StrH GH20b domain is fully conserved in 
BT0459GH20, suggesting the similar substrate specificity of these enzymes. 
 
Figure 4.48: Structure of BT0459GH20 overlaid with GH20 domains from StrH of S. pneumoniae. X-ray 
structures of BT0459GH20 overlaid with A) StrepGH20a and B) StrepGH20b. X-ray structure of BT0459GH20 was 
coloured rainbow from red (C-terminus) to blue (N-terminus). StrepGH20a was coloured in purple and 
StrepGH20b was coloured in pink.  
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Pluvinage et al., 2011 has successfully co-crystallised the exo-β-D-N-acetylglucosaminidase StrH from 
S. pneumonia with an N-glycan ligand bound to the active site of the GH20b domain. The crystal 
structure of BT0459GH20 was overlaid with the structure of StrH GH20BE805Q bound to the bisecting N-
glycan structure NGA2B (GlcNAcβ1,2Manα1,3(GlcNAcβ1,2Manα1,6(GlcNAcβ1,4))Manβ1,4GlcNAc) 
(Figure 4.49). The results showed that StrepGH20b has an aromatic ramp (W877, yellow) structure 
that serves as a platform to anchor the N-glycan in place but BT0459GH20 seem to lack such loop 
structure (Figure 4.49-C). BT0459GH20 appears to have a very open binding site, with the catalytic 
residues D332 and E333 in a close proximity of the modelled N-glycan structure. There also appears 
to be an aromatic tryptophan (W405) close to the active site, suggesting it may be required for the 
BT0459GH20 interactions with the complex N-glycan structures.  Combined, these results suggest 
BT0459GH20 may employ a different N-glycan binding strategy. 
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Figure 4.49: Investigating the predicted N-glycan binding site of BT0459GH20 crystal structure. A) X-
ray structure of BT0459GH20 overlaid with StrepGH20b bound to the N-Glycan structure. B) Model of 
BT0459GH20 bound to the N-glycan structure. C) StrH GH20B catalytic mutant E805Q bound to the model N-
glycan structure. The aromatic ramp structure is coloured yellow. D) BT0459GH20 catalytic residues D332 and 
E333 in close proximity of the model N-glycan structure. X-ray structure of BT0459GH20 was coloured rainbow 
from red (C-terminus) to blue (N-terminus) and StrepGH20b was coloured in pink. N-glycan structure is shown 
as blue sticks. 
 
 
The crystal structure of the BT0459GH20 suggests that it is in an open-state conformation. The relative 
position of the putative CBM domain (F5/8 type C) compared to the active site indicates that 
BT0459GH20 may adopt a conformational change in order to bind large carbohydrate substrates, such 
as N-glycans. A protein structure comparison server (DALI) search revealed that the BT0459GH20 F5/8 
type C domain was structurally related to the CBM32 from a Clostridium perfringens β-
hexosaminidase (Ficko-Blean et al., 2006; PDB ID: 1TVG), suggesting the F5/8 type C domain may be 
a CBM. A structural alignment showed that BT0459GH20 F5/8 type C domain is almost identical to the 
CpCBM32 but it contains large loop structures that may be required to anchor N-glycans in place 
(Figure 4.50). 
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Figure 4.50: The comparison of the BT0459GH20 CBM domain to the CBM32. X-ray structure of a 
putative BT0459GH20 CBM domain (F5/8 type_C) was coloured red and CBM32 (PDB ID: 1TVG) was coloured in 
teal. The structure was rotated 180 degrees between the two images. The large loop structures are highlighted 
with black arrows.  
 
 
Based on the search results using the Conserved Domain Architecture Retrieval Tool (NCBI.org), the 
domain composition of the BT0459GH20 is quite unique. Out of 27196 β-hexosaminidases produced 
by bacteria, only 1449 contained this domain composition with majority being GH20 glycosidases 
encoded by members of Bacteroides species. Due to the lack of aromatic ramp present in StrH and 
relative positioning of the model N-glycan, it was speculated that the CBM domain (F5/8 type C) 
together with the linker domain (CHB_HEX_C1) may be involved in the N-glycan binding. The binding 
model showing the conformational change of the open state BT0459GH20 to the closed state the 
BT0459GH20 was made. The model predicts the CBM domain movement towards the BT0459GH20 
active site to bind and anchor the glycan structures in place (Figure 4.51).  The similar kind of 
movement has been observed by the CBM domain of a GH5_4 family enzyme from B. licheniformis 
(Liberato et al., 2016). 
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Figure 4.51: The predicted BT0459GH20 binding model. A) The open conformation of BT0459GH20. B) CBM 
domain (red) starts to move towards the active site. C) The predicted closed form of BT0459GH20. CBM domain 
fully covers the active site, which would potentially help to anchor the bound glycans in place. X-ray structure 
of BT0459GH20 was coloured rainbow from red (C-terminus) to blue (N-terminus). N-glycan model is coloured in 
blue. 
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4.3.5.6. Investigating the CBM domain involvement in N-glycan binding 
4.3.5.6.1. Generating the predicted CBM mutants of BT0459GH20, BT0460GH20 and 
BT0506GH20 
The F5_F8_type_C domain of BT0459GH20 was previously shown to be structurally related to the 
CBM32 (Figure 4.50). Thus, in this study we wanted to investigate the C-terminal domains of the 
BT0459GH20, BT0460GH20 and BT0506GH20 proteins in more detail and determine whether they are 
carbohydrate-binding domains that could be involved in the N-glycan binding.  BT0456GH20 was not 
investigated because it did not have a defined C-terminal domain sequence. The F5/8_type_C 
domain of BT0459GH20 only shares 26% sequence similarity to the F5/8_type_C domain of BT0460GH20 
and 25% sequence similarity to the PA14 domain of BT0506GH20 whereas F5/8_type_C domain of 
BT0460GH20 is 22% similar to the PA14 domain of BT0506GH20 (Figure 4.29). Although F5/8_type_C 
domain appears to be related to the PA14 domain, these results suggest that the domains present in 
these three GH20s may have very different roles.  The cloned C-terminal domains were labelled 
BT0459F5/8, BT0460F5/8 and BT0506PA14, analysed using the SDS-PAGE and compared to the full length 
proteins. The generated mutants expressed well (Figure 4.52). 
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Figure 4.52: Expression of the C-terminal domains of the BT0459GH20, BT0460GH20 and BT0506GH20.  
A) The domain composition of BT0459GH20, BT0460GH20 and BT0506GH20. The region of each protein encoding 
the predicted C-terminal CBM is highlighted in red. B) Purification of the BT0459F5/8. C) Purification of the 
BT0460F5/8. D) Purification of the BT0506pA14. Mw is a wide-range molecular weight marker (Sigma). Full-size 
protein purification is also displayed in Figure 4.2. 
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4.3.5.6.2. Biochemical characterization of the GH20 C-terminal domains 
The key role of CBM domains is binding to the substrates. The binding affinities of the recombinant 
C-terminal domains from BT0459GH20, BT0460GH20 and BT0506GH20 were initially investigated using the 
isothermal titration calorimetry (ITC; Section 2.31). Galactose (Gal), N-acetylglucosamine (GlcNAc) 
and mannose (Man) were tested as they are major structural components of complex N-glycans but 
no binding was observed (Figure 4.53). 
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Figure 4.53: ITC analysis of monosaccharide binding by the putative CBMs of BT0459GH20, 
BT0460GH20 and BT0506GH20. For these experiments, 10 mM of each of the monosaccharides and 30 µM of 
purified recombinant putative CBMs were used.  
 
Because ITC requires very high concentrations of glycans that can get prohibitively expensive to test, 
it was decided to investigate and quantify the bio-molecular interactions between the putative 
carbohydrate-binding modules of GH20-family β-hexosaminidases and complex N-glycans using the 
Microscale Thermophoresis (MST) (Section 2.34). The N-glycans used for MST were derived from 
bovine α1-AGP using the BT1044GH18, BT0455GH33 and BT0461GH2 treatment following a protocol 
described in Section 2.3.7.  The MST studies on the purified amine labelled BT0459F5/8, BT0460F5/8 
and BT0506PA14 revealed that all three displayed affinities for complex N-glycan structures over 
simple mono- or di-saccharides (Figure 4.54), supporting the prediction that these domains are 
carbohydrate binding modules. However, the binding observed in all cases was in a relatively low 
affinity range. The binding model and Kd values could only be estimated for carbohydrate-binding 
modules of BT0459 (Kd=804.4 ± 175.1) and BT0460 (Kd=554.9 ± 123.4). These results suggest that 
these novel CBM domains of BT0459GH20, BT0460GH20 and BT0506GH20 are involved in N-glycan 
binding. 
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Figure 4.54: MST analyses of carbohydrate binding by recombinant CBM domains of BT0459GH20, 
BT0460GH20 and BT0506GH20. 100 nM of fluorescently labelled proteins was used in this assay. A) CBM 
binding curves to N-glycans (6mM). Kd of BT0459 CBM is 804.4 ± 175.1 whereas Kd of BT0460 CBM is 554.9 ± 
123.4. B) CBM binding to GlcNAc-β1,2-Man (10mM). No binding was observed. C) CBM binding to Man-β1,4-
GlcNAc (10mM). No binding was observed. The experiments were repeated three times to ensure the data was 
consistent.  
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4.3.5.6.3. Generating the BT0459∆CBM mutant 
The solving of the BT0459GH20 crystal structure provided insight into how this enzyme could work. It 
was previously shown that C-terminal domain (F5/8 type_C) is indeed a carbohydrate-binding 
domain (Figure 4.54). In this study, we wanted to further investigate the involvement of the CBM32-
like domain of BT0459GH20 in the N-glycan degradation and to determine what effect removing this 
domain would have on the enzyme activity and substrate specificity. A truncated form of BT0459GH20 
lacking the CBM domain, BT0459∆CBM, was generated using the data obtained from the crystal 
structure (Figure 4.50) and a protocol described in Section 2.1.13. Mutant was expressed and 
purified using the protocols described in Sections 2.1.20 and 2.1.21 (Figure 4.55).  A generated 
BT0459∆CBM mutant lacks the F5_F8_type_C (Pfam) domain and is predicted to be of 66 kDa in size. 
 
Figure 4.55: Generating a BT0459∆CBM mutant. A) The domain composition of BT0459GH20. The 
truncated BT0459∆CBM mutant lacks the F5_F8_type_C domain. B) SDS-PAGE gel of BT0459∆CBM 
purification. The predicted size of the mutant is ~66 kDa. Mw is a wide-range molecular weight marker (Sigma-
Aldrich). 
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4.3.5.6.4. Investigating the enzyme activity of the BT0459∆CBM 
To initially investigate the activity of the BT0459∆CBM, colorimetric assays against pNP-β-GlcNAc 
and pNP-β-GalNAc substrates were set up and incubated for 30 minutes at 37 °C. The positive results 
were observed via the change in assay colour to yellow and showed that BT0459∆CBM mutant 
retained its activity against these substrates. To investigate BT0459∆CBM activity further, enzyme 
assays against the simple disaccharide structures that BT0459GH20 was previously shown to be active 
against (see Figure 4.31) were set up and incubated for 1h at 37 °C (Section 2.3.5). Based on the 
release of monosaccharides, the results revealed no notable differences in BT0459∆CBM activity 
compared to the full-length BT0459GH20 against these substrates (Figure 4.56). 
 
Figure 4.56: Screening for BT0459∆CBM activity against simple disaccharides. 1µM of enzyme was 
incubated with 1mM of disaccharides. C – disaccharide control; +E– substrate incubated with the enzyme. 
1mM of monosaccharide standards were used. Thin-layer chromatography (TLC) plate was stained using the 
DPA stain. Monosaccharide products are indicated by arrows. 
 
No notable difference in BT0459∆CBM activity compared to the BT0459GH20 was observed when it 
was incubated with chito-oligosaccharides, suggesting the CBM32-like domain may not be required 
for the BT0459GH20 activity against these substrates (Figure 4.57). 
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Figure 4.57: Comparing the BT0459∆CBM activity versus BT0459GH20 against chito-oligosaccharides. 
1µM of enzyme was incubated with 1mM of chito-oligosaccharides. C – substrate control. 1mM of GlcNAc 
standard was used. Thin-layer chromatography (TLC) plate was stained using the DPA stain. Monosaccharide 
products are indicated by arrows. 
 
 
 
 
To investigate the differences in the BT0459GH20 and BT0459∆CBM catalytic efficiency, kinetic 
parameters were measured and compared (Section 2.3.5.1) The kinetic parameters and respective 
kinetic curves for each substrate are shown in Figure 4.58. These results suggest that BT0459GH20 is 
more catalytically efficient than BT0459∆CBM. Based on the kcat/KM values, BT0459GH20 is 1.2-fold 
more efficient in catalysing the hydrolysis of GlcNAc-β1,2-Man than BT0459∆CBM. The same pattern 
was observed in activity against pNP-β-GlcNAc substrate, suggesting the CBM domain may be 
involved in enhancing of the catalytic activity of the BT0459. 
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Figure 4.58: Kinetic parameters of BT0459∆CBM mutant. The reactions were performed at 37 °C in 20 
mM NaH2PO4 (pH 7.5). Rates were measured at 320 nm for pNP-linked substrates and 340 nm for GlcNAc-
β1,2-Man. The data was plotted in GraphPad Prism 7.0 software using non-regression analysis (see Section 
2.3.5). The standard errors were generated from technical triplicates.  
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To investigate the differences in BT0459GH20 and BT0459∆CBM activity against complex N-glycans, 
the enzyme assays against α1-AGP pre-treated with the BT1044GH18, BT0455GH18 and BT0461GH2 were 
set up by incubating 1µM of enzymes with 10mg/ml of N-glycan mixture for 20 minutes at 37 °C. The 
products were visualised using the HPAEC-PAD following a protocol described in Section 2.3.3. After 
quantifying the relative peak area (nC*min) of the tetrasaccharide product, the results show that 
there was no difference in complex N-glycan degradation pattern between the BT0459GH20 and 
BT0459∆CBM mutant, suggesting CBM domain may not be required for α1-AGP complex bi-
antennary N-glycan degradation (Figure 4.59). The experiment was repeated three times using 
freshly purified enzymes and different incubation timescales (0-16h) (Figure 4.60). Based on the 
appearance of a peak representative of a tetrasaccharide N-glycan structure, same pattern of N-
glycan degradation was observed. 
 
Figure 4.59: Investigating the differences in N-Glycan (α1-AGP) degradation by BT0459GH20 and 
BT0459∆CBM. 10mg/ml of N-glycoprotein was incubated with 1µM of enzymes in 20mM sodium phosphate 
(pH 7) for 1 h at 37°C. 1:10 dilution was loaded onto the machine. The concentration of monosaccharide 
standards used is 1mM.  
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Figure 4.60: Time course of N-Glycan (α1-AGP) degradation by BT0459GH20 and BT0459∆CBM. 
10mg/ml of N-glycoprotein was incubated with 1µM of enzymes in 20mM sodium phosphate (pH 7) at 37°C. 
1:10 dilution was loaded onto the machine. The concentration of monosaccharide standards used is 1mM. 
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4.3.6. BT0458GH2: investigating a mannosidase activity 
4.3.6.1. Introduction 
D-Mannose is a simple hexose sugar that forms a six-carbon ring. It is a 2-epimer of glucose that is 
primarily found as a sweet-flavoured α- or bitter-flavoured β-linked anomer of the pyranose. 
Mannose is widely spread in nature – it is often present as a structural component of carbohydrates 
found in plant cell walls, fungi, bacteria and mammals (Sharma et al., 2014). 
Mannosidases are a large group of enzymes that are specialised in catalysing the hydrolysis of the 
glycosidic mannose linkages found in complex carbohydrates. They are grouped into α-
mannosidases and β-mannosidases. Majority of β-mannosidases are classified into the glycoside 
hydrolase (GH) family number 2 (GH2) of the CAZy classification, along with β-galactosidases and β-
glucuronidases (www.cazy.org). To date, it is known that B. thetaiotaomicron produces 33 GH2-
family enzymes, 5 of which are annotated as β-mannosidases.  Like the rest of GH2 family of 
enzymes, β-mannosidases are retaining enzymes that follow a double-displacement Koshland 
mechanism (CAZypedia.org, GH2 family).  
In gastrointestinal tract (GI), mannose can be found in complex carbohydrate structures decorating 
glycoconjugates, such as N-glycoproteins. On N-glycoproteins, mannose residues usually form α3/6- 
and β1,4- glycosidic linkages. B. thetaiotaomicron, a dominant member of human gut microbiota, 
possesses a β1,4-mannosidase BT0458GH2 (BtMan2A) that has been previously characterised by Dr. 
Louise Tailford. It is a five-domain β-mannosidase that is structurally similar to E. coli LacZ β-
galactosidase (Tailford et al., 2007).  Although BT0458GH2 has been structurally and biochemically 
characterised, it was not investigated in the context of N-glycan degradation.  As previously 
discussed (Figure 3.7.1), BT0458GH2 is upregulated when B. thetaiotaomicron is grown on N-
glycoproteins as sole carbon sources, compared to the glucose control. Therefore, the aim of this 
study was to investigate the BT0458GH2 involvement in N-glycan degradation. 
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4.3.6.2. Bioinformatics analysis of BT0458GH2 
To investigate the similarities of BT0458GH2 to other known β-mannosidases, the BT0458GH2 amino 
acid sequence was used as a query for KEGG database search to identify the orthologous proteins. 
Sequence similarity database (SSDB) tool hosted by Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database was used to generate a dendrogram of top 50 best protein matches to BT0458GH2 
(Figure 4.61). The results show that BT0458GH2 type of GH2 β-mannosidase is highly conserved in 
Bacteroides and has closely-related orthologues in numerous members of gut microbiota, including 
β-mannosidase from B. fragilis that was previously shown to be involved in complex N-glycan 
degradation (Cao et al., 2014) 
 
 
Figure 4.61: A dendrogram showing the taxonomic relationship of BT0458GH2 to the 50 best 
orthologous β-mannosidases. KEGG SSDB tool was used to perform a sequence similarity search on 
BT0461. The results were visualised by producing a dendrogram of best orthologues to BT0458GH2 using a 
Smith-Waterman similarity score was used to identify the best hits. 
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Using the dendrogram displayed in Figure 4.61, β-mannosidases from B. vulgatus (BVU_4138), B. 
fragilis (BF_1728), B.ovatus (Bovatus_00311) and B. xylanisolvens (BXY_09330) were selected for the 
comparison due to their close taxonomic relationship to BT0458GH2. The sequences were aligned 
using the Clustal Omega Multiple Sequence Alignment tool and visualised using the ESPript 3.0 tool. 
Based on the fully conserved amino acid residues (highlighted in red), the results show that 
BT0458GH2 amino acid sequence is closely related to these β-mannosidases (Figure 4.62). The 
similarity matrix obtained from Clustal Omega alignment shows that BT0458GH2 is 80% identical to 
Bovatus_00311 and BXY_09330; 75% similar to BF_1728 and 64% related to BVU_4138. These 
results suggest that these mannosidases could have similar enzymatic activities and may target N-
glycan structures. This theory is reinforced by the fact that all four enzymes share the same active 
site residues, that have been previously identified in BT0458GH2 by Dr. Louise Tailford (Tailford et al., 
2007). These are Trp395, Asn461, Glu462, Try537, Glu555 and Trp645 in BT0458GH2.  
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Figure 4.62: Amino sequence alignments of B. thetaiotaomicron β-mannosidase BT0458GH2 to the 
orthologous Bacteroides spp. β-mannosidases. Amino acids highlighted in red are fully conserved. 
Conserved active site residues are highlighted in black boxes and labelled with an asterisk (*).  
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4.3.5.3. Confirming BT0458GH2 substrate specificity 
To initially screen BT0458GH2 enzyme activity and confirm the results obtained by Dr. Louise Tailford 
(Tailford et al., 2007), colorimetric assays against the para-Nitrophenol (pNP)-linked substrates were 
set up as described in Section 2.3.5.1 using 1 mM of pNP-substrate and incubation for 30 min at 37 
°C . Consistent with the results obtained by Tailford et al. (2007), the BT0458GH2 activity was only 
detected against p-nitrophenyl-β-mannopyranoside (pNP-β-Man). No activity was detected against 
pNP-α-Man nor pNP-β-Gal, confirming BT0458GH2 is a β-mannosidase. To investigate specific glycan 
structures β-mannosidase BT0458GH2 targets and investigate the potential differences compared to 
the activity of BT1033GH130,  a β-manno-phosphorylase that was shown to be upregulated in RNA-seq 
data when B. thetaiotaomicron was grown on N-glycoproteins (Figure 3.7.1) , enzyme assays against 
various disaccharide substrates were set up following a protocol described in Section 2.3.5. The 
assays were incubated in sodium phosphate 20mM (pH 7) for 16 hours at 37 °C, aerobically and 
visualised using the TLC following a protocol described in Section 2.3.2. Based on the appearance of 
the bands representative of monosaccharide products, the results showed that β-mannosidase 
BT0458GH2 and β-manno-phosphorylase BT1033GH130 are active against β1,4-mannobiose and Man-
β1,4-GlcNAc (Figure 4.63). Neither BT0458GH2 neither BT1033GH130 showed any activity against Man-
β1,2-GlcNAc, suggesting they both have a β1,4-linkage specificity.  BT1033GH130 catalyses the 
phosphorolysis of mannose disaccharides, thus it produces mannosyl-phosphate products (*, Dr. 
Lucy Crouch, unpublished data).  
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Figure 4.63: Screening for the enzyme activity of BT0458GH2 and BT1033GH130 against simple 
disaccharides. 1µM of BT0458GH2 and BT1033GH130 were incubated separately with 1mM of disaccharides. C – 
disaccharide control; +E0458 – substrate incubated with BT0458GH2. +E1033 – substrate incubated with 
BT1033GH130. Active enzymes are highlighted in red. 1mM of mannose standard was used. The bands labelled 
with an arrow show mannose release whereas the asterisks (*) show mannosyl-phosphate products. TLC plate 
was stained using the DPA stain.  
 
 
To investigate the catalytic efficiency of the β-mannosidase BT0458GH2 and compare to the results 
obtained by Dr. Louise Tailford (Tailford et al., 2007), the kinetic parameters of the enzyme against 
β1,4-Mannobiose was measured at 340nm using D-Mannose detection kit (Megazyme) following the 
manufacturer’s instructions (Section 2.3.5.2). Meanwhile, the BT0458GH2 activity against pNP-β-Man 
was measured at 320nm following a protocol described in Section 2.3.5.1. The kinetic parameters 
and respective kinetic curves for each disaccharide are shown in Figure 4.64. The difference in 
catalytic preference is displayed in variation in the kcat and KM values. Based on the kcat and KM values 
the results suggest that β1,4-mannobiose is not a preferred substrate for the BT0458GH2 β-
mannosidase.  Unfortunately, the enzyme kinetics experiments against Man-β1,4-GlcNAc could not 
be performed due to commercial unavailability of large quantities of this substrate. However, the 
kinetic properties obtained by Tailford et al. (2007) show that β-mannosidase BT0458GH2 has a 
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preference for Man-β1,4-GlcNAc over β1,4-Mannobiose. Man-β1,4-GlcNAc is a core structure found 
in all N-glycans, suggesting that this enzyme may have preference for it. 
 
Figure 4.64: Kinetic properties of BT0458GH2. The enzyme reactions were performed at 37 °C with 20 mM 
NaH2PO4 (pH 7.5). Rates were measured at 320 nm for pNP-Gal and 340 nm for the β1,4-Galactobiose. The 
results were plotted in GraphPad Prism 5.0 software using non-regression analysis (see Section 2.3.5). The 
standard errors were generated from biological triplicates. 
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4.4. Discussion 
In this chapter, the enzymes involved in complex N-glycan utilization by B. thetaiotaomicron were 
characterised and their biological roles in N-glycan degradation were identified. 
Seven enzymes encoded by the B.theta0455-0461 locus and BT0506GH20 were upregulated when the wild 
type B. thetaiotaomicron was grown on N-glycoproteins as sole carbon sources, compared to the 
glucose control (Figure 3.7.1). These genes include the sialidase BT0455GH33, four β-hexosaminidases 
BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20, β-mannosidase BT0458GH2 and β-galactosidase 
BT0461GH2. Very high basal expression levels of these genes suggests they are important for the N-
glycan metabolism and proliferation of the B. thetaiotaomicron. 
The BT0455GH33 is the only known sialidase produced by B. thetaiotaomicron. Investigation of its 
activities in the context of N-glycan degradation in vitro has identified it to be the key enzyme 
required for the removal of terminal sialic acid caps in order for other enzymes to access their 
carbohydrate targets. It is a broad-acting sialidase that can catalyse the hydrolysis of any terminal 
sialic acid linkages, such as α2-3/6/8-, present on both human and bovine N-glycoproteins (NeuAc 
and NeuGc) (Figure 4.6; Figure 4.7; Figure 4.8). These results suggested that the sialylated N-glycan 
degradation by B. thetaiotaomicron could be a sequential process. Interestingly, B. thetaiotaomicron 
cleaves the sialic acid caps but does not possess a genetic machinery to utilize this monosaccharide, 
releasing it into the environment where it can be digested by other specialised bacteria.  
The BT0457CE is a sialic acid esterase that works in conjunction with the sialidase BT0455GH33 (Figure 
4.14). It was found to be 60% homologous to the fully characterized sialic acid-specific 9-O-
acetylesterase from T. forsythia (Figure 4.10). Because B. thetaiotaomicron does not utilise the sialic 
acid as a substrate, the precise role of BT0457CE remains to determined. However, it may be required 
to boost the efficiency of the sialic acid removal from the N-glycans to uncap the underlying 
carbohydrate structures. 
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The BT0461GH2 β-galactosidase activity has been screened against a range of disaccharides, 
oligosaccharides and de-sialylated N-glycan structures (Figures 4.17-4.22). It has a Gal-β1,4- linkage 
specificity and shows a kinetic preference for Gal-β1,4-GlcNAc disaccharide, a structural component 
of complex N-glycan structures (Figure 4.18). Although BT0461GH2 could catalyse the hydrolysis of all 
β1,4-linked substrates tested, combined, these results suggest that Gal-β1,4-GlcNAc-linkages found 
on N-glycans are its preferential target. The requirement for the de-sialylation of N-glycan substrates 
by the sialidase BT0455GH33 before BT0461GH2 could cleave the galactose caps confirmed that 
BT0461GH2 is an exo-glycosidase and further reinforced the claim that N-glycan degradation by B. 
thetaiotaomicron is a sequential process.  
Four N-acetyl-β-hexosaminidases were characterised in this chapter: BT0456GH20, BT0459GH20, 
BT0460GH20 and BT0506GH20. It was a challenging task to investigate their substrate specificities. 
Despite having quite different amino acid sequences (Figure 4.29; Figure 4.30), the four enzymes 
appeared to display similar enzymatic activities against simple disaccharides (Figure 4.31) and chito-
oligosaccharides (Figure 4.32) tested. During the comparison, the overlapping specificities of the 
glycosidases were noted. The only significant difference that was observed at this point was the 
superior enzymatic efficiency of BT0459GH20 whereas the BT0456GH20 and BT0506GH20 displayed the 
lowest catalytic efficiency against these substrates, suggesting an importance of a +2 subsite of 
these glycoside hydrolases. These results suggested that BT0459GH20 prefers a GlcNAc in -1 subsite 
and can accommodate any other aldohexose in +1 subsite. The same pattern was observed in the 
enzyme kinetics data, however all four β-hexosaminidases showed a preference for GlcNAc-β1,2-
Man disaccharide commonly found on complex N-glycan structures in nature (Figure 4.34). The 
active site of the four GH20 glycosidases appears to be conserved, thus they likely possess different 
structural features responsible for these differences in activities. Furthermore, the BT0456GH20, 
BT0459GH20, BT0460GH20 and BT0506GH20 were confirmed to be exo-glycosidases (Figure 4.33). They 
require galactose caps to be removed by the galactosidase, such as BT0461GH2, before they can 
access their carbohydrate targets, further supporting the claim that N-glycan degradation is a 
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sequential process. It was also found that BT0459GH20 is the only enzyme out of the four GH20s that 
can efficiently digest all chito-oligosaccharides, including chitobiose (GlcNAc-β1,4-GlcNAc), 
suggesting it may be required to cleave the terminal GlcNAc-β1,4-GlcNAc linkage of the scavenged 
PNGaseF-cleaved N-glycan structure.  
The four GH20 enzymes displayed differential substrate specificities when screened for activity 
against various complex N-glycan structures (Figures 4.35-42). These results also confirmed that 
BT0459GH20 is a broad-acting enzyme. Interestingly, BT0506GH20 displayed almost identical N-glycan 
GlcNAc linkage degrading efficiency as BT0459GH20 (Figure 4.40), suggesting it is specialized in 
targeting complex N-glycans. This claim is supported by the RNA seq data analysis results, where 
BT0506GH20 is the highest upregulated β-hexosaminidase (Figure 3.7.1). Considering the minimal 
activity displayed against the disaccharide substrates tested (Figure 4.31), these results also support 
the hypothesis for the importance of the +2 subsite in BT0506GH20. Meanwhile, BT0456GH20 remained 
the least efficient enzyme of the four. It was found to be unable to degrade GlcNAc-β1,2 linkages, 
but could cleave GlcNAc-β1,3/6 linkages (Figures 4.38 and 4.42), suggesting a specificity for the 
bisecting, tri-antennary and tetra-antennary complex N-glycan structures. It would also explain such 
a low-fold upregulation of BT0456GH20 seen on the RNA seq data of B. thetaiotaomicron grown on 
primarily bi-antennary bovine α1-AGP complex N-glycans (Figure 3.7.1). On the other hand, 
BT0460GH20 showed preference for one of the GlcNAc-β1,2 linkages of the bi-antennary complex N-
glycan structure (Figure 4.41), suggesting the presence of GlcNAc caps on both of the bi-antennary 
N-glycan arms is required for its enzymatic efficiency or for binding. 
 Because N-glycoproteins can have an incredibly diverse glycosylation pattern, the degradation 
pathways of the fluorescently-labelled known complex N-glycan structures were analysed. This kind 
of assay is highly sensitive, thus allowing for an accurate identification of specific N-glycan linkages 
the four GH20s target (Figure 4.42). Based on these results, BT0460GH20 appears to have a bisecting 
GlcNAc-β1,4-Man linkage specificity. Similar to BT0459GH20 activity, BT0506GH20 could degrade all 
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GlcNAc linkages present on these complex N-glycan structures, with the exception of the bisecting 
GlcNAc. BT0456GH20 and BT0459GH20 showed a trace bisecting GlcNAc activity, but only when the 
galactose has been removed from both of the bi-antennary N-glycan arms, suggesting bisecting 
GlcNAc is not their preferential target (Figure 4.42-D). Enzymatic efficiency of BT0459GH20 on 
bisecting GlcNAc is also impaired by the presence of the core fucose on PNGaseF-cleaved IgG N-
glycan structures (Figure 4.42-D). Considering B. thetaiotaomicron does not normally see PNGaseF-
cleaved complex N-glycans, it is not surprising that BT0459GH20 struggles to target these core-
fucosylated N-glycan structures. Although it is active on all complex N-glycan structures tested, 
BT0459GH20 shows a slight preference for GH18-cleaved bi-antennary complex N-glycan structures 
over the PNGaseF-cleaved ones whereas BT0506GH20 and BT0460GH20 do not display any preference. 
Based on these results, when the four GH20 glycosidases are combined, they should be capable of 
cleaving off every GlcNAc linkage found on typical complex N-glycan structures.  
In the structure of BT0459GH20, the CBM32-like domain appears to be positioned above the active 
site like an ‘arm’, suggesting it may be involved in the binding of complex N-glycan structures (Figure 
4.48). Overlay of the BT0459GH20 structure with the StrepGH20b domain of N-acetyl-β-
hexosaminidase (StrH) from S. pneumonia bound to the NGA2b N-glycan structure identified a lack 
of a platform loop in BT0459GH20 that StrepGH20b possesses (Figure 4.49). This difference and the 
low sequence identity between StrH and BT0459GH20 (21%) suggests that BT0459GH20 could employ a 
different method of N-glycan binding. A proposed binding model involves a novel CBM domain 
(F5/8_typeC) closing down over the active site of GH20 domain, binding and anchoring the potential 
N-glycan substrate in place (Figure 4.51). This kind of domain movement has already been observed 
by the CBM domain of a GH5_4 family enzyme from B. licheniformis (Liberato et al., 2016). This 
hypothesis is further reinforced by the confirmation of the involvement of the CBM domains of 
BT0459GH20, BT0460GH20 and BT0506GH10 in the binding of the complex biantennary N-glycan 
structures (Figure 4.54). Most of the CBMs bind their ligands with relatively low affinities compared 
to protein-protein binding interactions and this was observed in this experiment, where low binding 
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affinity was displayed by the CBM domains of BT0459GH20, BT0460GH20 and BT0506GH20. More complex 
N-glycan structures (e.g. tetraantennary) should be tested to investigate whether these GH20 CBMs 
may be specialised in binding certain types of complex N-glycans.  
The truncated derivative of BT0459GH20 lacking its C-terminal CBM (BT0459∆CBM) domain displayed 
no significant difference in activity compared to the wild type BT0459GH20 when assayed against 
bovine α1-AGP N-glycans, suggesting the CBM is not required for the binding and degradation of 
simple biantennary N-glycan structures. Instead its role may be to effectively bind and degrade more 
complex tri- and tetra-antennary N-glycan structures, although this remains to be investigated.  
The work presented in this chapter indicates a model of N-glycan degradation where the activity of 
B. thetaiotaomicron enzymes is sequential. The BT0455GH33, BT0456GH20, BT0457CE, BT0459GH20, 
BT0460GH20, BT0461GH20 and BT0506GH20 enzymes characterised and discussed in this chapter can 
degrade the typical complex N-glycan structure down to the core N-glycan tetrasaccharide (Manα1-
3(Manα1-6)Manβ1-4GlcNAc) or pentasaccharide (Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc), 
depending on what enzyme was used to cleave it off the protein backbone (BT1044GH18 or PNGaseF). 
For the thermo-stable exo- β1,4-mannosidase BT0458GH2 to access its target Man-β1,4-GlcNAc, the 
α-mannoses capping it must be removed.  The RNA seq data analysis suggests that N-glycan 
degradation requires the cooperative activity of several binding proteins and degrading enzymes 
encoded by several other PULs (Figure 3.7.1; Figure 3.7.2). For example, the full degradation of the 
plant rhamnogalacturonan-II (RG-II) by B. thetaiotaomicron requires three different PULs (Ndeh et 
al., 2017). In order to establish this model of degradation, the other key enzymes required for the 
full N-glycan degradation must be characterised. 
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Chapter 5: Proposed model of N-glycan utilization by B. 
thetaiotaomicron 
 
5.1. Introduction  
All N-glycans share a common core structure (Man-α1,6(Man-α1,3)Man-β1,4GlcNAc-β1,4GlcNAc-β1-
Asn-X-) and are grouped into high-mannose, complex and hybrid structures (Stanley et al., 2009). 
Complex N-glycans are the most commonly found structures in the human gut in a form of dietary 
and host-derived N-glycoproteins. These structures can be further classified into biantennary, 
triantennary or tetraantennary structures and are commonly composed of N-acetylglucosamine 
(GlcNAc), mannose, galactose and sialic acid residues (Figure 5.1). In some cases, they can also 
contain a bisecting N-acetylglucosamine (GlcNAc) residue attached to the core mannose. For 
example, N-glycosylation patterns in immunoglobulin A (IgA), a most abundant secreted antibody in 
the human gut, are extremely diverse and change in response to the human health state (e.g. in 
disease, during pregnancy) (Bondt et al., 2017). In healthy individuals, IgA predominantly contains 
bisecting sialylated biantennary and triantennary complex N-glycan structures. In some rare cases, 
complex N-glycan structures can also contain N-acetylgalactosamine (GalNAc) residues (Goettig et 
al., 2016). 
The human gut microbiota is exposed to a range of dietary and host-derived sources of N-glycans. 
The N-glycan degradation pathways have been investigated in a number of pathogenic bacteria, 
such as an opportunistic pathogen B. fragilis, where it was found to be important for the survival in 
the extra-intestinal niche (Cao et al., 2014). However, the knowledge of N-glycan utilisation 
pathways by the symbiotic gut microbiota was lacking. 
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Figure 5.1: Schematic representation of complex N-glycan structures found on mammalian N-
glycoproteins. N-glycan structures can be biantennary, triantennary and tetraantennary. The N-glycan 
structures were built using the Glycan Builder tool hosted on Expasy.org.  
 
 
In Chapter 3 it was shown that a number of human gut Bacteroides can grow on the glycan 
component of N-linked glycoproteins and B. thetaiotaomicron was used as a model to understand 
the mechanism of the breakdown process (Figure 3.3). To degrade such complex N-glycan 
structures, B. thetaiotaomicron requires a cooperative activity of numerous enzymes encoded by 
multiple polysaccharide utilization loci (PULs). These PULs have been identified using the RNA seq 
data analysis (Figure 3.7.1). Previous studies outlined in Chapter 4 provided initial insights into how 
B. thetaiotaomicron degrades complex N-glycans and points to an exo-model of liberated N-glycan 
degradation where the N-glycan structures are first cleaved off protein backbone by GH18 
endoglycosidase. No full complex N-glycan degradation pathway has been described in a commensal 
gut microbe previously. For example, the N-glycan utilisation that was observed in an opportunistic 
pathogen B. fragilis in vitro also appears to rely on the activity of the GH18 endoglycosidase, a 
member of an outer member protein complex termed Don (Cao et al., 2014). However, the full 
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degradation pathway was not investigated and this PUL does not contain all types of enzymes 
required for a full deglycosylation of complex N-glycans, suggesting similar multi-PUL apparatus as 
described in this thesis could be employed by this bacterium.  
 However, to establish a model of degradation, the importance of all key N-glycan degrading 
enzymes identified in Chapters 3 and 4 to the proliferation of B. thetaiotaomicron must be clarified. 
The aim of this chapter was to review the enzyme activities, investigate their importance to the 
bacterium and ultimately, to build a model of N-glycan degradation and investigate how this 
apparatus is conserved in other members of gut microbiota. 
5.2. Research objectives 
I. Review and clarify the activities of enzymes involved in complex N-glycan degradation 
II. Confirm the cellular localization of the enzymes involved in complex N-glycan degradation 
III. Build a model of complex N-glycan degradation 
IV. Investigate the conservation of the key enzymes of N-glycan degradation apparatus in other 
members of gut microbiota 
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5.3. Results 
5.3.1. Overview of enzymes involved in N-glycan degradation 
To degrade complex N-glycan structures, B. thetaiotaomicron requires a cooperative activity of 
multiple N-glycan binding proteins and N-glycan degrading enzymes. In Chapter 4, enzymes encoded 
by B.theta0455-0461 locus and BT0506GH20 were characterised. These included a sialidase BT0455GH33, 
sialic acid esterase BT0457CE, β1,4-galactosidase BT0461GH2, four β-hexosaminidases BT0456GH20, 
BT0459GH20, BT0460GH20, BT0506GH20 and β1,4-mannosidase BT0458GH2 (Figure 5.2). Combined 
activity of these glycosidases displayed an exo-model of liberated complex N-glycan structures. Due 
to the complexity of the N-glycan structures, it was observed that full N-glycan degradation also 
requires α-mannosidases and endo-β-N-acetylglucosaminidases not present in B.theta0455-0461 locus. 
RNA sequencing data analysis identified BT0455-0461, BT0506-0507, BT1032-1051 and BT4404-4407 
as key loci upregulated by B. thetaiotaomicron in response to complex N-glycans (Figure 3.7.1). An 
α-fucosidase BT1625GH29 was also upregulated. This enzyme and enzymes encoded by the BT1032-
1051 locus have been investigated and characterised by Dr. Lucy Crouch (unpublished data). This 
locus encodes several key enzymes essential for N-glycan degradation, such as endo-β-N-
acetylglucosaminidase BT1044GH18; and α-mannosidase BT1032GH92. The endo-β-N-
acetylglucosaminidase BT1044GH18 was routinely used during the biochemical characterisation of 
BT0455-0461 and BT0506GH20 enzymes in Chapter 4. The overall information collected about these 
glycosidases is displayed in Table 5.1. Based on the data collected in Chapter 3, Chapter 4 and by Dr. 
Lucy Crouch, schematic representation of N-glycan linkages the key enzymes are predicted to target 
is displayed in Figure 5.3. It is important to note that the α1,3-mannosidase BT3991 that targets 
α1,3-Man linkages of N-glycans (Dr. Fiona Cuskin, unpublished data) was included in this model, but 
it was not used otherwise in the work presented in this thesis. 
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Figure 5.2: Composition of the key loci required for complex N-glycan utilisation by B. 
thetaiotaomicron. The combined information obtained from the Uniprot and KEGG databases was used to 
make this figure. The loci are color-coded for easier identification in Table 5.1. 
 
 
 
Table 5.1: Details of the characterized enzymes. 
Enzyme Classification  Linkage specificity CAZy 
family 
Predicted size 
(kDa) 
Predicted 
signal peptide 
BT0455 α-sialidase Sial-α2/3/6- GH33 61 SP I 
BT0456 β-hexosaminidase bisecting GlcNAc-
β1,4- 
GH20 78 SP I 
BT0457 sialic-acid-specific 9-O-
acetylesterase 
Neu9Ac- CE 79 SP I 
BT0458 β-mannosidase Man-β1,4- GH2 99 SP I 
BT0459 β-hexosaminidase GlcNAc-β1,2/3/4/6- GH20 87  SP II 
BT0460 β-hexosaminidase GlcNAc-β-1,2/4/6- GH20 78 SP I 
BT0461 β-galactosidase Gal-β1,4- GH2 95 SP I 
BT0506 β-hexosaminidase GlcNAc-β1,2/3/4/6- GH20 86  SP II 
BT1032* α-mannosidase Man-α1,6/- GH92 87 SP I 
BT1033* mannosyl-
phosphorylase 
Man-β1,4- GH130 37 SP II 
BT1035* LacNAc’ase Gal-β1,4-GlcNAc- 
β1,4- 
New 84 SP I 
BT1038* endo-β-N-
acetylglucosaminidase 
GlcNAc-β1,4-GlcNAc GH18 38  SP II 
BT1044* endo-β-N-
acetylglucosaminidase 
GlcNAc-β1,4-GlcNAc GH18 42  SP II 
BT1048* endo-β-N-
acetylglucosaminidase 
GlcNAc-β1,4-GlcNAc GH18 42  SP II 
BT1051* β-hexosaminidase GlcNAc-β1,4- GH20 87  SP II 
BT1625* α-fucosidase Fuc-α1,3- GH29 69  SP II 
Enzymes labelled with * were characterised by Dr. Lucy Crouch. SP I stands for signal peptide recognised by 
signal peptidase I and SP II stands for signal peptide recognised by signal peptidase II done using LipoP 1.0 
server. GH - glycoside hydrolase. CE – carbohydrate esterase.  
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Figure 5.3: Schematic representation of the complex N-glycan structure characterised enzymes 
would target. The linkages cleaved by each enzyme are shown by arrows. The GH20s BT0456, BT0459, 
BT0460 and BT0506 have overlapping linkage specificities, thus the linkages displayed in this figure are just an 
example of what structures they can target. Glycoside hydrolases are colour-coded based on the PULs they are 
found in: green (BT0455-0461), blue (BT0506-0507) and red (BT1032-1051).  
 
 
5.3.2. Cellular localization 
 
In order to fully understand the pathway of glycan degradation, it is important to know where the 
key enzymes are located in the context of the cell. The LipoP 1.0 Bioinformatics tool can be used to 
predict the cellular localization of the proteins based on their signal peptide (SP). Proteins with a SP 
type I (SP I) signal peptide are usually found in the periplasm whereas SP type II (SP II) signal peptide 
is characteristic of lipoproteins, that are usually found on the cell surface in Bacteroidetes (Zuckert et 
al., 2014). The predictions based on the signal peptides of the key Cazymes were obtained using the 
LipoP 1.0 tool and are listed in a Table 5.1. The results showed that BT0459GH20, BT0506GH20 and 
BT1044GH18 have SP II signal peptide, suggesting they may be localized on the cell surface. 
Interestingly, the only sialidase encoded by B. thetaiotaomicron, BT0455GH33, was predicted to have 
an ambigious SP I cleaving site which indicates it may be located in the periplasm.  
To investigate the cellular localization experimentally, rabbit polyclonal antibodies were raised 
against BT0455GH33, BT0456GH20, BT0459GH20, BT0460GH20, BT0506GH20 and BT1044GH18 (Eurogentec). 
Cellular localization assays were done following a protocol described in Section 2.3.9.1. The 
generated antibodies were tested against the purified recombinant proteins and were found to be 
very specific with relatively low background contamination. Based on the disappearance of the band 
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corresponding to the recombinant protein in the proteinase K-treated sample (+), the results 
displayed in Figure 5.4 show that BT1044GH18, as predicted by the SP II signal peptide, is localised 
outside of the cell. Despite having a predicted SP II signal peptide, the data suggests that BT0459GH20 
and BT0506GH20 are located inside of the cell, likely facing the periplasm to enable for efficient 
deglycosylation of the N-glycan structures. BT0455GH33, BT0456GH20 and BT0460GH20, as predicted by 
the SP I signal peptide, were shown to be inside of the cell. It was also investigated whether these 
proteins are secreted outside of the cell, but no secreted proteins were detected by Western Blot of 
concentrated spent media (data not shown). 
 
Figure 5.4: Cellular localization of Bt enzymes involved in N-glycan breakdown. The + stands for 
Proteinase K treated cells and the – stands for untreated cells. The presence of a band in samples treated with 
Proteinase K (+) shows that the protein has not been degraded and is likely located inside of the cell. The 
absence of the band shows that the protein is accessible to the protease and is therefore likely located outside 
of the cell. BT1044GH18 (41kDa) results (red box) suggest it is located outside of the cell. The ~60kDa band 
present in BT1044GH18 sample is suspected to be a protein that cross reacts with the polyclonal antibody. MW – 
MagicMarkTM molecular weight marker (ThermoFisher). 
 
 
5.3.3. Whole cell assays 
The cellular localization data indicated that N-glycans are cleaved off the protein backbone by 
BT1044GH18 externally prior to the import and further processing. To further confirm this activity was 
localised to the cell surface, wild type B. thetaiotaomicron was grown on α1-AGP until mid-
exponential phase (OD600nm=0.4-0.6) and whole cell assay was set up as outlined in Section 2.3.10. B. 
thetaiotaomicron is an obligate anaerobe, thus the whole cells harvested in this way are intact but 
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metabolically inactive due to the aerobic conditions and cannot actively import glycans because 
SusC-like transporters are TonB-dependent, therefore require energy to import the glycans across 
the outer membrane. Whole cells, supernatant and sonically-lysed cells were incubated with 2% α1-
AGP in PBS at 37 °C up to 24 hours. Samples were collected over the duration of time and analysed 
by TLC (Figure 5.5). Based on the appearance of the bands corresponding to different sugars, N-
glycan degradation was observed in whole cells and lysed cells but not in supernatant or Proteinase 
K (PK) treated cells, suggesting the N-glycans are cleaved off protein backbone and sialic acid is 
released at the cell surface. The sialidase activity was also observed in both whole cells and 
proteinase K-treated whole cells, suggesting the BT0455GH33 enzyme could be located both at the cell 
surface and in the periplasm. Although N-glycan degradation products are visible in the supernatant 
sample (B), no additional N-glycan degradation activity was observed, suggesting the required 
enzymes are not secreted. 
 
Figure 5.5: Whole cell assays show surface whole N-glycan release activity by the enzymes 
encoded by B. thetaiotaomicron. Assays were performed in the presence of 2% α1-acid glycoprotein with 
harvested whole cells (A), growth media supernatant (B), sonicated cell lysate (C) and proteinase K-treated 
whole cells (D). Control (E) contains whole cells incubated in PBS without a substrate. Reactions were 
incubated for up to 24 hours, with sampling at 1, 2, 4, 8 and 24 hours. The release of the sialic acid (S.A.) and 
predicted N-glycan structures (NG1-3) was observed. TLC plates were stained with DPA. 
 203 
 
5.3.4. Gene deletion analysis 
B. thetaiotaomicron was shown to be capable of utilising α1-AGP in-vitro as a sole carbon source 
(Figure 3.3). In this study, we wanted to test the role of the key enzymes from BT0455-0461 and 
BT1032-1051 loci in N-glycan utilization by B. thetaiotaomicron. To do this, it was attempted to 
generate the deletion mutants ∆BT0455GH33, ∆BT0455GH33+∆BT1035, ∆BT0458GH2, 
∆BT0458GH2+∆BT1033GH130, ∆BT0459GH20, ∆BT0460GH20, ∆BT0461GH2, ∆BT0506GH20 and a deletion 
mutant missing an entire ∆BT0455-0461 loci using the methods described in Sections 2.1.13 and 
2.1.18. The primers were designed to amplify 1kb of upstream and downstream of genomic region 
flanking the genes of interest and are listed in Supplemental table 3.2 (Figure 5.6).  For1 primer was 
engineered to contain SalI site and Rev1 primer was engineered to contain the Xbal site that allows 
for cloning of the sewing PCR product into the pExchange-tdk vector. 
 
 
Figure 5.6: Deletion mutant design. 1000nt downstream and 1000 nt upstream of the gene of interest 
were amplified and stitched together. 
 
 
 
Following the conjugation, recombinant mutants were screened for desired deletions. Clones 
carrying a desired deletion showed a ~1000 bp band amplified by using specially designed PCR 
primers (Supplemental table 3.2). Wild type B. thetaiotaomicron would produce a fragment of ~4000 
bp in size. An example of a successful conjugation is displayed in Figure 5.7. The successfully 
generated deletion mutants were: ∆BT0458GH2, ∆BT0459GH20, ∆BT0460GH20, ∆BT0461GH2 and 
∆BT0506GH20. The ∆BT1044GH18 mutant was generated by Dr. Lucy Crouch. 
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Figure 5.7: Screening for deletion mutants. PCR results showing the amplification of the B. 
thetaiotaomicron genomic DNA of ∆BT0461GH2 mutant. C – wild type B. thetaiotaomicron control. ∆ - deletion 
mutant. M- High fidelity DNA marker (Sigma). 
 
 
To investigate the effect of the deletion mutants on the ability of B. thetaiotaomicron to utilise N-
glycoproteins, wild type and deletion strains were grown separately in minimal media supplemented 
with either 1% glucose or 2% α1-AGP. Growths were monitored automatically by measuring the 
optical density of the cultures at 600nm every 15 minutes for 24 hours using the EpochTM Microplate 
Spectrophotometer (see Section 2.1.19). The results are displayed in Figure 5.8. Compared to the 
wild type B. thetaiotaomicron, the growth of all mutants on glucose had a much shorter lag phase. 
No defect was detected on ΔBT0461GH2 mutant growth on α1-AGP, suggesting B. thetaiotaomicron 
produces other GH2 β-galactosidases that have overlapping specificities with the BT0461GH2 (Figure 
5.8-A). When the deletion mutants of the β-hexosaminidases BT0459GH20, BT0460GH20 and BT0506GH20 
were compared, only the growth of ∆BT0460GH20 on α1-AGP was observed to be partially retarded in 
comparison to the wild type (Figure 5.8-B). These results suggest that the activities of these β-
hexosaminidases are redundant when B. thetaiotaomicron is grown on complex bi-antennary N-
glycan structures. The deletion of β-mannosidase BT0458GH2 does not appear to have any effect on 
B. thetaiotaomicron growth (Figure 5.8-E). These results indicate that B. thetaiotaomicron possesses 
enzymes that can replace the activities of some of the BT0455-0461 loci enzymes, but not as 
efficiently. In comparison, the deletion of the endo-β-N-acetylglucosaminidase BT1044GH18 has a 
severe growth defect compared to the wild type B. thetaiotaomicron (Figure 5.7-F). These results 
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indicate that BT1044GH18 is a key B. thetaiotaomicron enzyme required to initiate the N-glycan 
degradation by cleaving the complex biantennary N-glycans from the α1-AGP backbone.  
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Figure 5.8: Comparing the growth of the wild type B. thetaiotaomicron and deletion mutants on 
native α1-AGP N-glycans. A) ∆BT0461GH2; B) ∆BT0459GH20; C) ∆BT0460GH20; D) ∆BT0506GH20; E) ∆BT0458GH2; 
F) ∆BT1044GH18; G) Overlay of all mutant growth data (mean only). The strains were cultured in minimal media 
containing either 1% glucose or 2% α1-AGP. Growth data for each condition was obtained from triplicate 
cultures. The error bars indicate the standard deviation from the mean of each triplicate data set. 
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5.3.5. Proposed N-glycan utilization model 
The combination of the work presented in this thesis with the results of the studies conducted by Dr. 
Lucy Crouch (ICaMB, Newcastle University) enabled us to propose a model of N-glycan utilization by 
B. thetaiotaomicron (Figure 5.9). RNA sequencing data analysis followed by an extensive biochemical 
characterisation indicates that the complex N-glycan structure utilisation requires cooperative 
activity of multiple loci. Based on the upregulation data, the key enzymes required for the 
degradation of these structures are encoded by the BT0455-0461, BT0506-0507 and BT1032-1051 
loci. However, the KO mutant growth data (Figure 5.8) suggests that this pathway is much more 
complicated where only endoglycosidase BT1044GH18 was shown to be critical for complex 
biantennary α1-AGP N-glycan breakdown. Unfortunately, the failure to generate the ∆BT0455-0461 
mutant prevented us from investigating the importance of this locus for the B. thetaiotaomicron 
proliferation.  
Degradation of the complex N-glycans is likely initiated by the binding of the N-glycoproteins to the 
SGBPs at the cell surface, however it has not been shown yet. Here, the sialidase BT0455GH33 could 
cleave some of the sialic acid caps off the terminal N-glycan antennae. Cellular localization data 
(Figure 5.4) suggests that BT0455GH33 is located inside of the cell however the whole cell assay data 
(Figure 5.5) indicates that the sialic acid is cleaved off the N-glycan substrate following the 24 hours 
of incubation with the whole cells pre-treated with the Proteinase-K, protease that destroys all 
proteins localised at the cell surface. Considering BT0455GH33 is the only sialidase encoded by B. 
thetaiotaomicron, the observed sialic acid release suggests an BT0455GH33 activity. It is important to 
note that, based on the low LipoP prediction score of 2.59, the predicted signal peptide for 
BT0455GH33 SP-I is ambigious. Considering that the TonB-dependent outer membrane transporter 
complex (SusC/D-like) requires energy to import N-glycan structures into the cell for the degradation 
by periplasmic glycosidases, when combined these results support the proposition that the sialidase 
BT0455GH33 may employ an unknown mechanism of action to be able to be both surface and 
periplasm localised. This kind of activity could be required to desialylate N-glycan structures that 
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were imported into the cell before all sialic acid caps could be removed by the sialidase on the cell 
surface. BT1044GH18 then cleaves the N-glycans from the protein backbone generating glycan 
structures that can be imported into the periplasm by the SusC/D-like system. It is important to note 
that BT1044GH18 prefers de-sialylated complex N-glycan structures but can cleave sialylated 
structures as well (Dr. Lucy Crouch, unpublished data). Once inside the periplasm, the galactose caps 
are removed off the N-glycan structure by the β-1,4-galactosidase BT0461GH2. It was previously 
observed that BT0461GH2 can leave some galactose caps on the N-glycan structures. If that happens, 
a new GH-family enzyme that been identified and characterised by Dr. Lucy Crouch can cleave the 
Gal-β1,4-GlcNAc- disaccharide off the complex N-glycan structures. Then, various GlcNAc linkages 
are cleaved by four redundant β-hexosaminidases BT0456GH20, BT0459GH20, BT0460GH20 and 
BT0506GH20. However, because these glycosidases were shown to have overlapping specificities, it is 
currently unclear which linkages they would target in vivo. Based on the biochemistry data obtained 
in vitro that was discussed in Chapter 4, their predicted target linkages are displayed in the model. 
Once GlcNAc linkages are removed, the mannose caps are cleaved off by the α-mannosidases 
BT1032GH92 and BT3991GH92. The generated disaccharide (Man-β1,4-GlcNAc) is then either digested 
by the exo-acting β-mannosidase BT0458GH2 or imported into the cytoplasm to be processed by the 
phosphorylase BT1033GH130. It is possible that both, the released monosaccharides and the 
generated Man-β1,4-GlcNAc disaccharide can be imported into the cytoplasm. Based on the RNA 
seq-derived upregulation data (Figure 3.7.1.), B. thetaiotaomicron upregulates BT1033GH130 more in 
response to the presence of complex N-glycans. However, it is not clear what the levels of the 
BT0458GH2 mannosidase are present in the cell so it is currently unknown which enzyme of these two 
is preferred by this bacterium.  
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Figure 5.9: Proposed model of complex N-glycan utilization by B. thetaiotaomicron. The sequential 
degradation is represented by arrows. The list of key enzymes identified to be involved in complex N-glycan 
degradation is listed in the legend. For details see the text above. 
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5.3.6. N-glycan PULs in other Bacteroides  
 
Deglycosylation of N-glycoproteins has been previously observed in pathogens such as 
Capnocytophaga canimorsus, Streptococcus pyogenes, Streptococcus oralis, Streptococcus 
pneumoniae and Bacteroides fragilis (Renzi et al., 2011; Robb et al., 2017). To our knowledge, the N-
glycan degradation model described in this chapter is the first system devoted to foraging N-
glycoproteins by a commensal, symbiotic gut microbe. The ability to utilise N-glycans could give B. 
thetaiotaomicron an advantage during the periods of starvation and could play a role in the 
prevention of opportunistic infections. This suggests that the ability to deglycosylate dietary and 
host-derived N-glycoproteins could be a favourable trait in the gut ecosystem.  
The enzymes encoded by the BT0455-0461, BT0506-0507 and BT1032-1052 loci were characterised 
and found to be the key members of the N-glycan degradation apparatus in B. thetaiotaomicron. In 
this study, we wanted to compare and investigate the prevalence of the genes homologous to 
BT0455-0461, BT0506GH20 and BT1044GH18 in other members of human gut microbiota. Amino acid 
sequences of each of these proteins were used to identify homologous proteins on the KEGG 
database and Integrated Microbial Genomes (IMG) system. The BT0455-0461 locus was used as a 
query on the Polysaccharide Utilization Loci (PUL) database (PULDB) to predict homologous PULs in 
other Bacteroidetes species found in human gut microbiota (www.cazy.org/PULDB). The results from 
both searches were analysed and compared. Ten species of Bacteroides were found to encode 
similar apparatuses to B. thetaiotaomicron (Table 5.2). These include B. faecis, B. dorei, B. vulgatus, 
B. fragilis, B. ovatus, B. massiliensis, B. caccae, B. finegoldii, B. acidifaciens, B. xylanisolvens. All of 
these microbes contain homologues of endo-β-N-acetylglucosaminidase BT1044GH18, with an 
exception of B. dorei, B. massiliensis and B. caccae that do not encode any GH18 enzymes, 
suggesting they employ a different mechanism to cleave the N-glycans off the protein backbone, 
potentially by utilising a PNGaseF-like enzymes. All of these bacteria encode a GH33 sialidase 
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homologues and at least one GH2- and three GH20-family enzymes. The high similarity of the PULs 
identified in these microorganisms suggests they all could be specialised in N-glycan degradation. 
Table 5.2: Prevalence of key enzymes of N-glycan degradation apparatus in gut Bacteroides. 
 
PULs and enzymes homologous to BT0455-0461, BT0506GH20 and BT1044GH18 are displayed. IMG, KEGG and 
PULDB databases were used to identify these enzymes and to build the annotated composition figures. – 
means no homologous GH18 enzyme was found in these bacteria. 
 
 
Variations of these PULs were observed in other species of bacteria. For example, Akkermansia 
muciniphila and Akkermansia glycaniphila do not possess any GH18 family enzymes, but both 
produce two homologous sialidases to BT0455GH33 and several homologues of a BT0461GH2 
galactosidase. This could be explained by their preference for O-glycan mucin structures (Derrien et 
al., 2004). A dog oral cavity commensal Capnocytophaga canimorsus, that causes severe infections 
in dog bite wounds in humans, was also shown to be capable of deglycosylating N-glycans present 
on human IgG by utilising a large homologous complex of proteins that consists of a sialidase SiaC 
and GpdCDGEF PUL proteins. This PUL contains a SusC/D pair, a GH18 endo-β-N-acetyl-
glucosaminidase and two glycan binding proteins (Renzi et al., 2011). The comparison of these 
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results indicate that the members of Bacteroides spp. are more specialised in degradation of N-
glycan structures. 
 
5.3.7. Discussion 
The work described in this study revealed that the complex N-glycan degradation by B. 
thetaiotaomicron requires a cooperative activity of numerous enzymes encoded by multiple loci. 
Compared to the previously conducted carbohydrate utilisation studies where it was shown that Bt 
usually requires one to three specialised PULs to degrade complex glycan structures, such as 
heparin/herapan sulphate (1 PULHep; Cartmell et al., 2017), rhamnogalacturonan-I backbone (1 RGI-
PUL; Luis et al., 2018), galactan (1 Gal-PUL; Luis et al., 2018) and RG-II (3 discrete PULS; Ndeh et al., 
2017), the identification of this complex multi-PUL-dependent N-glycan degradation pathway is  
interesting. In case of these complex glycans, it was observed that the number of PULs required to 
degrade these structures usually increases with the variety and complexity of the glycan. So from the 
initial point of view it looks like the N-glycan degradation mechanism is not that different, however it 
appears to have a lot more redundancy compared to the apparatuses required to degrade other 
glycans, such as RG-I, which suggests that there may be a lot of heterogeneity in the N-glycan 
structures faced by the members of human gut. The combined results of the RNA-seq data analysis 
(Chapter 3), biochemical characterisation (Chapter 4), cellular localization and genetic analysis 
results described in this chapter have identified and confirmed that the BT0455-0461, BT0506-0507 
and BT1032-1051 loci are involved in complex N-glycan utilization.   
The glycoside hydrolases that were characterised in Chapter 4 are the broad-acting α2,3/6-sialidase 
BT0455GH33, four β-hexosaminidases with overlapping specificities BT0456GH20, BT0459GH20, 
BT0460GH20 and BT0506GH20, β1,4-mannosidase BT0458GH2 and β1,4-galactosidase BT0461GH2. In order 
to fully understand N-glycan degradation pathway and the roles of these enzymes, it was important 
to know where they are located in the context of the cell. The N-terminal signal peptide of these 
enzymes can be used to predict their cellular localization. A SP I signal peptide predicts the protein is 
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located in the cell periplasm whereas SP II predicts the protein is surface localized (Zuckert et al., 
2014). It is important to note that signal peptide prediction by bioinformatic tools, such as LipoP, is 
based on the machine-learning methods, such as training using known protein sequences as 
examples, and may not be as accurate when predicting signal peptides of novel proteins. So, utilizing 
cellular localization assays to confirm these predictions are accurate is of utmost importance. In this 
study, a cellular localization assay utilizing target-specific antibodies was used because it is a highly 
accurate and sensitive technique (Cuskin et al., 2015). Cellular fractionation technique could also be 
used to investigate where the protein of interest is located. It utilises ultracentrifugation method to 
separate organelles and macromolecules into separate fractions, such as whole cells, nuclei and 
cytoskeletons during the low-speed centrifugation, mitochondria and lysosomes during the medium-
speed centrifugation and microsomes together with ribosomes during the high-speed centrifugation. 
The presence of the protein in isolated fractions can then be investigated using SDS-PAGE and 
immunoblotting (Alberts et al., 2002). Other methods, such as fluorescence microscopy-based 
techniques (e.g. utilising fluorescent dyes) could also be used to investigate the cellular localization 
of the proteins, but these methods are not as sensitive (Collings, 2013). 
Although the broad-acting BT0459GH20 and BT0506GH20 β-hexosaminidases were initially predicted to 
be present on the cell surface (SP II signal peptide) with the rest of the proteins predicted to be 
periplasmic (SP I signal peptide) (Table 5.1), the cellular localization study revealed that all of them 
are located inside of the cell (Figure 5.4). In comparison, it was found that the endo-β-N-
acetylglucosaminidase BT1044GH18 (SP II) is surface localized. These results suggested a major role for 
this enzyme in the complex N-glycan utilization pathway. Surface localization indicates that 
BT1044GH18 is cleaving the complex N-glycan structures off the protein backbone prior to their import 
into the cell for further processing, suggesting that this is the initial step of N-glycan utilization 
pathway.  
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Considering that majority of complex N-glycans are heavily sialylated, sialic acid removal is a major 
step required for their utilization.  It was previously shown that BT0455GH33 is the only sialidase 
encoded by B. thetaiotaomicron, thus its importance to the N-glycan utilization in vitro is undeniable 
(Park et al., 2013). However, it is important to note that it is possible that in a competitive 
environment in vivo, B. thetaiotaomicron may be able to forage on N-glycan structures that were de-
sialylated by the other members of the human gut microbiota. When combined, cellular localization 
and the whole cell assay data presented in this chapter revealed that the sialidase BT0455GH33 may 
be both surface and periplasm localized, which is further supported by the ambiguous predicted 
SPI/SPII signal peptide. In support of this claim, the release of sialic acid from complex N-glycan 
structures was observed in both whole cell and Proteinase K-treated whole cell (after 24h 
incubation) assays suggesting that N-glycan structures could be de-sialylated both before and after 
the import into the cell.  
Apart from much longer lag phases compared to the wild type, the deletion of the single genes from 
the BT0455-0461 locus did not result in any significant growth defects in vitro when B. 
thetaiotaomicron was grown on α1-AGP N-glycans. However, considering how complex N-glycan 
structures can be, these genetic perturbations may affect the growth rate of the deletion strains on 
different source and structures of N-glycans. Furthermore, considering the broad activities and 
overlapping specificities of the BT0459GH20, BT0460GH20 and BT0506GH20 β-hexosaminidases discussed 
in Chapter 4, these enzymes appear to be redundant since they could all be individually knocked out 
without drastically affecting the growth of B. thetaiotaomicron cells. For future work, a triple 
deletion mutant should be generated to investigate the requirement of all three BT0459GH20, 
BT0460GH20 and BT0506GH20 β-hexosaminidases for the growth of B. thetaiotaomicron on complex N-
glycans. It is important to note that the activity of BT0461GH2 may also be redundant based on the 
growth assays performed in vitro because several other uncharacterised GH2-family galactosidases 
were identified in the RNA seq data analysis as being upregulated, albeit to a very low level in this 
non-competitive environment (see Supplemental Table 3.1).  The work presented in this thesis was 
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done in a non-competitive environment in vitro. However, when results are combined, they suggest 
that the enzymes encoded by BT0455-0461 locus could have specialised metabolically to efficiently 
function in N-glycan utilization in a competitive environment in vivo. This could be tested by setting 
up a competitive growth assay of various deletion mutant strains of B. thetaiotaomicron in the 
presence of other members of gut microbiota, such as B. massiliensis, B. uniformis and B. fragilis that 
were previously shown to be capable of utilising complex α1-AGP N-glycans (Chapter 3). 
A BT1044GH18 endo-β-N-acetylglucosaminidase was identified as a key enzyme B. thetaiotaomicron 
requires to initiate the utilisation of the complex biantennary α1-AGP N-glycans. Interestingly, 
several other GH18 family enzymes are encoded in BT1032-1051 PUL, however only the deletion of 
BT1044GH18 was shown to have a profound defect (Dr. Lucy Crouch, unpublished data). These results 
indicate that the other GH18 enzymes could be specialised in targeting different types of N-glycan 
structures, such as tetraantennary. 
When these results were combined, it allowed us to propose a model of N-glycan utilization by B. 
thetaiotaomicron in which N-glycan structure is degraded sequentially by a cooperative activity of 15 
enzymes encoded by the BT0455-0461, BT0506-0507 and BT1032-1051 loci. This model has been 
tested in vitro where all enzymes were incubated with α1-AGP and complete degradation of the N-
glycan structures was observed (Dr. Lucy Crouch, unpublished data). The activities of these enzymes 
were also screened against several other sources of complex N-glycans, such as fetuin and 
transferrin, where a similar pattern of degradation was observed (Chapter 4).  
The enzymes important for the complex N-glycan degradation by B. thetaiotaomicron were 
identified as the glycoside hydrolases encoded by the BT0455-0461 locus, broad-acting β-
hexosaminidase BT0506GH20 and endo-β-N-acetylglucosaminidase BT1044GH18. When these were 
screened against IMG and PULDB databases, homologous enzymes in ten other members of 
Bacteroides were identified. Interestingly, this system appears to be fully conserved in B. faecis, 
suggesting the same complex N-glycan specificity for these two species of bacteria. It was also 
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observed that the homologues of the sialidase BT0455GH33, β-hexosaminidases BT0459GH20, 
BT0506GH20 and BT0460GH20 and β-galactosidase BT0461GH2 are conserved in all ten species of 
Bacteroides, suggesting an importance of these enzymes for the N-glycan utilization. With an 
exception of B. ovatus, the rest of the identified Bacteroides have four GH20-family enzymes, which 
indicates that the number of GH20s present in this intricate N-glycan degradation apparatus of B. 
thetaiotaomicron is not a special trait. However, with an exception of B. faecis, the homologous PULs 
identified in the rest of Bacteroides encode predicted SusC/D pairs. This TonB-dependent outer 
membrane complex is not present in the B. thetaiotaomicron BT0455-0461 locus, which makes it 
quite special considering SusC/D pair is a hallmark of a typical glycan utilization locus.  Surprisingly, 
three members of Bacteroides, B. dorei, B. massiliensis and B. caccae, do not possess any GH18-
family endo-glycosidases, suggesting they must employ a different strategy to cleave N-glycan 
structures off the protein backbones, potentially by utilising PNGaseF-like enzymes. In overall, these 
findings suggest that the variant of this intricate N-glycan utilization apparatus identified in B. 
thetaiotaomicron could be employed by the majority of Bacteroides present in the human gut. 
However, this remains to be tested in vitro.   
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Chapter 6: Final discussion 
The human gut microbiota is a glycan-rich environment that is metabolically well-equipped to utilise 
a diverse range of complex dietary and host-derived glycan sources present in the human gut, such 
as N-glycoproteins. N-linked glycosylation is a major post-translational modification of proteins 
produced by mammalians, plants, bacteria, insects and fungi. The structures produced by these 
organisms can be incredibly complex and based on their basic composition are classified into three 
main groups: complex, high mannose and hybrid structures (Staudacher et al., 2015). The N-glycans 
are prominent in human gut in a form of dietary and host-derived N-glycoproteins (e.g. IgA), and 
judging by their structural complexity, they would require a cooperative activity of numerous 
enzymes to fully degrade and utilise. Despite their prevalence in the human gut, the investigation of 
the N-glycan degradation pathways has been mainly focused on pathogenic bacteria, such as an 
opportunistic pathogen B. fragilis, where the capacity to utilize N-glycans has been linked to the 
increased rate of survival in the extra-intestinal niche (Cao et al., 2014). However, the knowledge of 
metabolic capacity of the commensal members of human gut microbiota to utilise these highly 
complex N-glycan structures was lacking. This chapter will review the work presented in this thesis 
and focus on how it contributed to the understanding of the complex N-glycan utilisation pathways 
of commensal gut microbes by proposing a model of degradation by B. thetaiotaomicron. 
Members of Bacteroidetes, such as B. thetaiotaomicron, have adapted to metabolise extremely 
complex glycan structures present in the human gut by expanding their genetic repertoire of 
enzymes, each specialised in targeting specific glycan structures, such as plant pectin 
rhamnogalacturonan-II (RG-II; Ndeh et al., 2018). This ability to metabolise highly complex glycan 
structures was observed in Chapter 3, where several prominent members of human gut microbiota 
were found to be capable of utilising complex N-glycans as a sole carbon source in vitro. These 
include wild type B. thetaiotaomicron, B. fragilis, B. massiliensis and B. uniformis, all of which 
displayed a relatively efficient capacity to metabolise the levels of complex biantennary N-glycan 
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structures present on the bovine α1-Acid Glycoprotein used in this study (Figure 3.1). This level of 
metabolism could suggest that N-glycans are not their nutrient of choice and they could have 
evolved to utilise these structures as a last resort in times of starvation. Because α1-AGP is not 
usually found in the human gut environment, it is also plausible that they prefer more complex N-
glycan structures actually present in the human gut, such as tetraantennary immunoglobulin A (IgA) 
structures. Considering nutrient cross-feeding has been previously observed among the members of 
gut microbiota (Luis et al., 2018; Seth et al., 2014), another explanation for such reduced maximum 
growth levels of these species would be that the members of Bacteroides actually work as a 
community to degrade these highly complex structures more efficiently in vivo. It is probable that 
growth on complex N-glycans is more metabolically taxing to the bacterium than growth on simple 
monosaccharides such as GlcNAc or glucose, because it is dependent on the production of many 
factors (e.g. enzymes) required to utilise these glycoconjugates.  In overall, the metabolic ability to 
utilise complex N-glycans appears to be a favourable trait in this ecosystem.  
It was also observed that B. thetaiotaomicron had a metabolic capacity to efficient utilise a range of 
different N-glycoproteins, such as transferrin, fetuin and α1-AGP (Figure 3.2). These structures 
contain a variation of complex biantennary, triantennary and tetraantennary N-glycan structures, 
suggesting B. thetaiotaomicron must possess a number of specialised enzymes capable of 
accommodating and degrading such highly complex glycan structures. Transcriptomic data analysis 
helped to identify this complex N-glycan utilization apparatus in B. thetaiotaomicron. Based on these 
data (Figure 3.7.1), the main loci upregulated on α1-AGP N-glycan were found to be BT0455-0461, 
BT0506-0507 and BT1032-1051.  
As suspected, numerous enzymes are required to fully degrade complex N-glycan structures. In 
Chapter 4, the enzymes encoded by the BT0455-0461 and BT0506-0507 loci were characterised and 
their biological roles in complex N-glycan degradation were identified. The utilisation of liberated 
complex N-glycan structures is achieved by a sequential exo-mode of degradation where the 
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cooperative activity of multiple linkage-specific glycoside hydrolases is required. These included a 
broad-acting α-sialidase BT0455GH33 and β1,4-galactosidase BT0461GH2. B. thetaiotaomicron appears 
to require a cooperative activity of four different β-hexosaminidases for the complex N-glycan 
degradation, BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20. Although these enzymes have 
overlapping specificities for simple disaccharides and some of the glycosidic linkages found on 
biantennary complex N-glycan structures (e.g. GlcNAc-β1,2-), slight linkage preferences were 
observed in degradation of complex bisecting, triantennary and tetraantennary N-glycan structures 
that contain a broader spectrum of GH20 target linkages, such as GlcNAc-β1,2/4/6 and bisecting 
GlcNAc-β1,4-Man (Figure 4.42). The requirement for such an array of GH20-family enzymes could be 
explained by the variability of linkages present on complex N-glycan structures found in mucosal and 
luminal niches of the human gut. For example, GlcNAc-β1,2/4/6 and bisecting GlcNAc-β1,4-Man 
linkages present on a heavily N-glycosylated host-derived IgA antibody, a major part of the innate 
immune system of the gut, would require a number of specialised GH20-family enzymes to degrade 
(Figure 6.1; Huang et al., 2015).  Four GH20s may also be needed due to the requirement for a quick, 
metabolically efficient degradation of these structures in vivo. It was previously observed that the 
initial targeting of a bisecting GlcNAc linkage by a multimodular GH20-family exo-β-D-N-
acetylglucosaminidase StrH in S. pneumoniae limited the ability of this enzyme to target antennaery 
GlcNAc linkages of the complex N-glycan structure, reducing the N-glycan degradation efficiency 
(Pulvinage et al., 2011).  
 
Figure 6.1: An example of a complex N-glycan structure found on human colostrum IgA.  
The glycosidic linkages the four β-hexosaminidases BT0456GH20, BT0460GH20, BT0459GH20 and BT0506GH20 
could target (once sialic acid and galactose are removed) are highlighted and color-coded. Structure was built 
using a GlycanBuilder tool based on the linkage information obtained from Huang et al., 2015.  
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Carbohydrate binding modules (CBMs) are an integral part of numerous glycoside hydrolases (GHs) 
where they contribute to the glycan degradation by enhancing substrate-to-enzyme interactions. 
The classical function of the CBM domains in the endo-acting enzymes is to tether it to an insoluble 
target polysaccharide via a flexible linker domain whereas in exo-glycosidases the CBM domains are 
more closely associated with more structured, rigid linker domains, making their role less clear 
(Gilbert et al., 2010). Recently, a novel CBM domain was identified in a T. forsythia sialidase NanH, 
where the CBM was shown to be involved in glycosidase-ligand binding of host-derived sialoglycans 
(Frey et al., 2018). In Chapter 4, the characterisation of β-hexosaminidases BT0459GH20, BT0460GH20 
and BT0506GH20 also identified novel CBM domains that specifically bind to complex N-glycans 
derived from α1-AGP (Figure 4.54). To our knowledge, it is the first time the F5/8 type_C domains 
present in BT0459GH20 and BT0460GH20, and PA14 domain present in BT0506GH20 were shown to be 
involved in carbohydrate binding and it was observed that the overall domain structure of these 
GH20s is quite unique and present predominantly in Bacteroides. The binding to N-glycan structures 
rather than monosaccharides (ITC, Figure 4.53) and disaccharides found on these structures 
suggested that these CBMs target the whole complex N-glycan structure. Considering all of the 
upregulated GH20s have similar domain composition, it is plausible that this domain structure is 
specialised to target N-glycans. The structural characterization of BT0459GH20 allowed for a model for 
substrate binding to be proposed, where substrate binding to the CBM32-like F5/F8 Type C domain 
induces a movement of the CBM and the flexible linker domain to position the substrate in the 
active site, possibly enhancing the degradation efficiency or modulating substrate preference (Figure 
4.51). Although the removal of the CBM domain appeared to decrease the catalytic efficiency of 
BT0459GH20 against simple disaccharides (Figure 4.58), it appeared to have no impact on BT0459GH20 
activity against complex biantennary α1-AGP structures. However, it may be required for efficient 
degradation of triantennary, tetraantennary and bisecting complex N-glycan linkages (Figure 6.2). 
This model remains to be tested by investigating the structure of a substrate-bound BT0459GH20.  
Interestingly, majority of the B. thetaiotaomicron putative and characterised GH20-family enzymes, 
 221 
 
including the BT0460GH20, contain the same predicted CBM domain (F5/8_type_C) as BT0459GH20, 
suggesting they all could employ similar binding strategy.  
 
Figure 6.2: The proposed model of N-glycan binding by BT0459GH20. A) Open state of BT0459GH20. CBM 
domain and the flexible linker domain are in ‘arm-like’ position above the open binding site of the catalytic 
GH20 domain. Model N-glycan structure is colored in blue. Examples of linkages present on N-glycan 
structures that BT0459GH20 was found to be active against are displayed. B) Proposed closed state of an N-
glycan-bound BT0459GH20. X-ray structure of BT0459GH20 was coloured rainbow from red (C-terminus) to blue 
(N-terminus).  
 
 
On the basis of the results presented in this thesis and in the context of our current knowledge, a 
model of complex N-glycan utilization by B. thetaiotaomicron was proposed (Chapter 5), where the 
degradation is achieved by a cooperative activity of numerous N-glycan degrading enzymes encoded 
by multiple loci (Figure 5.8). The characterised machinery required for the complete complex N-
glycan degradation is encoded by three discrete loci. Combined, they encode 15 specialised 
enzymes, three predicted SusC/D-like pairs of outer membrane transporter systems, two predicted 
surface glycan-binding proteins (SGBPs) and two predicted regulator proteins. Based on the deletion 
mutant growth results, extracellular endo-glycosidase BT1044GH18 is a key enzyme required to 
initiate complex N-glycan degradation by releasing it from the protein backbone (Figure 5.7). The 
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liberated N-glycan structure is then imported into the cell where it is sequentially degraded by a 
number of exo-glycosidases. Although the full N-glycan degradation pathway has not been described 
in any bacterium yet, this degradation pathway appears to be very different from a mode of action 
of the pathogenic microbe S. pneumoniae where the complex N-glycan structures are first 
depolymerised down to the Man3GlcNAc2 core by a number of extracellular glycosidases before it is 
cleaved off the protein backbone and imported into the cell (Burnaugh et al., 2008; Robb et al., 
2017). The important difference observed between the S. pneumoniae N-glycan degradation 
apparatus and the B. thetaiotaomicron apparatus described in this thesis, is the number and the 
redundancy of the enzymes required. In S. pneumoniae, deglycosylation of complex N-glycans down 
to the Man3GlcNAc2 core depends on an exo-sialidase (NanA), an exo-galactosidase (BgaA) and an 
exo-N-acetylglucosaminidase (StrH). The deletion of any of these enzymes resulted in a severe 
retardation of S. pneumoniae growth on complex N-glycans. However, the main difference observed 
between these two bacteria is the requirement for an GH18 endo-β-N-acetylglucosaminidase 
activity. In S. pneumoniae, it was observed that the deletion of this endo-glycosidase (EndoD) has no 
substancial defect when it was grown on complex N-glycans as a sole carbon source (Robb et al., 
2017). In comparison, the deletion of the GH18 endo-glycosidase BT1044GH18 displayed a severe 
growth defect in B. thetaiotaomicron (Figure 5.8). These differences suggest different strategies of 
complex N-glycan utilization could be employed by pathogenic and symbiotic bacteria. 
Furthermore, the identification of genes homologous to BT0455-0461, BT0506GH20 and BT1044GH18 in 
ten prominent members of Bacteroides spp. suggests that the variant of this proposed model of the 
complex N-glycan degradation may also be widely utilised by thes human gut Bacteroides.  
Combined, the work presented in this thesis contributes to the knowledge of complex N-glycan 
degradation by prominent, symbiotic members of human gut microbiota by identifying and 
characterising the key enzymes of the N-glycan degradation apparatus in B. thetaiotaomicron. 
Understanding how complex N-glycans are utilised by the HGM helps us to better appreciate the 
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metabolic potential of this ecosystem and contributes to our understanding of its role in human 
health. Classically, deglycosylation of complex N-glycan structures has been considered a virulence 
factor, strongly linked with an increased risk of inflammation by various human pathogens (Cao et 
al., 2014; Robb et al., 2017). However, considering a commensal generalist B. thetaiotaomicron is 
capable of foraging on these complex N-glycans structures that are prominent in the human mucosal 
and luminal niches in a form of dietary and host-derived glycoproteins, such as IgA and mucins, this 
process may also have a different role. For example, by utilising N-glycans present on the glycocalyx 
of sloughed epithelial cells, B. thetaiotaomicron could contribute to the efficiency of the gastric 
epithelial cell turnover. Epithelial cell turnover is a natural, balanced process required to maintain 
gut homeostasis. Moreover, removal of the relatively low numbers of N-glycan structures present on 
predominantly O-glycosylated mucins would enable for a better access to these structures for other 
specialised members of gut microbiota. This could potentially benefit the inter-microbial 
relationships of the sub-communities formed by specialised members of HGM. However, the precise 
role of complex N-glycan degradation by commensal human gut microbes in human health remains 
to be determined. 
 
6.1. Future work  
Research into N-glycan degradation by the members of human gut microbiota is still in early stages. 
The successful identification of complex N-glycan degradation apparatus in B. thetaiotaomicron has 
opened a new avenue of studying N-glycan degradation by commensal gut microbes. The successful 
cloning, expression and purification of N-glycan binding proteins and degrading enzymes B. 
thetaiotaomicron requires to utilise dietary and host-derived heavily N-glycosylated glycoproteins 
present in the human gut allowed us to propose a model for complex N-glycan degradation. 
Questions which remain include, what role do the rest of the upregulated enzymes play? Can this 
model of degradation be applied to more complex N-glycan structure degradation? Biochemical 
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characterisation of all upregulated enzymes would provide a clearer picture of N-glycan degradation 
by this bacterium.  
Regarding the four GH20 glycosidases; how exactly do the mechanisms of β-hexosaminidases 
BT0456GH20, BT0459GH20, BT0460GH20 and BT0506GH20 N-glycan binding and degradation differ? Do the 
CBM domains contribute to the N-glycan degradation efficiency? What binding residues are 
necessary for these enzymes to recognise the substrate? Crystal structures of ligand-bound catalytic 
mutants of these enzymes would be invaluable in answering these questions.  
Furthermore, what is the mode of action of the broad-acting sialidase BT0455GH33? The cellular 
localization and whole cell assay data suggests it may be both surface and periplasm localised. 
Considering BT0455GH33 is the only sialidase encoded by B. thetaiotaomicron, investigating its 
mechanism of action is of utmost importance to fully understand N-glycan degradation apparatus of 
this bacterium. 
Finally, does the mechanism of complex N-glycan degradation observed in B. thetaiotaomicron apply 
to other members of Bacteroides present in the human gut? The PUL composition comparison 
revealed homologous PULs in numerous other Bacteroides. Dissecting these PULs to investigate 
whether the encoded homologous apparatus is also utilised to forage on complex N-glycans would 
provide further insight into N-glycan degradation pathways of the dominant members of HGM.  
The human gut microbiota composition heavily depends on the availability of different nutrient 
sources in the gut, in turn influencing the host-microbiota symbiosis. The ability to utilise N-glycans 
by the members of human gut microbiota could be important in times of starvation and may play an 
important role in human health. The work presented in this thesis addressed some of the questions 
on how commensal gut microbes utilise complex N-glycans but many questions, such as whether 
and how it contributes to the host-microbe symbiosis, remain to be answered. 
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Appendix A 
 
Supplemental table 3.1: RNA-seq data table showing differentially upregulated genes in wild type 
B. thetaiotaomicron grown on bovine α1-AGP as a carbon source versus glucose as control. 
Gene_id BaseMean 
(Glucose) 
BaseMean (α1-
AGP) 
log2 Fold Change 
(α1-AGP vs Gluc) 
Fold Change (α1-
AGP vs Gluc) 
lfcSE stat pvalue padj 
BT_0081 26.17 54.78 1.09 2.13 0.31 3.53 0.00042 0.001027 
BT_0082 1314.75 2890.29 1.14 2.20 0.07 16.94 2.34E-64 4.4E-63 
BT_0124 486.55 1104.46 1.18 2.27 0.09 12.89 5.04E-38 6.15E-37 
BT_0224 899.92 4204.66 2.22 4.67 0.07 33.17 3E-241 2E-239 
BT_0225 1965.92 8951.05 2.19 4.55 0.06 38.41 0 0 
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BT_0226 1147.48 5560.14 2.28 4.85 0.07 34.62 1.2E-262 8.9E-261 
BT_0227 12884.04 61245.14 2.25 4.75 0.06 39.63 0 0 
BT_0297 740.89 1863.69 1.33 2.52 0.08 17.25 1.12E-66 2.21E-65 
BT_0298 546.05 1168.13 1.10 2.14 0.08 13.82 2.07E-43 2.81E-42 
BT_0300 1650.79 3991.53 1.27 2.42 0.07 17.18 3.54E-66 6.85E-65 
BT_0301 720.29 1610.60 1.16 2.23 0.08 14.56 4.79E-48 7.16E-47 
BT_0302 616.56 1379.54 1.16 2.24 0.08 14.31 1.9E-46 2.72E-45 
BT_0315 2018.39 10574.13 2.39 5.23 0.07 33.02 3.9E-239 2.5E-237 
BT_0316 4414.40 27214.19 2.62 6.16 0.05 49.90 0 0 
BT_0320 1969.17 8280.90 2.07 4.20 0.06 36.09 2.9E-285 2.2E-283 
BT_0321 500.47 1804.33 1.85 3.60 0.11 16.49 4.23E-61 7.69E-60 
BT_0348 150.88 324.63 1.11 2.15 0.14 8.08 6.3E-16 3.95E-15 
BT_0459 10974.70 40235.79 1.87 3.67 0.07 25.55 5.1E-144 2.2E-142 
BT_0461 4797.80 10997.96 1.21 2.32 0.08 15.89 7E-57 1.19E-55 
BT_0498 47.45 118.16 1.31 2.49 0.22 5.89 3.83E-09 1.56E-08 
BT_0504 1212.03 2565.40 1.08 2.12 0.07 15.61 6.15E-55 1.03E-53 
BT_0506 400.45 34658.25 6.43 86.31 0.07 86.09 0 0 
BT_0507 35.29 7849.35 7.82 225.66 0.17 46.99 0 0 
BT_0508 9.12 158.10 4.09 17.01 0.35 11.74 7.84E-32 8.18E-31 
BT_0509 29.63 348.50 3.55 11.67 0.21 17.06 3.18E-65 6.05E-64 
BT_0510 731.04 2142.49 1.55 2.93 0.08 20.57 5.32E-94 1.42E-92 
BT_0511 967.07 2280.96 1.24 2.36 0.07 17.32 3.13E-67 6.23E-66 
BT_0521 532.58 2937.96 2.46 5.51 0.08 30.08 1E-198 5.4E-197 
BT_0522 249.61 1160.58 2.21 4.64 0.10 23.19 6.4E-119 2.2E-117 
BT_0523 1279.25 5654.94 2.14 4.42 0.07 30.40 6.2E-203 3.4E-201 
BT_0524 1827.23 5232.86 1.52 2.86 0.06 23.42 2.9E-121 9.8E-120 
BT_0525 2842.06 12715.09 2.16 4.47 0.06 38.98 0 0 
BT_0537 199.78 686.25 1.78 3.44 0.11 15.71 1.25E-55 2.11E-54 
BT_0586 1508.60 3571.36 1.24 2.37 0.07 17.34 2.33E-67 4.65E-66 
BT_0669 101.65 309.47 1.61 3.05 0.16 10.36 3.61E-25 3.16E-24 
BT_0670 150.17 442.67 1.57 2.97 0.14 11.16 6.43E-29 6.24E-28 
BT_0671 38.24 118.77 1.63 3.09 0.23 7.03 2.07E-12 1.06E-11 
BT_0683 72.59 4387.71 5.91 60.05 0.13 46.38 0 0 
BT_0724 40.17 175.09 2.11 4.31 0.21 9.94 2.72E-23 2.26E-22 
BT_0784 5515.36 13419.44 1.28 2.43 0.07 17.52 1.07E-68 2.2E-67 
BT_0817 3270.64 6841.59 1.06 2.09 0.06 16.40 1.86E-60 3.34E-59 
BT_0839 236.23 723.74 1.62 3.07 0.11 14.96 1.31E-50 2.03E-49 
BT_0840 1075.65 3212.04 1.58 2.99 0.08 20.98 9.33E-98 2.54E-96 
BT_0841 745.05 2141.55 1.53 2.88 0.08 19.06 5.67E-81 1.34E-79 
BT_0842 246.73 707.62 1.52 2.87 0.10 14.64 1.66E-48 2.5E-47 
BT_0843 547.47 1393.32 1.35 2.54 0.09 15.56 1.29E-54 2.15E-53 
BT_0844 530.37 1318.82 1.32 2.49 0.09 15.12 1.2E-51 1.91E-50 
BT_0845 603.13 1768.41 1.55 2.94 0.08 18.93 6.23E-80 1.46E-78 
BT_0846 876.45 1853.30 1.08 2.12 0.08 13.20 8.31E-40 1.06E-38 
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BT_0865 429.25 981.60 1.19 2.29 0.09 13.43 4.19E-41 5.49E-40 
BT_0866 283.70 706.41 1.32 2.49 0.11 12.07 1.57E-33 1.72E-32 
BT_0867 470.54 1443.63 1.62 3.07 0.10 16.68 1.76E-62 3.24E-61 
BT_0881 376.69 838.59 1.16 2.23 0.11 10.30 6.99E-25 6.01E-24 
BT_0902 8804.15 22065.29 1.33 2.51 0.08 16.15 1.13E-58 1.97E-57 
BT_0922 3078.50 7769.06 1.34 2.52 0.06 23.61 2.7E-123 9.8E-122 
BT_0923 1601.01 4197.01 1.39 2.62 0.07 20.48 3.44E-93 9.05E-92 
BT_0933 46.38 99.70 1.11 2.16 0.22 5.04 4.74E-07 1.62E-06 
BT_0934 55.16 111.36 1.02 2.03 0.21 4.90 9.53E-07 3.17E-06 
BT_0935 45.16 92.20 1.02 2.03 0.23 4.54 5.65E-06 1.74E-05 
BT_0944 561.06 1185.07 1.08 2.11 0.09 12.45 1.45E-35 1.68E-34 
BT_0945 957.53 1957.09 1.03 2.04 0.07 14.43 3.52E-47 5.14E-46 
BT_0947 1168.65 2629.95 1.17 2.25 0.10 12.14 6.14E-34 6.81E-33 
BT_0998 9392.75 21806.18 1.22 2.32 0.06 20.00 5.8E-89 1.43E-87 
BT_0999 840.27 1867.03 1.15 2.22 0.08 14.69 7.06E-49 1.07E-47 
BT_1031 8.75 25.14 1.50 2.83 0.46 3.25 0.001147 0.002613 
BT_1032 3039.46 105062.36 5.11 34.57 0.06 90.72 0 0 
BT_1033 1521.15 52217.67 5.10 34.34 0.06 83.59 0 0 
BT_1034 145.31 20386.18 7.14 140.78 0.10 74.65 0 0 
BT_1035 205.03 23939.00 6.86 116.34 0.09 79.34 0 0 
BT_1036 265.81 96057.41 8.49 360.66 0.09 98.43 0 0 
BT_1037 159.46 48381.46 8.24 303.21 0.11 76.18 0 0 
BT_1038 135.87 30719.73 7.82 226.59 0.12 64.79 0 0 
BT_1039 188.52 44143.54 7.87 234.27 0.12 65.08 0 0 
BT_1040 305.24 111397.78 8.51 365.71 0.11 74.17 0 0 
BT_1042 529.92 230144.95 8.76 434.88 0.10 85.13 0 0 
BT_1043 206.47 65115.88 8.31 316.50 0.12 69.52 0 0 
BT_1044 171.48 41685.28 7.93 243.83 0.11 70.18 0 0 
BT_1045 199.38 61808.95 8.28 310.54 0.10 85.61 0 0 
BT_1046 75.62 936.01 3.62 12.34 0.16 22.39 4.8E-111 1.5E-109 
BT_1047 51.30 402.17 2.97 7.83 0.21 14.41 4.56E-47 6.63E-46 
BT_1048 33.26 276.70 3.06 8.33 0.23 13.33 1.54E-40 2E-39 
BT_1049 42.01 314.76 2.90 7.48 0.20 14.81 1.18E-49 1.81E-48 
BT_1050 38.92 416.97 3.43 10.81 0.20 17.39 9.03E-68 1.81E-66 
BT_1052 2284.82 13916.52 2.61 6.09 0.08 32.04 2.8E-225 1.7E-223 
BT_1142 226.66 1736.60 2.94 7.65 0.09 31.03 2.2E-211 1.2E-209 
BT_1163 579.30 1776.02 1.62 3.06 0.08 21.52 1E-102 2.9E-101 
BT_1164 487.24 3714.05 2.93 7.64 0.08 37.17 2.3E-302 1.9E-300 
BT_1165 306.19 2198.75 2.84 7.17 0.09 31.67 4.5E-220 2.7E-218 
BT_1166 106.09 975.12 3.21 9.26 0.13 25.29 4.6E-141 1.9E-139 
BT_1167 88.34 842.82 3.26 9.59 0.13 25.36 6.9E-142 2.9E-140 
BT_1168 13.27 31.71 1.25 2.37 0.39 3.17 0.001544 0.003447 
BT_1177 271.18 612.98 1.18 2.26 0.10 11.25 2.29E-29 2.26E-28 
BT_1178 978.93 2427.48 1.31 2.48 0.07 19.29 5.93E-83 1.41E-81 
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BT_1179 333.51 1321.39 1.98 3.96 0.09 21.84 9.9E-106 3E-104 
BT_1180 331.30 1452.04 2.13 4.39 0.09 24.35 5.9E-131 2.3E-129 
BT_1181 173.96 723.57 2.05 4.15 0.12 17.69 5.15E-70 1.09E-68 
BT_1182 278.66 1196.94 2.10 4.29 0.09 22.16 7.5E-109 2.4E-107 
BT_1183 2303.92 5954.90 1.37 2.59 0.06 23.69 4.4E-124 1.6E-122 
BT_1184 407.80 1320.29 1.70 3.25 0.09 18.22 3.86E-74 8.53E-73 
BT_1226 8255.53 20089.59 1.28 2.43 0.05 23.63 2.1E-123 7.6E-122 
BT_1230 91.38 4257.93 5.54 46.45 0.12 44.96 0 0 
BT_1231 193.17 428.56 1.15 2.21 0.13 9.01 2.1E-19 1.53E-18 
BT_1233 856.54 1966.52 1.20 2.30 0.07 16.40 2.01E-60 3.59E-59 
BT_1234 795.93 1774.18 1.16 2.23 0.07 15.60 6.78E-55 1.13E-53 
BT_1236 949.74 1989.09 1.07 2.10 0.08 13.85 1.34E-43 1.83E-42 
BT_1277 499.88 1024.56 1.04 2.05 0.09 11.20 3.94E-29 3.86E-28 
BT_1280 333.66 752.10 1.17 2.25 0.09 12.61 1.87E-36 2.22E-35 
BT_1282 74.60 157.29 1.08 2.12 0.19 5.72 1.06E-08 4.13E-08 
BT_1283 96.21 251.43 1.39 2.63 0.16 8.77 1.8E-18 1.26E-17 
BT_1284 137.97 323.62 1.22 2.33 0.15 7.90 2.88E-15 1.75E-14 
BT_1285 324.23 711.34 1.14 2.20 0.10 10.90 1.21E-27 1.14E-26 
BT_1286 36.79 173.32 2.25 4.75 0.21 10.48 1.04E-25 9.26E-25 
BT_1414 1710.28 3716.58 1.12 2.17 0.07 16.20 5.33E-59 9.37E-58 
BT_1416 2660.32 5336.70 1.00 2.01 0.07 14.55 5.5E-48 8.2E-47 
BT_1417 4652.05 10606.16 1.19 2.28 0.06 18.51 1.75E-76 3.99E-75 
BT_1418 1317.36 3073.80 1.22 2.33 0.07 18.51 1.71E-76 3.92E-75 
BT_1427 27.48 56.35 1.03 2.04 0.29 3.53 0.00042 0.001027 
BT_1442 3463.42 7291.85 1.07 2.11 0.06 17.49 1.83E-68 3.71E-67 
BT_1443 1012.58 2493.83 1.30 2.46 0.08 16.23 3.09E-59 5.47E-58 
BT_1444 531.73 1441.83 1.44 2.71 0.09 16.53 2.26E-61 4.12E-60 
BT_1445 593.35 1598.24 1.43 2.70 0.08 17.23 1.67E-66 3.27E-65 
BT_1446 1167.75 2997.12 1.36 2.57 0.08 17.40 8.34E-68 1.68E-66 
BT_1486 568.30 68261.60 6.91 120.32 0.07 93.01 0 0 
BT_1487 231.89 14993.26 6.01 64.64 0.09 65.19 0 0 
BT_1488 345.26 33270.82 6.59 96.65 0.08 81.73 0 0 
BT_1489 1056.23 11070.63 3.39 10.49 0.07 51.87 0 0 
BT_1490 1034.03 9918.54 3.26 9.60 0.06 52.06 0 0 
BT_1491 3641.18 33329.63 3.19 9.16 0.05 60.40 0 0 
BT_1492 545.72 1253.15 1.20 2.30 0.09 14.08 4.87E-45 6.77E-44 
BT_1591 243.53 507.99 1.06 2.09 0.11 9.76 1.68E-22 1.35E-21 
BT_1618 229.11 564.43 1.30 2.47 0.11 11.97 5.21E-33 5.6E-32 
BT_1620 273.24 569.44 1.06 2.08 0.11 9.83 7.99E-23 6.52E-22 
BT_1624 3002.27 13250.18 2.14 4.41 0.06 38.44 0 0 
BT_1625 1710.03 7313.67 2.10 4.28 0.06 32.27 1.7E-228 1E-226 
BT_1626 588.31 1698.68 1.53 2.88 0.08 19.69 2.88E-86 7.05E-85 
BT_1636 4193.62 11271.39 1.43 2.69 0.06 23.79 3.9E-125 1.5E-123 
BT_1752 1767.09 5054.87 1.52 2.86 0.06 24.26 5.3E-130 2.1E-128 
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BT_1863 8.59 25.14 1.57 2.96 0.46 3.37 0.000746 0.001747 
BT_1915 2099.14 30398.50 3.86 14.48 0.06 59.36 0 0 
BT_1916 527.70 7698.81 3.87 14.61 0.08 49.34 0 0 
BT_1917 3001.62 52511.73 4.13 17.50 0.05 76.62 0 0 
BT_1928 17.26 43.63 1.36 2.56 0.35 3.90 9.53E-05 0.000252 
BT_1948 0.86 19.98 4.62 24.54 1.10 4.18 2.92E-05 8.26E-05 
BT_1949 43.67 2327.82 5.73 52.91 0.16 36.65 4.2E-294 3.3E-292 
BT_1950 49.56 2572.40 5.67 51.04 0.15 38.67 0 0 
BT_1951 55.38 1921.41 5.13 34.91 0.14 35.43 5.7E-275 4.2E-273 
BT_1952 126.47 6085.21 5.59 48.23 0.10 55.24 0 0 
BT_1953 376.66 15466.96 5.36 40.96 0.07 73.36 0 0 
BT_1954 254.14 12941.59 5.67 50.97 0.08 66.97 0 0 
BT_1955 804.12 44373.39 5.79 55.22 0.07 78.00 0 0 
BT_1956 741.55 44539.76 5.91 60.13 0.07 80.72 0 0 
BT_1957 879.35 57719.87 6.04 65.76 0.07 83.31 0 0 
BT_1994 97.41 212.30 1.13 2.18 0.16 7.20 6.09E-13 3.2E-12 
BT_1995 240.47 602.24 1.32 2.50 0.11 12.26 1.43E-34 1.62E-33 
BT_1997 27.57 101.39 1.87 3.66 0.25 7.41 1.27E-13 7.03E-13 
BT_1998 12138.92 53602.63 2.14 4.42 0.06 33.71 4.6E-249 3.1E-247 
BT_2094 151.54 2585.74 4.08 16.95 0.11 37.41 2.3E-306 1.9E-304 
BT_2095 188.03 2909.04 3.95 15.48 0.10 37.88 0 0 
BT_2131 468.50 2334.10 2.31 4.98 0.09 25.93 2.9E-148 1.3E-146 
BT_2167 1933.93 16979.49 3.13 8.78 0.06 48.71 0 0 
BT_2170 648.59 3845.74 2.57 5.93 0.07 35.21 1.7E-271 1.2E-269 
BT_2171 1545.91 8728.32 2.50 5.65 0.06 40.68 0 0 
BT_2172 791.92 4787.47 2.59 6.04 0.07 36.19 1E-286 7.9E-285 
BT_2173 182.63 1102.33 2.59 6.04 0.11 24.54 5.1E-133 2E-131 
BT_2424 23.11 49.18 1.10 2.14 0.31 3.52 0.000432 0.001052 
BT_2426 17.01 68.15 2.01 4.02 0.33 6.17 6.79E-10 2.92E-09 
BT_2500 445.93 926.84 1.06 2.08 0.10 10.66 1.53E-26 1.4E-25 
BT_2502 1356.86 6276.02 2.21 4.63 0.06 37.14 6.6E-302 5.4E-300 
BT_2503 680.53 3432.55 2.34 5.05 0.07 33.58 3.1E-247 2.1E-245 
BT_2504 631.33 3066.68 2.28 4.86 0.07 32.47 3.1E-231 1.9E-229 
BT_2540 1490.53 3581.78 1.26 2.40 0.06 20.22 6.82E-91 1.75E-89 
BT_2570 8194.91 22165.68 1.44 2.70 0.09 15.47 5.74E-54 9.47E-53 
BT_2571 5198.91 12046.54 1.21 2.32 0.09 13.62 3E-42 4.03E-41 
BT_2574 389.44 829.87 1.09 2.13 0.09 11.97 5.41E-33 5.8E-32 
BT_2672 15.97 62.42 1.94 3.83 0.35 5.61 2.05E-08 7.84E-08 
BT_2828 783.07 2322.44 1.57 2.96 0.07 21.65 6.1E-104 1.8E-102 
BT_2928 21.28 74.57 1.81 3.50 0.29 6.24 4.37E-10 1.91E-09 
BT_3011 128.69 261.48 1.03 2.04 0.15 6.81 9.66E-12 4.76E-11 
BT_3012 432.40 922.85 1.09 2.13 0.09 11.75 6.87E-32 7.17E-31 
BT_3013 235.23 514.02 1.12 2.18 0.12 9.32 1.16E-20 8.79E-20 
BT_3014 101.96 218.07 1.09 2.13 0.16 6.96 3.42E-12 1.72E-11 
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BT_3015 395.56 1016.53 1.36 2.57 0.09 15.47 5.84E-54 9.6E-53 
BT_3057 909.32 2850.62 1.65 3.13 0.07 22.91 3.9E-116 1.3E-114 
BT_3059 57.57 243.88 2.07 4.21 0.18 11.79 4.65E-32 4.87E-31 
BT_3169 5956.56 14705.21 1.30 2.47 0.06 22.94 1.7E-116 5.7E-115 
BT_3197 34.33 69.28 1.02 2.02 0.27 3.80 0.000142 0.000368 
BT_3198 28.80 112.62 1.96 3.89 0.25 7.89 2.91E-15 1.76E-14 
BT_3199 98.15 224.68 1.19 2.27 0.16 7.59 3.19E-14 1.81E-13 
BT_3200 13.28 100.82 2.89 7.39 0.32 8.95 3.48E-19 2.51E-18 
BT_3201 35.23 113.48 1.68 3.20 0.23 7.35 2.04E-13 1.11E-12 
BT_3259 154.61 358.66 1.22 2.32 0.14 8.45 2.83E-17 1.88E-16 
BT_3322 391.00 1006.62 1.36 2.57 0.10 14.26 3.78E-46 5.39E-45 
BT_3390 4585.05 10611.70 1.21 2.31 0.10 12.08 1.28E-33 1.41E-32 
BT_3418 1629.20 4381.21 1.43 2.69 0.07 19.88 5.51E-88 1.35E-86 
BT_3436 164.37 328.10 1.00 2.00 0.13 7.81 5.9E-15 3.51E-14 
BT_3437 341.23 833.90 1.29 2.45 0.09 13.81 2.17E-43 2.95E-42 
BT_3438 386.89 789.66 1.03 2.04 0.10 10.28 9.13E-25 7.82E-24 
BT_3536 822.71 1874.91 1.19 2.28 0.07 16.03 8.03E-58 1.38E-56 
BT_3537 41.50 123.62 1.58 2.99 0.24 6.65 2.84E-11 1.35E-10 
BT_3737 3288.82 7387.98 1.17 2.25 0.07 16.56 1.37E-61 2.51E-60 
BT_3793 338.03 789.03 1.22 2.33 0.10 12.34 5.59E-35 6.39E-34 
BT_3825 1.68 10.21 2.64 6.23 0.92 2.88 0.003997 0.008331 
BT_3831 10.57 30.39 1.53 2.89 0.43 3.58 0.000344 0.00085 
BT_3868 1554.49 3600.87 1.21 2.32 0.07 17.31 3.9E-67 7.72E-66 
BT_3909 1845.66 4112.29 1.16 2.23 0.06 18.30 8.27E-75 1.83E-73 
BT_3910 840.07 1850.40 1.14 2.20 0.08 14.84 8.37E-50 1.29E-48 
BT_3968 26.69 53.31 1.00 2.01 0.29 3.47 0.000528 0.001268 
BT_3990 3931.90 9701.43 1.30 2.47 0.06 22.68 7.1E-114 2.3E-112 
BT_3992 1546.75 3817.02 1.30 2.47 0.06 20.35 4.62E-92 1.2E-90 
BT_4050 5170.69 12108.71 1.23 2.34 0.06 21.51 1.2E-102 3.6E-101 
BT_4069 2555.46 5113.84 1.00 2.00 0.08 12.99 1.36E-38 1.68E-37 
BT_4223 7.97 26.58 1.73 3.31 0.47 3.65 0.000262 0.000657 
BT_4224 68.31 206.54 1.60 3.03 0.18 8.77 1.81E-18 1.27E-17 
BT_4225 8.77 68.11 3.00 7.97 0.39 7.69 1.52E-14 8.82E-14 
BT_4226 9.78 67.30 2.79 6.90 0.38 7.36 1.83E-13 1E-12 
BT_4227 58.52 704.66 3.60 12.16 0.15 23.49 5.3E-122 1.8E-120 
BT_4233 57.80 242.68 2.06 4.18 0.17 11.84 2.52E-32 2.66E-31 
BT_4234 24.00 129.73 2.44 5.44 0.25 9.71 2.66E-22 2.14E-21 
BT_4235 2684.53 7567.65 1.49 2.82 0.10 14.95 1.45E-50 2.24E-49 
BT_4283 62.94 129.21 1.05 2.07 0.20 5.19 2.08E-07 7.37E-07 
BT_4284 76.83 164.05 1.10 2.14 0.17 6.30 2.96E-10 1.31E-09 
BT_4301 731.85 1655.01 1.18 2.26 0.08 15.53 2.04E-54 3.37E-53 
BT_4311 2241.07 5834.47 1.38 2.60 0.07 20.64 1.13E-94 3.01E-93 
BT_4384 45.89 99.78 1.12 2.17 0.22 5.05 4.52E-07 1.55E-06 
BT_4393 60.02 191.96 1.67 3.18 0.19 9.03 1.79E-19 1.31E-18 
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BT_4394 951.42 1909.22 1.00 2.00 0.09 11.28 1.68E-29 1.66E-28 
BT_4395 6525.25 13837.24 1.08 2.12 0.06 17.90 1.12E-71 2.41E-70 
BT_4403 1243.72 8051.32 2.69 6.47 0.06 44.74 0 0 
BT_4404 889.42 29120.83 5.03 32.74 0.09 57.23 0 0 
BT_4405 265.67 7946.93 4.90 29.92 0.12 41.55 0 0 
BT_4406 242.33 6091.07 4.65 25.09 0.12 37.83 0 0 
BT_4407 603.78 15545.11 4.69 25.79 0.08 61.47 0 0 
BT_4408 236.84 746.71 1.66 3.15 0.10 16.14 1.24E-58 2.16E-57 
BT_4575 436.86 968.36 1.15 2.21 0.09 12.83 1.15E-37 1.39E-36 
BT_4613 322.19 1016.49 1.66 3.15 0.09 18.61 2.72E-77 6.3E-76 
BT_4681 2442.35 6838.19 1.49 2.80 0.07 20.49 2.68E-93 7.1E-92 
BT_4683 119.73 380.03 1.67 3.18 0.13 12.66 1.04E-36 1.24E-35 
BT_4684 209.50 560.49 1.42 2.67 0.11 12.91 3.87E-38 4.73E-37 
BT_4685 35.76 71.32 1.00 2.00 0.25 4.03 5.48E-05 0.000149 
BT_4688 80.83 315.65 1.95 3.88 0.17 11.61 3.69E-31 3.78E-30 
BT_4689 110.10 424.96 1.95 3.86 0.15 13.27 3.64E-40 4.7E-39 
 
Supplemental table 3.2: List of primers used in this study. 
Primer name Sequence Use 
0455_KO_For1 attataGTCGACATGTCCGTATTTTTTTAAGAATTCACCACCCTGAAC KO 
0455_KO_Rev1 TCGAAGACTTTTCATGGGGGTATTAGTTAATTTAACGAAGGCAAAGATAAG KO 
0455_KO_For1 CTAATACCCCCATGAAAAGTCTTCGAATCTTTTTGGGGATTGCATTT KO 
0455_KO_Rev2 attataTCTAGAACTTTGGAGTTATCGTGGCAAAGCCCAACA KO 
0458_KO_For1 attataGTCGACCATACTATTTTGGTAAGATGCTAAGAGATA KO 
0458_KO_Rev1 GAGTTGTTTCATAGTGGGGGCATTAGATATTAACGG KO 
0458_KO_For2 CTAATGCCCCCACTATGAAACAACTCCTAAAATTAACAGGATGTGTG KO 
0458_KO_Rev2 attataTCTAGATTTCAATCAATTCGCCATATACATCTTCCA KO 
0459_KO_For1 attataGTCGACATGGGGGACAGGAGACAGTCATAATTGGGGAGTCTGGT KO 
0459_KO_Rev1 TAGTGTATCTCTTTCAAAATAAAAATTAGGTGTTAGTAGTTAATA KO 
0459_KO_For2 GAAAGAGATACACTAAAGTTTGTCTTTTCTTATGGG KO 
0459_KO_Rev2 attataTCTAGATCCAAGCCGCCTTACCAGCCTCATCGCCTCCTACAT KO 
0460_KO_For1 attataGTCGACATGAACCTTTCGGTATCGGAGGTTATTTGCCGATGGAA KO 
0460_KO_Rev1 TCATAAATTATACATCTGGTGATTTCGTCTACAAATAAAAAG KO 
0460_KO_For2 CAGATGTATAATTTATGACTATAAATATTAGATATC KO 
0460_KO_Rev2 attataTCTAGACATACGCCTTTGAATGAAGTTCTCTTTCCATTTAAG KO 
0506_KO_For1 attataGTCGACCGGGATTCCAACTATATCTACGGTCCTTCGCTTCCG KO 
0506_KO_Rev1 CTTCAGGAGATCTGTAAGGTTAACTGTTTAATAAGTTGATTACTT KO 
0506_KO_For2 ACAGATCTCCTGAAGATTTTTTATTAGGTATTAATATAGAT KO 
0506_KO_Rev2 attataTCTAGATCCAACTCGCTTATCTTGCTGCCATGCAACAAAAGC KO 
1033_KO_For1 attataGTCGACATGGCAGAACTGAATAAAGAGGATCAG KO 
1033_KO_Rev1 GATGACCTATTTTATACCTTTTACGTATGATGATTCATGAGACGTATATT KO 
1033_KO_For2 CGTATGATGATTCATGAGACGTATATTATTAACTTGCACACTGGCT KO 
1033_KO_Rev2 attataTCTAGATACAGTGATACGTGACAAGTCATCGTT KO 
0455-61PULKO_For1 attataGTCGACATGTCCGTATTTTTTTAAGAATTCACCACCCTGAAC KO 
0455-61PULKO_Rev1 GCAATGAAACACTTAGAGGGGGGTATTAGTTAATTTAACGAA KO 
0455-61PULKO_For2 AACTAATACCCCCCTCTAAGTGTTTCATTGCGATACACTTAGAGG KO 
0455-61PULKO_Rev2 attataTCTAGAGTACCTGAACCACCGGCTAAAACAATTCCTTTCAT KO 
0459D->N_For atccatgtaggtggtAATgaatgtccg Cat mut 
0459D->N_Rev cggacattcATTaccacctacatggat Cat mut 
0459E->A_For atgtaggtggtgacGCCtgtccgaagg Cat mut 
0459E->A_Rev ccttcggacaGGCgtcaccacctacat Cat mut 
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0460D->N_For attcatgtaggaggcAATGAGgctggt Cat mut 
0460D->N_Rev accagcCTCATTgcctcctacatgaat Cat mut 
0460E->A_For attcatgtaggaggcGATGCCgctggt Cat mut 
0460E->A_Rev accagcGGCATCgcctcctacatgaat Cat mut 
0506D->N_For tatgtacacatggggggtAATgaagtcgag Cat mut 
0506D->N_Rev ctcgacttcATTaccccccatgtgtacata Cat mut 
0459_CBMMut_For attataGCTAGCtgtggctcggtacaagaagcc   ∆ mut 
0459_CBMMut_Rev attataCTCGAGTGAatcagccggattcggagtaaattc ∆ mut 
CBM_0459_For attataGCTAGCatgaagccgattgttgctaatcagccg ∆ mut 
CBM_0459_Rev attataCTCGAGTGAattaattgtgatttcgtctacaaataa ∆ mut 
CBM_0460_For attataGCTAGCaatgctccgtatagtcctcac ∆ mut 
CBM_0460_Rev attataCTCGAGTGAtttcactactatttcatctgtaaa ∆ mut 
CBM_0506_For attataGCTAGCATGgtcaaagctccttatgcg ∆ mut 
CBM_0506_Rev attataCTCGAGTGAttcatgtttcagccattcttt ∆ mut 
28_BT0506_For attataGCTAGCtgcacgcctacggtgaagcaggag   cloning 
28_BT0506_Rev attataCTCGAGTGAaggaagcacttctttctcacccttttcattgac cloning 
28_BT0683_FOR attataGCTAGCtgtagtagcccgaaaacagaggtccag cloning 
28_BT0683_REV attataCTCGAGTGAaacgaaacagcctgcccgcctccg cloning 
BT0452_FOR ATGTGGCATCTCTGGATGAA qPCR 
BT0452_REV TTAACAGTTCGTCGCCTTTG     qPCR 
BT0455_FOR CCGAAAGACATCATTCATCG qPCR 
BT0455_REV CGGACATCATATACGCCAAG qPCR 
BT0456_FOR TATGTCCGTGACAAAGGGAA qPCR 
BT0456_REV GGGAGTCAATAGCGGGAATA qPCR 
BT0457_FOR ATAGTTGGCGGAAGAATTGG   qPCR 
BT0457_REV CCAGAGAATCACCATGATCG qPCR 
BT0458_FOR TCTCAACGGCTCATTACTGC qPCR 
BT0458_REV ATTGGAAGCATATTGTGGCA qPCR 
BT0459_FOR GAATCCGGCTGATGGTACTT qPCR 
BT0459_REV CTTCAAAGCGCCATCATAAA qPCR 
BT0460_FOR GTAAGTTGCTGGGTTGGGAT qPCR 
BT0460_REV CAAATATCCTCCGATGGCTT qPCR 
BT0461_FOR CGTGCAGGAGCTAATGGTAA qPCR 
BT0461_REV CGGTTGCTCTGTCGAAGATA qPCR 
BT1032_FOR TGCACACTGGCTTTCACCCT qPCR 
BT1032_REV GGACATCATTCCATTCGGGCAAA qPCR 
BT1038_FOR ACGGTTGAGCAACAGGCTGA qPCR 
BT1038_REV CGCTTCCTTCACTGCATCATCG qPCR 
BT1044_FOR CCAGACAATCAGTCCTAGCGGTAA qPCR 
BT1044_REV GAGATCCGGCTGACCATCCA qPCR 
BT1048_FOR TGCTGCTATGGATGGCGGAT qPCR 
BT1048_REV ACTCCGCCTTTACGGAAACCA qPCR 
BT1051_FOR AGAAGATGTGCTCTGTGCAGGA qPCR 
 
